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Abstract 
 
Poor acceptability has been associated with low compliance, particularly in special 
patient populations. Patient acceptability assessment of individual dosage form 
attributes offers the advantage of providing information to the manufacturer on the 
strategy to adopt for optimising the dosage form design at an early drug product 
development stage. The development of in vitro methods capable of predicting attribute 
acceptability based on the quantitative measurement of relevant formulation variables 
could provide the manufacturer with a decision-supporting toolkit to guide the 
development of acceptable drug products. However, there is a great need of defining 
standard methodologies for the assessment of patient acceptability as the current 
knowledge is fragmented in this field. The orodispersible film (ODF) platform is 
considered patient-centric, however its attributes have rarely been assessed for 
acceptability on an individual basis. The aims of this study are to identify key 
acceptability attributes of the ODF platform by in vivo methods, and to develop and 
optimise in vitro methods to predict acceptability. ODF placebo samples differing in 
specific formulation variables were prepared and the corresponding acceptability 
attributes were assessed by human panel. Only some attributes differed among 
samples in the human panel study, and therefore were identified as key acceptability 
attributes. A series of in vitro methods for the prediction of ODF attribute acceptability 
were developed and optimised, and the same sample set was tested. In vitro methods 
were considered predictive if the measured variable directly or indirectly correlated with 
the in vivo acceptability assessment. Application of the proposed strategy in the 
acceptability assessment of oral dosage forms was shown, and key acceptability 
attributes (stickiness, disintegration time) and in vitro predictive methods (dynamic 
mechanical analysis, mechanical oral cavity model) were identified for the ODF 
platform. 
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Impact statement 
 
Patient acceptability can significantly affect the safety and efficacy of medicinal 
treatments. The non-acceptance of a medicinal product could lead to non-adherence or 
to the manipulation of the dosage form, potentially causing medication errors, and 
suboptimal treatment effect. Therefore assessing patient acceptability is important to 
ensure that the medicinal product is taken as intended. The current knowledge on 
patient acceptability testing is fragmented, and there is no harmonised strategy that 
defines suitable assessment methods. The adoption of an acceptability assessment 
strategy to be integrated in the non-clinical phase of the drug product development 
could drive the formulation design towards the optimisation of highly acceptable 
medicinal products.  
 
ODFs are acceptable dosage forms, however some attributes such as the perceived 
stickiness, time to disintegration, thickness and others can influence patient 
acceptability. The perception of such attributes can be controlled by modifying 
formulation variables such as the film-forming polymer type and molecular weight.  
In the present work an attribute-dependent ODF acceptability assessment strategy was 
developed and optimised. The strategy involved the identification of key acceptability 
attributes of the ODF platform, their association with formulation variables that can 
control attributes’ quality, and the development of in vitro methods capable of 
predicting the acceptability of individual key attributes. 
 
In the short term, the implementation of the proposed strategy could benefit the 
patients by improving the ODF formulation patient acceptability, and the 
pharmaceutical industry by enabling the implementation of acceptability information 
into the early stage of the drug product development. The present study was 
conducted on the young healthy adult population. Based on the data obtained from this 
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study, the ODF attributes can be tailored to meet the requirements of specific patient 
groups such as neurodegenerative disease and mental health patients. 
 
In the medium term, future studies aiming at the development of in vitro predictive 
methods for the acceptability of ODF attributes complementary to the tools designed in 
this study, will enable the complete decision-supporting toolkit that could be 
implemented in the non-clinical phase. In particular, rheology- or tribology-based in 
vitro methods for the prediction of ODF thickening effect acceptability could be 
developed. In this way manufacturers would be able to optimise highly acceptable ODF 
products from an early stage, thus preventing the re-formulation or repurposing of the 
marketed drug product due to poor patient acceptability. 
 
In the long term, the developed acceptability assessment strategy can be adapted to 
dosage forms other than ODFs, and it could represent a way to implement the patient 
acceptability component into the drug product development process.  
The integration of the proposed acceptability testing method for ODF will allow 
exploring different aspects of patient acceptability, and hence contributing to new 
regulatory guidelines, provided sufficient engagement from the regulatory agencies is 
obtained, and enabling healthcare professionals to make prescribing decisions based 
on the appropriateness of medicinal products to patients.  
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Chapter 1.  Introduction 
 
1.1 Patient acceptability 
Patient acceptability was defined by the European Medicines Agency as the ability and 
willingness of a patient to take a medicinal product as intended [1,2]. Depending on the 
target patient population, or on the specific medical condition of the patient, taking 
certain medicinal products or treatments might present difficulties. Several patient 
groups have been identified as frequently experiencing problems related to 
acceptability, for different reasons.  
 
1.1.1 The paediatric patient acceptability 
 
At first, acceptability issues were identified in the paediatric patient population, mostly 
because of the limited availability of purposely-developed medicinal products [3]. The 
ability to take medicines varies greatly with the child’s age and physical development 
[4]. In this respect, the classification of paediatric patients in age groups has been 
described as a conventional method to identify the most appropriate dosage form and 
way of administration [4]. Advantages and disadvantages of adopting a specific route 
of administration or dosage form, and its appropriateness in relation to the child’s age 
were also described. Attributes such as taste, smell, and texture, also called 
palatability, are likely to influence the paediatric patient’s acceptability of orally 
administered medicines [2]. The shape, and size of the medicinal product may 
influence the ability to swallow solid dosage forms (swallowability), and is a key factor 
in determining the paediatric patient acceptability [2,5]. In addition, the required dose 
(number of tablets, dosing volume, etc.), dosing frequency, and duration of the 
treatment, the administration device, the primary and secondary packaging, and the 
actual mode of administration of the medicine are all factors potentially influencing 
patient acceptability [2]. In addition, factors related to the child’s conditions such as the 
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influence of the illness (presence of any pain or discomfort), the convenience of the 
parent/caregiver to administer a certain product, and the presence of a disability, or 
cultural background might also affect acceptability [2,4].  
As a result of the raised awareness on the relevance of patient acceptability, the 
European Medicines Agency issued a guidance document where patient acceptability 
is considered an integral part of the in the paediatric drug development [2,6]. Currently, 
there is a great need of appropriate dosage forms for paediatric patients [7], and 
regulatory agencies have been offering incentives to favour the development of 
paediatric medicinal products, particularly for the actives included in priority lists [8]. 
 
1.1.2 The geriatric patient acceptability 
 
Similarly, geriatric patients might encounter difficulties in taking medications. The 
demographic trend shows that the percentage of people over 65 years of age is rapidly 
increasing, and is likely to represent the 24.5% of the total population of developed and 
developing Countries by 2050 [9], and 30% in the European Union [10]. In turn, this will 
correspond to an increase in the demand of medicinal products designed to meet the 
needs of this heterogeneous patient population. Similarities in the acceptability 
requirements for oral dosage forms were described between the paediatric and 
geriatric population [11,12]. However, the marked differences in physiological, and 
pathological conditions between the two patient populations led to the need for a 
separate acceptability assessment and dedicated strategies for the development of 
geriatric-centric dosage form development [9,13–16]. Whereas age can represent an 
indicator for the acceptability requirements of the paediatric patient, the same cannot 
be assumed for the geriatric patient. Age is considered a poor predictor of the health 
conditions of the older patient due to the heterogeneity of the population [15]. The 
number of morbidities and co-morbidities impacting on the physical performances of 
patients, and the rise in the complexity of drug therapy due to polypharmacy do not 
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depend on the age of the patient [15]. Clinical conditions including dementia, 
frailty/disability/sarcopenia, chronic inflammation, sensory impairment, cancer, pain, or 
a combination of them contribute to the therapeutic needs of the patient [15]. In 
addition, the psychological and cognitive condition of the patient could either improve 
or worsen his/her interfacing with, and attitude towards the medicinal product. In turn, 
specific difficulties and problems with medicine administration could be encountered, 
particularly if the patient is self-medicating. Among the most common problems with 
medications faced by the geriatric patient there are those related to the appropriate 
identification of the right medicinal product due to visual or cognitive impairment issues, 
the ability to correctly remember the day and time when the medications should be 
taken, or understanding instructions due to cognitive problems, difficulties in opening 
the packaging, picking or handling the dosage form due to motor dysfunctions, and 
difficulties in medicines oral intake due to dysphagia or dry-mouth syndrome conditions 
[9,11,17,18]. According to the European Medicines Agency, geriatric patient 
acceptability might be influenced by product characteristics such as the selected route 
of administration, the site of dermal application (if topical), the product appearance and 
swallowability, the recommended single dose, dose frequency, treatment duration, and 
instructions, the packaging characteristics, the selection of medical device (if required), 
the need of handling the product prior to use, the need of assistance, and the settings 
where the medicinal product is taken [1]. Under the regulatory perspective, geriatric 
patient acceptability has been addressed since 1994, with two International 
Conference on Harmonization (ICH) guidelines [19,20], a Geriatric Medicine Strategy 
[21], and a concept paper [10,22] that resulted in a draft reflection paper on the 
pharmaceutical development of medicines for use in the older population [23].  
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1.1.3 Other patient groups acceptability 
 
Besides children and elderly, other patient populations have specific characteristics 
and needs that could trigger different acceptability-related issues [24]. Packaging 
design-related, and dosage form design-related acceptability or preference were 
analysed in a systematic review conducted in different patient populations [24]. 
Examples of patient populations with specific needs include long-term cancer 
survivors, and the cognitive impaired [25], however potentially any patient group 
affected by a specific pathology or group of pathologies could require a dedicated 
approach to medicine administration. It would be therefore non-appropriate to develop 
the entire patient-centric drug product design based on a fixed strategy, as each 
patient group has a different set of needs and requirements that must be appropriately 
considered.  
 
1.2 Impact of poorly acceptable medicines on the risks to patients 
 
Patient acceptability was reported to have a significant impact on the adherence to 
treatment [1,26], on the quality of life of the patient and the caregiver [1], on the 
institutional or hospital system of medication safety [1], and on the risk vs. benefits 
profile of the medication [1]. In turn, a good treatment adherence was associated with 
lower mortality [27,28]. Patient non-compliance has been reported to cause poor 
treatment outcomes in patients affected by diabetes, epilepsy, AIDS (acquired 
immunodeficiency syndrome), asthma, tuberculosis, hypertension, and organ 
transplants [29,30]. Poor compliance has been identified as the main reason for the 
lack in blood pressure control in patients with hypertension, and therefore, in the 
increased risk of stroke, myocardial infarction, and renal impairment [30]. In the case of 
patients affected by infectious diseases, poor adherence is not only dangerous for the 
subject, but also for other people [30]. 
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1.2.1 Risks associated with the use of non-appropriate medicinal products in 
children 
 
One of the most significant factors determining poor patient acceptability is represented 
by the lack of appropriateness of the dosage form. This case has been particularly well 
documented in paediatric patients. The lack of dosage forms of appropriate strength, 
shape, taste, smell, or other key acceptability attribute(s) may lead the caregiver to 
adopt coping techniques such as splitting or crushing tablets, opening capsules, or 
mixing with foods and liquids [7,31]. The unlicensed or off-label use of medicinal 
products may result in medication errors, and put at risk the safety of the patient. 
Potential risks include over/under dosing [31], dose variability [31], problems with the 
stability of the drug [7], and errors related to the instructions for manipulation [7]. The 
non-appropriateness of the dosage form could also expose patients to the risk of 
chocking, aspiration, local irritation, fluid overload, or electrolyte imbalance [32]. 
 
1.2.2 Risks associated with the use of non-appropriate medicinal products in 
older people 
 
Similarly, the use of non-appropriate medicinal products in the geriatric patient 
population might lead to risks and medication errors. The risk of chocking or aspiration 
is linked to the administration of tablet and capsules. The use of liquid medications may 
pose risks associated with errors when measuring the dose, and excipient overload. 
Uncoated solid formulations may stick to the mucosa in case of scarce salivary flow. 
Also, safety issues might be associated with the need of tablet breaking, splitting, 
crumbling, crushing or chewing. The risk of excipients overload could be increased if a 
patient takes chewable tablets multiple times. Problems with the dissolution of 
orodispersible tablets can be encountered in case of low salivary rates, and their 
moisture-protecting packaging might be difficult to open. Under-dosing and sodium 
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overload could occur with effervescent tablets, whereas capsules might need to be 
opened in some circumstances [1]. Additional risks are also associated with non-oral 
dosage forms. 
 
1.3 Patient acceptability of oral dosage forms 
 
The oral route is the most used way of administration in children and elderly [1,11]. 
Oral dosage forms are available in a variety of forms and shapes, from the monolithic 
dosage forms such as tablets and capsules, to liquids and multiparticulates.  
 
1.4 Designing patient-centric medicine 
 
The need to formulate medicines capable of meeting the requirements of the target 
patient population, in order to be perceived as highly-acceptable is increasing. This 
happened in response of the raise in awareness from the scientific community of the 
consequences of poorly-acceptable medicines on the success of the medicinal 
treatment and patient safety. Considerable efforts are being made towards the 
definition of strategies for the design of patient-centric dosage forms. The patient-
centric drug product design differs from the conventional drug product design because 
the interaction between patient and product, and the consequences of such interaction 
are considered [25,33]. In particular, effects on the adherence, and medication errors 
are scrutinised. In this sense, both product-related, and patient-related characteristics 
must be taken into consideration. As a result, specific design drivers should be 
identified and used to guide the product design until the best resulting product is 
achieved. A list of potential design drivers, design inputs, and design outputs were 
identified by Stegemann and colleagues, and are summarised in Tab. 1.1 [25]. 
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Table 1.1. Summary of Design Drivers, Design Inputs, and related Patient Needs, reported without 
modifications from Stegemann et al., 2016 [25]. 
Design drivers Design Inputs Design Outputs 
   
Characteristic 
disease/condition 
• Disease-specific 
expression 
• Multi- and co-morbidity 
• Frailty 
• Disease severity/burden 
• Disease stage 
• Individual drug/drug combination 
• Individual drug dose accuracy 
• Dose range 
• Disease-specific disabilities 
Characteristics drug 
substance/ 
physiology 
• Developmental stage 
(maturation, declining body 
functions) 
• Oro-esophageal and GI 
transit 
• Permeability 
• Fat/water ratio 
• Drug metabolism and 
clearance 
• Homeostasis 
• Reserves 
• Flexible dose adjustment 
• Appropriate dosage form 
• Excipient safety/total amount of 
excipients 
• Low adverse drug reactions 
• Low intake/administration frequency 
Characteristics drug 
therapy 
• Need for different types of 
dosage forms 
• Availability of combination 
products 
• Reimbursement 
• Dose tracking 
Characteristics drug 
product 
• Multiple and polypharmacy 
• Therapeutic complexity 
• Prescription guidelines 
• Different dosage forms 
• Possibility of product 
modifications 
(manipulations) 
• Range of trademarks 
• Simplified regimen 
• Appropriate dosage form 
• Drug product identification 
• Drug product recall 
• Dosing frequency 
• Dosing moments 
• Dispensing, substitution, and re-
substitutions 
• Reimbursement 
• Dose tracking 
Patient 
characteristics 
• Age, gender, socio-
emotional development 
• Mobility (travel) 
• Perceived wellbeing 
• Functional limitations 
(motoric, sensory, 
cognitive) 
• Health literacy 
(disease/therapy 
understanding) 
• Dehydration/malnutrition 
• Motivation 
• Psychological traits 
• Remaining life time 
• Living alone or with others 
• Daily occupation (work, 
school) 
• Social support and 
interaction 
• Stress resistance 
• Usability/ergonomics 
• Self-explaining/intuitive use 
• Drug product information 
• Product identification 
• Swallowability 
• Palatability (taste, smell, texture) 
• Reminder 
• Dosing frequency/moments 
• Least number of units/drug products 
• Feedback/communication/motivation 
Medication 
management 
(adherence and 
administration) 
• Intended and non-intended 
non-adherence 
• Therapy simplification 
• Pill boxes and compliance 
aids 
• Hoarding 
• Environment where the 
medication needs to be 
prepared and taken 
• Access/cost 
• Identification/differentiation outside 
packaging 
• Dosing frequency/moments 
• In-use stability (e.g., external “Pill 
box” airport scanning) 
• Ease of storage 
• Convenience of use (e.g., specific 
requirements like before breakfast) 
• Use discretion 
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• Co-medications and 
changing (generic) 
prescriptions 
• Portability 
• Food effects 
• Refill reminders 
• Harmonized labeling, naming 
elements, product elements (e.g., 
packaging), or cue tags 
Usability (handling, 
storage, 
and disposal) 
• Drug product appearance 
• Drug product shelf life 
• Drug product storage 
• Drug product disposal 
• Drug product packaging 
• Dose measurement and 
preparation 
• Dosing frequency 
• Need for administration 
device 
• Ability to self-administer 
with ease 
• Need for help from 
caregiver 
• Learned usage/experience 
• Handling issues (e.g., round tablets 
roll off the table) 
• Ergonomics 
• Formulations enabling (easier) self-
administration 
• Refrigeration requirements 
• Stability during use period 
• Minimize waste (dose form, 
packaging) 
• Mechanical stress stability of the 
product  
• “Predicted usage” (modification by 
patient) 
 
The consideration of all the points listed in Tab. 1.1 is a useful strategy for the initial 
stages of the drug product design process. However, the appropriateness, and 
acceptability of the final medicinal product cannot be certain without the feedback of 
the patient. It would therefore be useful to adopt an assessment method for the 
verification of the end-user acceptability that could directly involve the target patient 
population [34].  
 
1.4.1 Assessment of patient acceptability  
 
Various published works have focused on assessing the patients acceptability of 
medicinal products in clinical studies. Methods such as visual analogue scales (VAS) 
and hedonic facial scales have proven to be reliable for the acceptability assessment of 
paediatric patients [35]. Other scales and assessment methods have been used to 
evaluate acceptability in different patient populations [36–39], many of which were 
implemented from techniques used in the field of food sensory evaluation [35]. The 
patient acceptability of medicinal products is often limited to the assessment of the 
formulation aspects of the drug product [39], and the used methods often fail to take 
into account all the dimensions of patient acceptability [40–42]. Advantages and 
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disadvantages were also reported when the medicinal product was already being 
prescribed to the study participants, or when a placebo formulation was administered 
instead for the purpose of prospecting the acceptability of the final product in pre-
marketed formulations [39]. The second case is particularly advantageous during the 
drug development process. The scientific debate on the suitability of methods for the 
assessment of patient acceptability has evidenced a fragmented knowledge, and the 
lack of a harmonised strategy [41]. 
 
1.4.2 Applicability of acceptability testing to the drug development life cycle  
 
Regulatory agencies are now encouraging studies to investigate the acceptability of 
new medicinal products [34]. The collection of acceptability information might find place 
during the clinical phases of the drug development life cycle (Fig 1.1). 
 
 
Figure 1.1. Drug development life cycle. 
 
However, before the clinical stage, the drug product must have already been optimised 
and must have passed the pre-clinical phase tests. If evidence of poor patient 
acceptability is obtained during the clinical phase, the costs of re-formulating and re-
testing the drug product would be too high, and the total development time frame too 
long. 
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Therefore, from the drug developer perspective, acquiring information on patient 
acceptability in the early drug development stage is undoubtedly more convenient. 
However issues may arise with regards to the costs, time, and safety of a human study 
conducted during the pre-clinical phase. Unless the corresponding placebo formulation 
is tested, safety risks associated with the administration of the untested active 
pharmaceutical ingredient (API) will preclude the authorisation of any human study. In 
the case of a placebo formulation testing, provided that all the excipients are evaluated 
as safe for the target patient population, the time required for the study design, the 
ethical committee authorisation, recruitment, data collection and data analysis might 
heavily impact on the total span of the drug development process. 
Consequently, human testing does not seem to represent a viable solution. 
As in vitro methods are utilised in the pre-clinical drug development phase to inform on 
the safety and characteristics of the formulation, so in vitro methods could be used in 
the prediction of patient acceptability.  
Increasing efforts are being made towards the development of in vitro and animal 
testing methods that could inform on the patient acceptability of formulations. Animal 
methods have been extensively studied for the assessment of taste, and a positive 
correlation between murine and human taste perception has been found [37]. 
However, technical difficulties have been encountered when attributes other than taste 
have been assessed using the brief animal taste aversion (BATA) test. In vitro 
dissolution, in vitro assays, and biomimetic taste sensing systems, are used for the 
prediction of the taste of solutions [38]. In vitro methods assessing polymer adhesion 
were also developed [43], and might be used to predict the safety of swallowing of 
pharmaceutical products.  
Although a comprehensive assessment of the overall acceptability of a drug product 
cannot be obtained, in vitro methods represent the most valuable alternative to human 
testing. In this regard, the formulation variables with the potential to influence patient 
acceptability must be assessed separately, so that in vitro predictive methods to 
assess the acceptability of each specific attribute can be developed.  
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1.5  A strategy for the identification of dosage form acceptability attributes 
 
In order to obtain in vitro methods capable to guide the drug development process 
towards an acceptable medicinal product, accurate information on the patient 
acceptability of the study dosage form should be obtained from the target patient 
population. Such information should be quantitative, in order to be used for in vivo/in 
vitro correlation studies. Once acceptability information has been obtained, the 
following stage is to identify appropriate formulation variables that could potentially 
influence patient acceptability, optimise an in vitro quantification method, and verify the 
correlation of such variable with patient acceptability outcomes. A diagram of the 
proposed strategy is summarised in Fig. 1.2. 
.  
Figure 1.2. Flow chart of strategy for the identification of key acceptability attributes of dosage forms, and 
development of in vitro decision-supporting tools for the development of acceptable medicinal products. 
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1.5.1 Identification of dosage form acceptability attributes 
 
No two medicinal products are the same, and depending on the dosage form and the 
specific characteristics of the formulation being investigated, the attributes influencing 
the end used acceptability may vary. Therefore the selection of the in vitro tools should 
follow the identification of the attributes that are more likely to affect the end user 
acceptability. Acceptability attributes of oral dosage forms should be identified based 
on the intended use of the product, on its intake process, and on its behaviour once 
inside the mouth (Fig. 1.3).  
 
 
Figure 1.3: Phases of the intake process of oral dosage form. 
 
For example, conventional tablets are removed from the packaging, picked up, brought 
to the mouth, and directly swallowed with the aid of water, without any oral processing 
being required. As a consequence attributes such as taste and smell are unlikely to 
significantly affect the end user acceptability. On the other hand, the size, shape, 
colour, and swallowability may play a prominent role. Gels and jellies are, on the 
contrary, very different from tablets. The oral processing required is much more 
Secondary 
packaging opening
Primary packaging opening
Picking/measuring
Intake
Oral processing 
(if applicable)
Swallowing
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significant, and attributes such as taste, smell, size, and gumminess may have a more 
prominent role in determining the end user acceptability. In this respect, a 
categorisation based on the dosage form platform adopted might serve as guideline to 
help with the identification of the key acceptability attributes.  
 
1.5.1.1 Identification of dosage form attributes influencing patient 
acceptability prior to oral intake 
 
Type of packaging, measuring system, and size, shape, colour, thickness, and 
adhesiveness of dosage forms can greatly affect the patient acceptability during the 
handling process, particularly for specific patient populations. Usability has been 
defined as “the extent to which a product can be used by specified users to achieve 
specified goals with effectiveness, efficiency and satisfaction in a specified context of 
use”, and it has been often used in relation to medical devices and packaging [44–46]. 
However, usability can also refer to the ability of patients to use medicinal products 
[24]. In this sense, attributes such as colour could be important for the correct 
identification of the dosage form, whereas shape, size, thickness, and adhesiveness, 
among others, could influence the handling of the product.  
 
1.5.1.2 Identification of palatability-related attributes for oral dosage form 
acceptability testing 
 
In order to describe the attributes of the different dosage forms once placed inside the 
mouth, the appropriate wording might be borrowed from food science, especially in 
relation to palatability. Palatability comprises taste, aftertaste, and mouthfeel (e.g. 
grittiness, texture, cooling, heating) [23,47]. Mouthfeel with reference to medicinal 
products has been defined as “The sensation from the ingestion, mastication and 
swallowing of the medicine, all of which are influenced by the physical and chemical 
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properties of the medicine being administered” [48]. As it was pointed out by Batchelor 
and co-workers, the mouthfeel of a medicinal product is not studied with the intention to 
maximise the sensory pleasure, but rather to avoid mouthfeel to represent an 
acceptability barrier to the patient [48]. Mouthfeel is the result of a combination of other 
attributes. In food science the vocabulary used to describe the mouthfeel of products is 
very rich, with different product types having their specific word list. It might be useful to 
extract the appropriate vocabulary in order to facilitate the description of mouthfeel in 
medicinal products by focussing on the terms that describe attributes related to 
rheological and tribological properties. A suggested list of some commonly used 
attributes used in food science that could also apply to medicinal products is presented 
in Tab. 1.2. 
 
Table 1.2: Description of palatability attributes. 
Palatability attribute Description Reference literature 
(if available) 
Adhesion   
Stickiness Tendency of the sample to induce a sticky sensation on the palate or between the teeth 
[49] 
Sliminess Tendency of a viscous liquid to stay in the mouth  
[49] 
Slipperiness Tendency of the sample to slip away in the mouth (no grip) 
[49] 
Filminess Tendency of the sample to stay behind as a layer in the mouth 
[49] 
Adhesiveness to palate 
Force required to remove product completely 
from palate, using tongue, after compression 
of the sample between tongue and palate 
[50] 
Breakdown   
Initial bite cohesiveness 
Amount of deformation undergone by the 
material before rupture when biting 
completely through sample by molars 
[50] 
Fracturability 
Force with which the sample ruptures when 
placed between molars and bitten completely 
down at a fast rate 
[50] 
Hardness Force required to bite completely through sample placed between two molars 
[50] 
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Denseness 
Compactness of the cross-section of the 
sample after biting completely through with 
molars 
[50] 
Viscoelasticity   
Firmness Force required to compress the sample between the tongue and the palate 
[51] 
Springiness 
Force with which the sample returns to its 
original size/shape after partial compression 
(without failure) between the tongue and the 
palate 
[50] 
Thickness 
Thickness of the food in the mouth after the 
food is compressed via up and down motions 
of tongue against palate 
[52] 
Melting Thinning of the product in the mouth and spreading throughout the mouth 
[52] 
Degranulation   
Smoothness 
Degree in which the food contains granules 
detected by moving the tongue parallel to 
palate 
[52] 
Powderiness Tendency of the sample to form small particles (e.g. flour) 
[49] 
Grittiness A rough feeling in the mouth 
[53] 
Flow   
Prickliness 
A tingling feeling sensed by the tongue, 
typically associated with slightly carbonated 
soft drinks 
[52] 
Thickness 
Thickness of the liquid in the mouth after the 
food is compressed via up and down motions 
of tongue against palate 
[52] 
 
As the dosage form is placed inside the mouth the size and shape could potentially 
lead to difficulties in the subsequent oral processing. The size of oral dosage forms 
must be appropriate for the age and physical development of the patient. Also, the 
presence of sharp edges might cause injuries to the oral mucosa. 
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1.5.1.2.1 Palatability attributes related to solid dosage form 
composition 
 
Taste has been defined the most predominant mouthfeel attribute influencing patient 
compliance and acceptability [54]. Sweetness, sourness and bitterness are at the basis 
of all the neurochemical information reaching the human sensory system. After 
integration with the olfactory information coming from the nose, it drives the proneness 
or recalcitrance of the subject to consume or not the edible product. In pharmaceutical 
formulations, taste and smell are determined by the type of API and excipients [54]. In 
the majority of the cases neutral-tasting pharmaceutical excipients are preferred 
because they do not contribute to the overall taste or smell of the formulation, leaving 
the taste of the API to be often the only contributor. In case the API exhibits unpleasant 
taste, the addition of sweetening or flavouring agents, or the implementation of taste-
masking technologies is explored [54]. With the purpose of developing in vitro methods 
for the prediction of the palatability of medicinal products, considerable efforts are 
being made. However due to several reasons, among which the complexity of the 
human oral sensory system, and the involvement of genetic, and sociodemographic 
aspects in determining the variability of taste perception and palatability evaluation, 
and the variety of dosage forms [55], the design and development of an in vitro method 
for the prediction of medicines palatability would require a dedicated project that would 
deviate from the aims of the present work. Proof-of-concept of the possibility to develop 
a series of in vitro decision-supporting tools to help driving patient-centric medicinal 
product design can be obtained by analysing other mouthfeel and acceptability 
attributes. Integration with in vitro palatability predictive methods can occur at a later 
stage, when such methods will be validated for the dosage form platform of interest. 
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1.5.1.2.2 Palatability attributes related to solid dosage form 
adhesion 
 
The term “sticky” in relation to food products has been used predominantly for thick 
and viscous, and less frequently for thin and liquid products [49]. Excessive stickiness 
could lead to a negative hedonic evaluation of foods, however it is not considered a 
predominant mouthfeel attribute [49]. In the case of pharmaceutical dosage forms, high 
stickiness could cover a more predominant role in determining patient acceptability. 
Some polymers used for tablet coating, capsule shells, orodispersibles, and jellies may 
have adhesive properties, and could affect the residence time and swallowing process 
in case the dosage form adheres too strongly to the palate and oesophagus. For this 
reason mouthfeel attributes associated with adhesion such as sticky, slimy, slippery, 
powdery, and filmy are worthy to be explored in the context of medicine administration.  
 
1.5.1.2.3 Palatability attributes related to solid dosage form 
breakdown 
 
In case of chewable tablets or any other dosage form that requires mastication, the 
breakdown behaviour can trigger specific mouthfeel sensations, towards which 
attributes such as cohesiveness, fracturability, hardness and denseness play the most 
prominent role. For example, a chewable tablet must possess sufficient cohesiveness 
to maintain its compactness, but should not exceed in hardness and denseness so that 
the patient can process it. 
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1.5.1.2.4 Palatability attributes related to solid dosage form 
viscoelasticity and rheology 
 
Some orodispersible dosage forms undergo a disintegration process upon contact with 
saliva. In this case, the patient might perceive melting of the dosage forms due to the 
change in their viscoelastic and rheological properties. Moreover all the dosage forms 
that require oral manipulation can be perceived differently based on their viscous and 
elastic moduli. Firmness, springiness, thickness, and melting represent some of the 
terminology used to describe viscoelastic moduli whilst the medicinal product is being 
processed in the mouth, and they can apply to both solid and semi-solid products. 
 
1.5.1.2.5 Palatability attributes related to solid dosage form 
degranulation 
 
Upon disintegration, orodispersible tablets tend to break down into small particles. 
Similarly, multiparticulates such as minitablets, powders and granules can confer 
mouthfeel associated with the shape, number and size of particles as soon as they are 
taken into the mouth. In this respect smoothness or powderiness/grittiness attributes 
could be perceived as potentially uncomfortable. Also, failing to swallow all the 
particles constituting the required dose might lead to unintentional under-dosing, 
therefore assessing partial dose loss might be useful in order to assess the ability of 
the patient to take the medicinal product as intended. 
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1.5.1.2.6 Palatability attributes related to liquid dosage forms 
 
Effervescent tablets or granules often contain carbonates to make the resulting drink 
slightly fizzy. Although fizzy drinks are often considered pleasant, in some cases 
excessive fizziness can result uncomfortable. Attributes such as prickliness could be 
evaluated in order to assess the related acceptability. Syrups and other drinks might 
also be subjected to the influence of thickness/viscosity of the liquid. 
 
1.5.1.3 Acceptability attributes studied in conventional and novel dosage 
forms 
 
In Tab. 1.3 the main oral dosage form acceptability attributes are listed, and references 
to the literature works where such attributes were analysed were indicated, where 
available.  
 
Table 1.3. Acceptability attributes of oral dosage forms. 
Oral dosage form Acceptability attribute Reference literature (if 
available) 
Conventional dosage 
form 
  
Capsule 
Size [6] 
Shape [6] 
Taste/aftertaste (uncoated) [6] 
Swallowability [39] 
Colour  
Tablet 
Size [6,11] 
Shape [6] 
Taste/aftertaste (uncoated) [6] 
Swallowability [39] 
Colour [56] 
Powder/granule 
Swallowability [39] 
Grittiness [57] 
Size [6] 
Shape [6] 
Taste [6] 
Colour  
Liquid 
Taste/aftertaste [6] 
Smell [6] 
Volume [6] 
Colour  
Viscosity  
Swallowability [39] 
Effervescent tablet/powder Taste [58] 
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Smell  
Colour  
Prickliness  
Novel dosage form   
Soft capsule 
Size  
Shape   
Colour  
Hardness/softness [6] 
Swallowability [39] 
Resistance to rupture  
Minitablet 
Taste (uncoated) [6] 
Size [6] 
Shape [6] 
Colour  
Number per dose  
Grittiness [53] 
Swallowability [39] 
Orodispersible tablet 
Taste [59] 
Size  
Shape  
Colour  
Grittiness  
Disintegration time  
Swallowability [39] 
Orodispersible film 
Taste [60] 
Size [61] 
Colour  
Shape  
Thickness [61] 
Disintegration time [62] (time measurement) 
Stickiness  
Stiffness  
Thickening effect  
Grittiness [60] 
Swallowability [39] 
Chewable tablet 
Taste  
Size   
Colour  
Shape  
Hardness [63] 
Chewiness  
Gel and jelly 
Taste  
Smell  
Size  
Colour  
Shape  
Gumminess  
Swallowability  
 
Some work has been done on the assessment of the patient acceptability of 
conventional dosage form platforms such as tablets, liquids and capsules, however 
less information is currently available on novel dosage form platforms.  
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1.5.1.3.1  Acceptability attributes studied in conventional dosage 
forms 
 
Swallowability of tablets, capsules, suspensions, powders, liquids, and syrups was 
assessed and reported in a systematic review [39]. Size, shape, taste, aftertaste, 
number of units per dose, and colour of conventional tablets and capsules have been 
assessed for patient acceptability in the paediatric patient population [6,11,56]. 
Similarly, size, shape, and taste/aftertaste of uncoated multiparticulates, and volume, 
taste/aftertaste and smell of liquid medicines have been studied [6]. The taste of 
effervescent tablets has also been studied in children [58]. 
 
1.5.1.3.2  Acceptability attributes studied in novel dosage forms 
 
It was reported that novel dosage forms are more acceptable than conventional 
dosage forms [64]. However studies conducted on multiparticulates evidenced the 
relevant role played by grittiness on the end user acceptability in adults and children 
[53]. Taste and mouthfeel were considered more critical acceptability parameters than 
disintegration time in orodispersible tablets (ODT) [59], however it was acknowledged 
that all play a key role in acceptability [65]. The swallowability of minitablets, soft 
capsules, film-coated dispersible tablets, and orodispersible films (ODFs) were 
assessed and results were presented in a systematic review [39]. Preference of soft vs. 
chewable tablets has also been reported in children [6]. However, studies conducted 
on such platforms not always include an exhaustive assessment of the acceptability of 
all relevant attributes. One of the main reasons for the lack of acceptability information, 
besides the novelty of the dosage form platform, is the fragmented approach to 
acceptability testing, and the lack of a standardised methodology. As a result, data are 
poorly comparable, and often information on specific attributes is missing. 
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1.5.1.4  Advantages of individual attribute acceptability versus overall 
acceptability assessment of dosage forms 
 
Criticisms on how the available literature has failed to analyse the complexity of patient 
acceptability have been raised [40]. This implies that the assessment of the 
acceptability of single attributes of the formulation platform might further reduce the 
information related to acceptability aspects other that those formulation-related. 
However, one of the main advantages of focussing on the acceptability assessment of 
single attributes of the dosage form platform is that, often, the quality of such attributes 
can be controlled during the manufacturing process. For example, the grittiness for the 
minitablet platform correlates with the size (diameter) of the individual unit [53]. 
Similarly, one or a combination of formulation variables can control other acceptability 
attributes. This represents a great advantage to manufacturers because acceptability 
information about a specific attribute can in many cases guide the optimisation process 
of the formulation being developed. However, work on the correlation between 
formulation variables and the acceptability of the formulation variables is required, and 
exploring a potential strategy for doing so is one of the objectives of the present work. 
 
1.5.2 In vivo assessment of dosage form acceptability attributes 
  
The in vivo assessment of the dosage form platform focussing on the evaluation of 
single attributes would require human panel participants to take samples differing in the 
quality of attributes, and rate their acceptability using scales. This method has been 
adopted in the past, however the goal of the study is to also analyse the correlation 
between attribute acceptability and formulation variables, hence the evaluation of the 
intensity of the feeling linked to such attributes should be carried out. In addition, since 
the initial selection of the acceptability attributes to analyse might leave out some 
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important aspects, the use of a face-to-face interview will provide more information 
from the panel participants.  
 
1.5.2.1  Terminology use 
 
Of all the aforementioned oral dosage form acceptability attributes, not all can be easily 
assessed by the lay person, as it must be taken into consideration that patients are 
non-trained assessors. Therefore, a simplified terminology should be adopted, yet it 
should be clear enough to avoid misunderstanding.  
 
1.5.2.2  Assessment modality 
 
Questionnaires/interviews should be appropriately designed for the target patient 
population to be investigated. For example, electronic questionnaires might be more 
convenient to use in adults and adolescents as they are more likely to be technology 
literates, whereas computerised questionnaires might result difficult to use by the older 
individuals [66]. On the other hand, paper-based questionnaires might be more 
appropriate for use in the paediatric population, or in other patient populations suffering 
from cognitive impairment. 
 
1.5.2.3  Acceptability and sensory assessment scales 
 
Acceptability assessment scales should be selected based on the target patient 
population. For example, children below a certain age might find hedonic scales 
difficult to use [67], however the ability to use the scales improved if verbal anchoring 
was provided [68].  
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Concerning the sensory evaluation methods aimed at assessing the intensity of a 
stimulus, various scales have been used in the past. Seven- or nine-points 
scales/ranking systems are often used in food science [69,70], however score 
point/ranking systems no wider than five points might, once again, result easier to use 
by non-trained panellists.  
 
1.5.2.4  Participant burden 
 
In every human panel study, participants should never be subjected to 
difficult/frustrating tasks, long assessment duration, or samples overload. Particularly in 
the case of patient populations that could already feel debilitated by medical conditions, 
additional ethical considerations must be made in order to ensure the preservation of 
patients’ safety and wellbeing during and after the assessment session. 
 
1.5.2.5  Independent observation 
 
In some studies involving the acceptability assessment in small children and babies, 
the parent or carer is responsible for assessing the reaction of the subject to the 
sample [71,72], since the subject is not able or reliable enough to use scales 
autonomously [67]. This method could also represent an additional confirmation of the 
acceptability of the sample, if used in combination to the questionnaire and scales, and 
if carried out by an independent person. 
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1.5.2.6  Expected participant-reported outcomes (PROs) 
 
The information obtained from panellists differs depending on the assessment method 
adopted. Hedonic scales and score point/ranking systems measure quantitative 
categorical variables, whereas interviews will provide additional qualitative information. 
In general, all the information obtained from the subject is referred to as participant-
reported outcomes (PROs). All the quantitative PROs obtained from the study 
represent the fixed variable dataset to be used for the assessment of the in vivo/in vitro 
correlation with in vitro acceptability-predicting methods. 
 
1.5.3 In vitro assessment of dosage form acceptability attributes  
 
1.5.3.1  Identification of formulation variables influencing acceptability  
 
Depending on the analysed dosage form platform, different formulation variables are 
expected to influence the properties of the medicinal products. For example, the 
surface area of multiparticulate preparations will determine the amount of API that can 
be loaded per unit, and therefore, the number of particles required to achieve the full 
dose [73]. Whereas this is considered an advantage because it confers dose flexibility, 
a large amount of particles could be perceived as difficult to measure, and 
uncomfortable to take. Similarly, the type and concentration of a superdisintegrant in 
an ODT will influence its disintegration [74]. Type and molecular weight of polymers 
can determine the viscosity of a solution, or the adhesion of a capsule [43]. 
Formulation variables and related attributes are not only oral dosage form-dependent, 
but also formulation-dependent parameters, therefore, it is difficult to categorise them. 
Only the formulator will be sufficiently knowledgeable of its formulation, and will be able 
to identify the relevant formulation variables. This type of information can be easily 
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sourced by literature search, or by consulting the manufacturer of the excipients 
employed. Alternatively, laboratory experiments can help identifying formulation 
variables and their influence on the final product. 
 
1.5.3.2  Development of in vitro methods for the evaluation of 
acceptability of dosage form attributes 
 
In the simplest case, the quantitative assessment of a formulation variable directly 
correlates with the qualitative assessment of the corresponding acceptability attribute. 
Therefore, once a quantitative in vitro method for the measurement of the formulation 
variable is available, the patient acceptability of the corresponding acceptability 
attribute can be predicted. For example, if the disintegration time of an ODT is 
identified as a key acceptability attribute, and it is directly correlating with the seconds 
required for the tablet to disintegrate, then a conventional in vitro disintegration time 
measurement method will also provide information on patient acceptability. 
Consequently, if the use of a certain concentration of superdisintegrant causes the 
ODT under development to disintegrate too slowly, the increase of superdisintegrant 
concentration will probably reduce the disintegration time, and improve patient 
acceptability.  
Sometimes, the acceptability evaluation of an attribute could correlate with a 
combination of formulation variables. Conversely, more than one acceptability attribute 
could be determined by the same formulation variable. This is a more complicated 
case that requires an in-depth investigation on the relationship between variables. After 
doing so, the integration of two or more in vitro methods in one 
apparatus/measurement session might provide data correlating with the in vivo 
acceptability evaluation. 
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1.6 The orodispersible film platform 
 
Orodispersible films are stamp-size polymer-made thin wafers that rapidly disintegrate 
upon contact with saliva immediately after intake. ODFs are relatively recent dosage 
form platforms and have appeared on the market a decade ago. Commercially 
available ODF products exist for a range of therapeutic areas, among which there are 
those for the treatment of Alzheimer’s disease (Donepezil – Labtech, Kyukyu 
Pharmaceuticals, Hexal Pharmaceuticals), emesis (Ondansetron – Monosol, Labtech, 
Aavishkar), schizophrenia (Olanzapine – Labtech, Hexal Pharmaceuticals), migraine 
(Zolmitriptan – Monosol, Labtech, NAL Pharma) etc. In Borges et al., 2015, a 
comprehensive list of registered, marketed, or withdrawn ODF products is presented 
[75].  
 
1.6.1 ODF manufacturing techniques 
 
ODFs are conventionally manufactured by solvent casting, although less used methods 
include semisolid casting, and hot melt sheet extrusion [76,77]. The API(s) is/are 
dissolved or suspended in a solution or feedstock with other excipients, and 
formulation or processing aids, and then processed into the final product. A typical 
manufacturing process by solvent casting requires a continuous-coating liner on which 
the aqueous or non-aqueous casting solution is deposited, levelled, and dried, as 
thoroughly described in Hoffmann et al., 2011 [78]. The final step requires the cutting of 
the film matrix into single films of desired size. However, the manufacturing process is 
still subjected to limitations related to content uniformity, low drug loading [79], dose 
diversification, and the safety of organic solvents. Other techniques such as hot melt 
extrusion do not imply the use of solvents [80,81], however other potential 
disadvantages such as the limited availability of suitable polymers, and the high 
temperatures may impact on the stability of the API [78]. Novel technologies such as 
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electrospinning represent potential alternatives to the current manufacturing techniques 
[82], although issues with the poor mechanical properties of the final product, and the 
technology scale-up have not yet been resolved.  
 
1.6.2 ODF manufacturing parameters  
 
In general, the ODF design process should take into consideration parameters such as 
the therapeutic target, the target patient population, the product safety, the 
compatibility between API and excipients, the processability of the excipient mixture, 
the stability of the final product, its physicochemical and mechanical properties, the 
drug release profile, and packaging suitability, in addition to patient acceptability. The 
cost of ODF manufacturing may also be consistent, and it largely depends on the 
availability and readiness for industrialisation of the manufacturing technologies; on the 
type of equipment, its cleaning and maintenance costs, and the possibility of scaling 
up/down; on the critical process parameters, and the process integration, control, and 
monitoring system; on the possibility of conducting batch or continuous manufacturing; 
on the throughput capacity, and on the type of packaging. ODF manufacturing is an 
expensive process, and it often requires considerable investments. Failing to assess 
any of the manufacturing parameters described above, including the end user 
acceptability of the final product, could potentially result in insufficient investment 
returns. 
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1.6.3 General formulation principles of ODFs 
 
The main constituents of ODFs are polymers. Film-forming polymers are of natural, 
semi-synthetic, or synthetic origin, and can be used alone or, more commonly, in 
combination [76,79]. Constituents of the film matrix are polysaccharides, cellulose 
derivatives, proteins, acrylates, and other polymers [75], that can be available in 
different grades and molecular weights, thus offering the flexibility necessary to 
achieve the desired drug loading, mechanical properties, and disintegration time. Film-
forming polymers are normally dissolved in the appropriate solvent or mix of solvents in 
order to be processed, however, the formulation often requires the addition of a 
plasticiser to achieve satisfactory mechanical properties [83]. Plasticisers are short 
molecules that insert among the longer polymeric chains, reducing the mechanical 
cohesion, and thus improving the flexibility of the film [84]. In addition to the plasticiser, 
other excipients may be required to improve the drug solubility, and the disintegration, 
the appearance, or the taste of the ODF product. Such excipients include 
superdisintegrants, colouring, sweetening and flavouring agents, surfactants, saliva 
stimulating agents, fillers, and, of course, the API(s) [79]. The resulting formulation 
should meet the requirements for processability, in vitro characterisation, and in vivo 
pharmaceutical performance. 
 
1.6.4 Orodispersible films as patient-centric dosage forms 
 
ODFs are generally considered patient-centric dosage forms. Their thin and soft 
nature, rapid melting, and no requirement of water aid for intake was considered 
advantageous for those patients being uncooperative, or experiencing difficulties of 
swallowing [76,77,85]. The delivery of actives through the oral mucosa by ODF 
administration could provide a fast onset of action [86], that can prove particularly 
useful in case of emergency circumstances [87] such as anaphylactic shocks, 
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congestive heart failures, sudden epileptic seizures, breakthrough pain [88]. Various 
technologies such as inkjet/2D printing, and multilayering were implemented in order to 
improve dosing precision, to improve the flexibility of the dosage form, and to allow 
developing fixed-dose combinations [79,89–93]. Moreover, taste-masking technologies 
can be applied, potentially improving acceptability. Patient acceptability of ODFs has 
been confirmed in several in vivo studies, and in different patient groups. Attributes 
such as swallowability, palatability, presence of residues in the mouth after intake, 
grittiness, taste masking, mouth freshening, size, thickness, solubility, disintegration 
time, ease of administration were assessed [60,61,71,94–97]. In a review paper, 
Krampe and colleagues considered ODF mouthfeel and texture as key characteristics 
potentially affecting patient acceptability, and the “gummy” nature of the film product 
after wetting as potentially contributing to the ODF mouthfeel [77]. However, there is no 
evidence that the ODF attributes assessed in vivo are actually the main contributors to 
the end-user acceptability, according to patients. 
 
1.6.5 Identification of ODF acceptability attributes  
 
A convenient way to investigate the ODF acceptability attributes might be to consider 
the phases of ODF intake, as previously suggested (Tab. 1.4). 
 
Table 1.4: ODF acceptability attributes potentially affecting patient acceptability. 
ODF acceptability attributes 
Handling phase Intake phase Oral processing phase 
Post-swallowing 
phase 
Ease of opening 
(packaging) Smell Taste 
Presence of viscous 
residuals 
Colour Size Thickness Aftertaste 
Size Shape Sliminess Filminess 
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Thickness Stiffness Thickening effect Astringency/dryness 
Stickiness Adhesiveness to palate (Stickiness) Disintegration time 
 
 
1.6.5.1 Handling phase 
 
ODFs are often highly hygroscopic and the loaded API might be light-sensitive. For this 
reason, they may require specific packaging that must be moisture-resistance, opaque, 
compatible with the formulation composition, and, in many cases, child-resistant [87]. 
The combination of these factors often leads to the adoption of sealed aluminium or 
composite pouches that may be difficult to open or may require specific opening 
instructions. If the target patient population for the study product present poor manual 
dexterity, reduced pinch strength, lowered sight, or cognitive impairment, the ease of 
opening should be explored. Patients with lowered sight might benefit from coloured 
formulations with sufficiently wide film area. Similarly, patients with reduced pinch 
strength or poor manual dexterity might prefer products that are not too thin, and which 
stickiness does not interfere with the handling. 
 
1.6.5.2 Intake phase 
 
Immediately before intake, the ODF is at the closest distance from the patient’s nose. 
This is where smell plays an important role in the acceptability of the medicinal product. 
Upon positioning in the oral cavity, ODFs should possess adequate size and shape to 
fit comfortably in the patient’s mouth. They should be soft and avoid the presence of 
sharp edges, but flexibility should not hinder the correct placement. Moreover the 
adhesiveness should ensure rapid adhesion to palate but not to the lips or teeth, and 
should not be perceived as uncomfortable. 
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1.6.5.3 Oral processing phase 
 
After ODFs are placed in the mouth, they uptake saliva and start melting. This is the 
phase where taste begins to be perceived. Also, the thickness of the formulation 
changes rapidly, and if the disintegration time is long, a very thick film could result 
uncomfortable. At this stage the consistency of the ODF also changes, rapidly turning 
into a viscous fluid. This is when the sliminess, and thickening effect could become 
unpleasant. Although the swallowability of ODFs has been assessed in few articles, the 
likelihood of experiencing difficulties to swallow thickened fluids should be low.  
 
1.6.5.4 Post-swallowing phase 
 
The residual thickened liquid remaining in the mouth after swallowing, could mean that 
part of the dose has not been taken. Therefore, verifying whether there is residual 
formulation after swallowing is advisable.  
Other post-swallowing effects, such as the aftertaste and filminess could become 
relevant acceptability attributes at this stage. Sometimes the rapid salivary uptake by 
the ODF polymeric matrix may trigger a sensation of astringency or dryness in the 
mouth, that could result uncomfortable.  
 
1.6.6 In vivo and in vitro assessment of ODF acceptability attributes  
 
As the suggested method for the in vivo identification of key acceptability attributes of a 
dosage form platform has not been fully tested before, the design of a small-sample 
size, pilot human panel might inform on the reliability of the method, and on the 
appropriateness of the wording chosen. In this sense, the presence of a negative and a 
positive control attribute could help verifying and assess the reliability of the sample 
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population for the evaluation of the acceptability and sensory attributes. Among the 
proposed acceptability attributes listed in Tab. 1.4, the ease of opening, size, 
thickness, stickiness, and disintegration time are term of common use, and their 
meaning in respect to the description of ODF attributes might be more recognised and 
widely understood compared to more technical terms such as filminess or astringency. 
Moreover, panel participants could quantify the intensity of the sensory stimulus 
produced by the stickiness, and by the disintegration time. Such intensity 
evaluations/quantifications could be used to test their correlation with the formulation 
variables most likely determining them. In this respect, the disintegration time of an 
ODF is determined by the type and molecular weight of the film-forming polymer, and 
could be measured by conventional in vitro disintegration time measurement methods 
such as the petri dish method [98]. The stickiness of ODFs is normally determined by 
their composition, and in particular, by the type of film-forming polymer used [76]. In 
turn, in vitro methods allowing the quantitative measurement of tack might provide data 
in correlation with the in vivo evaluated intensity and acceptability.  
If a toolkit of in vitro methods capable of predicting the acceptability of ODF attributes 
can be developed and verified, such in vitro methodologies could be used during the 
early drug development phase, and drive the formulation development towards the 
achievement of a highly acceptable product. The present study represents a feasibility 
evaluation of the application of the proposed strategy to the ODF platform 
development. 
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1.7  Identification of knowledge gaps  
 
Poor patient acceptability has been linked to poor compliance and to risks associated 
with off-label use, manipulation, and modification of non-appropriate dosage forms. 
The assessment of patients acceptability is becoming a relevant requirement for drug 
development, particularly in special patient populations. 
There is a lack of a harmonised approach to assess the patient acceptability of 
medicinal products. Several acceptability assessment methods have been proposed, 
each exhibiting specific advantages and disadvantages. Assessment methods aimed 
at evaluating the acceptability of individual oral dosage form attributes possess the 
advantage of informing on the strategy to drive the optimisation of the drug product by 
investigating the correlation between attributes’ acceptability and formulation variables. 
In turn, the correlation with formulation variables might serve as guide for the 
development of in vitro methods for the prediction of single attributes’ acceptability, 
thus improving the overall acceptability of the medicinal product.  
The strategy for achieving such goal involves an in vivo, and an in vitro phase, each 
that must be designed and optimised according to the dosage form platform being 
analysed. The ODF is considered a patient-friendly platform, and patient acceptability 
has been assessed in different populations. However, an in-depth study on the 
acceptability of specific ODF attributes has never been conducted. 
Currently such strategy needs to be defined and tested for feasibility.  
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1.8 Scope of the thesis 
 
The main focus of this thesis was the design of a proof-of-concept study for the 
implementation of a novel strategy for the end-user acceptability assessment of ODFs. 
The strategy was developed in the context of a fragmented knowledge on patient 
medicine acceptability assessment that is currently leading to an unharmonised 
approach towards the design of assessment methods and data interpretation. The 
developed strategy is intended to simplify the patient-centric drug product design by 
providing formulation scientists with a decision-supporting tool at an early drug 
development stage, and without resorting to pre-clinical studies on human subjects. 
The strategy consists of an in vivo phase where human panel studies were conducted 
for the identification of key acceptability attributes of the ODF formulation platform; and 
of an in vitro phase, where novel or existing in vitro methods were designed or adapted 
for the prediction of ODF key acceptability attributes on the basis of correlating 
formulation variables. Some considerations on the obtained results were made with the 
purpose of further refining the strategy design and to envisage its potential 
implementation in the design of different formulation platforms and for different target 
patient populations. 
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1.9 Thesis aims 
 
The overall aims of this thesis are: 
 
1. To review the current knowledge on patient acceptability assessment methods 
(chapter 1) 
 
2. To define, test and optimise a strategy for the in vivo identification of the key 
acceptability attributes of the ODF platform (chapters 1, 2, and 5). 
 
3. To define, test and optimise a strategy for the identification, development and 
optimisation of in vitro methods with the potential to predict ODF attribute 
acceptability (chapters 1, 3 and 4).  
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Chapter 2.  Identification of key acceptability attributes of 
orodispersible films 
 
This chapter describes the identification of key acceptability attributes of the 
orodispersible film (ODF) platform by a pilot exploratory human panel carried out on 
healthy young adults. Potential film-forming polymers for ODF sample preparation were 
selected based on safety, solution pourability, film-forming, and mechanical properties. 
Four drug-free single-polymer ODF samples differing in film-forming polymer type, and 
molecular weight were prepared and presented to volunteers to assess. Four attributes 
were evaluated both when ODF samples were handled, and taken orally. Sample 
acceptability was evaluated on a five-point hedonic facial scale, whereas the intensity 
of the perceived ODF samples stickiness was determined using a four-point score 
system, and ODF samples disintegration time was measured by stopwatch. A second 
evaluation of sample acceptability was performed by the researchers using a two-point 
score system. Among all the attributes assessed, perceived stickiness and perceived 
disintegration time were found to be key acceptability characteristics of the ODF 
dosage form platform. The influence of polymer type and molecular weight on the end-
user acceptability of perceived stickiness and disintegration time was identified by 
statistical methods.  
 
Aim:  
- To identify key attributes of the ODF platform potentially affecting the end-user 
acceptability based on a pilot human panel. 
Objectives: 
- To prepare single-polymer ODF formulations differing in selected formulation 
variables. 
- To assess the suitability of the film-forming polymers by casting solution 
pourability and film-forming capability assessment. 
- To conduct a pilot human panel for the identification of ODF key acceptability 
attributes. 
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2.1  Introduction 
 
2.1.1 Existing literature on ODF acceptability 
 
Orodispersible films have been described in the literature as patient-centric dosage 
forms [11,71,77,87], however concerns remain with regards to the end-user 
acceptability, especially about appearance, taste, mouthfeel, mucosal irritation and 
mucoadhesion [77]. Visser suggested that low ODF stickiness was associated with 
poor patient acceptance in the paediatric population [99], however Hoffmann identified 
the non-tackiness of ODFs a desirable attribute [78]. According to the European 
Pharmacopoeia, orodispersible formulations should disintegrate fast, preferably in less 
than 3 minutes [100]. The pharmacopoeial guideline not only offers the parameters for 
the definition of orodispersible films, but it also indirectly points to the potential role of 
disintegration time in ODF acceptability. The existing literature offers fragmented 
information, and little work has been done on structured studies for the assessment of 
ODF acceptability.  
Moreover, the acceptability of a dosage form might change depending on the needs of 
specific target populations analysed [11,14,25,101,102]. 
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2.1.2 Attributes of the ODF platform with potential to influence the end-user 
acceptability 
 
2.1.2.1 Opening of packaging 
 
Due to the limited available literature, the selection of ODF attributes that should be 
objective of study for their influence on the end-user acceptability cannot be done 
based on published information. Alternatively, such selection should be based on the 
consideration of the whole intake process of the dosage form. ODFs are, with some 
exceptions, packaged in unit dose sealed pouches that need to be opened by the end-
user. In order to take the ODF, patients need to be able to open the packaging first. 
The packaging of medicinal products are designed to be easily opened by the end-
user, however they must also prevent non-intended users such as children, to access 
the medication [25]. In case the end-user is affected by movement disorders, lowered 
sight, or cognitive problems, he/she can experience difficulties in opening the 
packaging, seeing or understanding the opening and administration instructions. Such 
issues have been reported in several published documents, and research papers 
[17,103,104], mostly in relation to the older patient population. In 2015, Braun-Munker 
and Ecker adapted the International Organisation for Standardisation (ISO) standard 
CEN/TS 15945 to assess the ease of opening for blisters [45,105]. The methodology 
involved the evaluation of three parameters: Efficiency, effectiveness, and satisfaction. 
Efficiency was defined as the ability of the assessor to acquaint him/herself with the 
packaging and its opening mechanisms, and then open it within five minutes. 
Effectiveness was defined as the ability of the assessor to open a second packaging, 
identical to the previous one, within one minute. Finally, the satisfaction was rated by 
the assessor using a bipolar five-step scale ranging from -2 (very poor) to +2 (very 
good) [45]. A similar approach could be used to assess the ease of opening for ODF 
pouches. 
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2.1.2.2 ODF intake 
 
After opening, ODFs must be handled by the end-user in order to remove them from 
the packaging, and take them to the mouth, as prescribed. This process requires eye-
hand coordination, processing of the visual inputs, and their translation into a 
coordinated movement of arms, hands and fingers [106]. In this phase, attributes such 
as size [71] and thickness of ODFs might play a significant role, especially for special 
patient populations affected by movement disorders, or lowered sight. ODFs that are 
too small in size or too thin/thick might make the picking process less easy. Colour [71] 
and opacity might also play a significant role in the identification of the ODF shape 
against the background of the packaging, or in determining acceptability. ODF intake 
instructions usually advise to ensure that the hands of the end-user are dry. Such 
instructions are specified in order to avoid issues related to the premature moistening 
of ODFs by the sweat because, in order to undergo disintegration in the mouth, the 
film-forming polymers, and thus the resulting film, must have hygroscopic properties. 
Should such moistening occur, the ODF would be likely to become sticky as a result of 
the initiation of the dissolution process, and interfere with the correct handling.  
 
2.1.2.3 Oral processing 
 
Once placed in the mouth, ODFs are wet by the saliva, and may or may not adhere to 
the tongue or palate. ODF adherence to the oral mucosa might also be more or less 
prolonged, and could last until disintegration. Size and thickness of the ODFs might be 
perceived as more or less comfortable also inside the mouth, and, of course, the 
duration of the disintegration time might also be perceived as uncomfortable, if 
prolonged.  
The dominant attribute of the disintegrating film, although this has never been studied 
in vivo, is probably the taste [71]. Many published studies focused on the 
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implementation of taste-masking technologies in ODF formulations, in order to 
minimise the effects of the unpleasant taste of the active pharmaceutical ingredient 
(API) [95,107–109]. Taste acceptability depends on many factors: type of API, and 
addition of sweeteners or flavours to the formulation [110]. Many other ODF attributes 
could be influencing the end-user acceptability, particularly those in relation to 
mouthfeel. A specific terminology is often used to describe mouthfeel attributes of food 
products, and can be adapted to describe mouthfeel attributes of ODFs. However, 
such terminology might be too specific and poorly understood by non-trained panellists, 
and therefore not always suitable for the assessment of ODF attribute acceptability by 
patients or non-trained end-users. Each of the previously described ODF attributes 
could have a significant impact on the end-user acceptability, however not all of them 
can be safely tested in an in vivo study. In fact, safety concerns might be raised if the 
size of the tested ODFs causes choking if accidentally aspirated [111]. On the other 
hand, smaller ODFs might further limit the maximum amount of API that can be 
administered. Also, because of their adhesive properties, ODFs loaded with APIs 
cannot be completely spat out until dissolution by the assessors, and some, if not all 
the API loaded in the film, is therefore absorbed. Thus, safer protocols for the in vivo 
assessment of ODF taste must be optimised before such study can be safely 
conducted.  
An intensity evaluation of the tested ODF attributes should ideally lead to the 
identification of formulation parameters that can control such attribute intensity. For 
example, the time to disintegration was suggested to be a function of the chain length 
of the film-forming polymer used [112,113]. Therefore, by selecting polymers with 
different molecular weights, a difference in the perceived disintegration time of the 
resulting ODFs should be observed. A similar example involves the role of different 
polymeric types [76], and molecular weight [109] in the adhesiveness, and therefore 
perceived stickiness, of the tested ODFs, based on their mucoadhesive behaviour. 
Finally, avoiding a biased evaluation by the assessors is also another important factor 
to consider in the design of an in vivo study. Understanding in advance what can bias 
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the mouthfeel evaluation of ODFs is not an easy task, however there is the risk that 
coloured vs. plain, clear vs. opaque, sweetened vs. unsweetened, and flavoured vs. 
unflavoured ODFs might lead assessors to be influenced in the evaluation of other 
attributes [114,115]. In order to limit the risk of obtaining a biased outcome, and to limit 
the burden on participants, only a limited number of attributes were studied, and clear, 
unsweetened, unflavoured, ODFs were used. Moreover, in order to easily identify the 
manufacturing variables influencing the acceptability attributes analysed, any 
excipients with the potential to affect attribute perception were excluded from the 
formulation, leading to the preparation of single-polymer ODFs. 
 
2.1.3 Sensory evaluation methods 
 
The target population studied was composed exclusively of healthy young adults. 
Hedonic scales have been proven to be good instruments for the acceptability 
assessment of the organoleptic properties of foods [69], and pharmaceutical products, 
especially in children [6,35], however they were mostly used for the evaluation of the 
overall acceptability or palatability, with no evaluation of a set of specific attributes. A 
score point system defined medicine acceptability scale (MAS) has been also used to 
assess ODF acceptability in infants and pre-school children [71] that could not reliably 
express preferences. The intensity of a perceived attribute has been evaluated by 
using a ranking system [116]. To explore other potential attributes affecting the 
acceptability of ODFs, a semi-structured interview would allow gathering the personal 
feedbacks of participants on the administered test ODFs, potentially identifying relevant 
ODF attributes that were perceived as desired or uncomfortable, and were not 
evaluated using the scales. 
A combination of such scaling systems presented in a plain-worded questionnaire 
should lead to the optimisation of a method for the assessment of both the end-user 
acceptability and intensity of specific ODF attributes, and to address the questionnaire 
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to target populations that can clearly express their preferences, or that may be too 
young or encountering difficulties in so doing.  
 
2.1.4 Identification of suitable film-forming polymers for ODF in vivo testing 
 
Once the characteristics of the test ODFs have been identified, an additional selection 
step must be taken in order to ensure the safety of the materials used for human 
testing. In this regard, film-forming polymers must be available as excipient grade 
suitable for oral consumption, complete with all the safety data on oral toxicity in 
animals and humans. Participants safety is paramount in in vivo studies, and the used 
materials must be administered in amounts that are well below the acceptable daily 
intake (ADI), and must avoid causing undesired reactions or side effects. Moreover, 
given the hypothesis of the potential influence of polymeric type and molecular weight 
on the acceptability of perceived stickiness and disintegration time, the polymers must 
be available in a variety of chain lengths. Considering all the restrictions applied for the 
selection of suitable polymers, the chances of finding polymers capable of forming films 
by themselves are low. Therefore, a further screening of a range of molecular weight, 
polymeric concentrations, and casting volumes was necessary.  
  
 62 
2.2 Materials and methods 
 
2.2.1 Materials 
 
Four drug-free single-polymer ODF samples were prepared by solvent casting. 
Poly(vinyl) alcohol (PVOH), and carboxymethylcellulose (CMC), each in two different 
grades were used. Each PVOH grades had the same degree of hydrolysis (85-89%), 
but differed in molecular weight, whereas CMC grades differed in molecular weight and 
degree of substitution (DS). Emproveâ PVOH 4-88 (39 kDa), and 40-88 (197 kDa) 
were purchased from Merck-Millipore (Darmstadt, Germany). Blanoseâ CMC 12M31P 
(395 KDa, DS 1.2) and 7HF-PH (725 KDa, DS 0.7) were provided by Ashland 
(Wilmington, Delaware, U.S.). Metoloseâ 65SH 1500, and 90SH 4000 hydroxypropyl 
methylcellulose (HPMC) (Shin-Etsu Chemical Co., Ltd, Chiyoda-ku, Tokyo, Japan), and 
Kollidonâ 30 (30 kDa), 90 (90 kDa) polyvinylpyrrolidone (PVP) (BASF, Ludwigshafen, 
Germany), were also assessed as film-forming polymers. Sterile water for injection was 
purchased from Gibco (Grand Island, New York, U.S.). 
 
2.2.2 ODF solution preparation 
 
Polymeric powders or granules were weighted accurately and dissolved in deionised 
water until a clear solution was obtained. Granules were heated under stirring to either 
70 °C or 90 °C depending on the grade. Several concentrations were tested for each 
polymer type and grade.  
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2.2.3 Solution pourability assessment 
 
Casting solution viscosity was assessed by testing its pourability performance using a 
10 mL disposable syringe (Terumo, New Jersey, US) without needle, according to a 
modified version of the pourability test [117]. Polymeric solutions were put into the 
syringe and gently poured into a beaker. The pourability performance was evaluated by 
assigning pourability criteria corresponding to: 
 
a) Appears as a solid, does not pour 
b) Viscous liquid, pours very slowly 
c) Fluid, pours readily 
 
Solutions marked with a) were discarded, whereas solutions marked with b) or c) were 
further evaluated for film-forming capability. 
 
2.2.4 ODF sample preparation by solvent casting 
 
Selected solutions were used for ODF sample preparation by solvent casting [118]. A 
15 x15 cm polyvinyl chloride sheet (PVC) (Tierrafilm - Nac Industrial, London, U.K.) 
was positioned on the plane of a hot plate (IKA Labotechnik, Staufen, Germany) that 
was previously levelled carefully. A silicone ring with an 8 cm internal diameter 
(Shenzhen Yimeifen Technology, Guangdong, China) was placed in contact with the 
PVC sheet, and a weight was added in order to eliminate any gaps between the ring 
and the sheet. A solution volume of 7.5 mL or 15 mL was measured using a 10 mL 
syringe without needle, and poured onto the acetate sheet, and inside the silicone 
mould, and carefully spread to the whole area of the silicone ring. The film was left to 
dry at 50 °C. The formed film was then peeled off the acetate sheet and stored until 
use. Depending on the following use, manufacturing and storage conditions changed 
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accordingly. For laboratory-based experiments, films were wrapped in aluminium foil, 
and stored in a desiccator maintained at low relative humidity with phosphorous 
pentoxide (Sigma-Aldrich, Gillingham, U.K.), at room temperature for at least one 
week. Then, films were equilibrated at room humidity for two hours before testing. For 
human panel test samples, solutions and films were prepared in a class II clean room, 
using purposely dedicated sterile or food-compatible materials, and with operators 
wearing appropriate food manufacturing clothing. Dry films were vacuum sealed and 
stored in a dedicated container at room temperature until two hours before the 
assessment. 
 
2.2.5 Film-forming capability assessment 
 
The film-forming capability of polymers was assessed by visual inspection, and 
evaluated based on several criteria. Factors such as brittleness, adhesion to the 
substrate, homogeneity, existence of lumps, and ease of peeling were also assessed. 
A positive or negative evaluation (+ or -) was given for each characteristic inspected, 
and only the films receiving positive evaluation in all criteria were selected for the 
following studies.  
 
2.2.6 ODF thickness measurement 
 
The thickness of the ODF samples was measured in five different locations, as shown 
in Fig. 2.1, using a thickness gauge (Mercer Ltd, Manchester, U.K.). The method was 
adapted from Liew and colleagues [60]. 
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Figure 2.1: ODF thickness measurement areas. 
 
2.2.7 Pilot human panel on healthy young adults 
 
2.2.7.1 ODF acceptability study 
 
A pilot single centre, single blind, crossover human panel study was designed in three 
sessions, each taking place in a different day, in order to gain insight into the reliability 
of the method. Volunteers who accepted to participate in the study were asked to 
attend all the three sessions.  
The study was approved by the University College London (UCL) Research Ethics 
Committee (REC ID 8249/001) on 10th October 2016. All the relevant information on 
study design, safety data of all the excipient used for the preparation of the samples, 
manufacturing process and storage, target participant cohort, recruitment process, and 
assessment conditions was provided in the REC application (Appendix 1). 
Authorisation for personal data collection, handling, and storage was granted by the 
UCL Data Protection Office (Data Registration Number: Z6364106/2016/08/68), and 
conducted in compliance with the Data Protection Act 1998. Participants were informed 
on how their data were handled, and on how the results of their assessment were 
analysed, presented, and distributed. A Participant Information Sheet (PIS) containing 
all the details of the study, including eligibility criteria, composition and safety 
information of the ODF samples, and assessment tasks, was provided to each 
participant (Appendix 1), and any question or concern was addressed promptly. Before 
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the study, the details of the assessment were explained verbally, and a consent form 
was signed by each participant. 
 
2.2.7.2 Study participants and inclusion/exclusion criteria 
 
The sample size was selected based on the work published by Thyssen and 
colleagues [119]. The panel described in Thyssen’s work involved a sensory attribute 
assessment of a pharmaceutical dosage form on a five-point step scale [119]. Male or 
female volunteers able to speak and understand English were included in the present 
study. Volunteers who had received dental care in the 15 days preceding the study, 
anaesthetics into the mouth in the 24 hours preceding the study, or volunteers taking 
medicines altering salivation, with any known hypersensitivity to excipients, or affected 
by sensory disorders of the mouth were excluded from the study. 
 
2.2.7.3 Study design  
 
The design of the study is summarised in Figure 2.2. In each session, participants 
received four single-polymer, coded ODF samples, (composition and coding shown in 
Tab. 2.6) presented in a randomised sequence [36].  
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Figure 2.2: Flow chart of pilot human panel study (Figure from Scarpa et al., 2018) [120]. 
 
Participants were instructed to take the sample, place it on top of their tongue, and 
immediately start the stopwatch that they were provided with before the start of the 
study. They were asked to stop the stopwatch as soon as they perceived that the 
sample film had completely dissolved.  
 
2.2.7.4 Data collection 
 
During sample assessment, a researcher took note of the participants’ intake 
performance and their reaction to the sample on a two-point medicine acceptability 
scale (MAS) [121], following the criteria listed in Tab. 2.1. The researcher’s feedback 
was regarded as Researcher-Reported Outcomes (RROs).  
 
Table 2.1: Researcher-Reported Outcomes (RROs) of sample intake performance, and participants reaction 
to sample on MAS scale. 
Points Facial expression 
outcome 
Jaw movement outcome Sample intake 
outcome 
0 
Signs of distress (grimacing, 
squinting eyes, etc…) 
More than 3, or repeated chews, or 
observed tongue movements 
Sample spit out 
completely 
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1 No facial expression 1 to 3 chews until swallow 
Sample spit out with 
partial loss 
2 
Positive face or other signs of 
approval 
No jaw movements until swallow 
Sample swallowed 
without loss 
 
 
After the film sample had completely dissolved in the mouth, participants were asked to 
answer a questionnaire, and to rate their comfort/discomfort with respect to attributes 
such as perceived size, perceived thickness, and perceived stickiness on sample 
handling, and perceived size, thickness, stickiness, and disintegration time on sample 
intake using a five-point hedonic facial scale [6,69] (Tab. 2.2).  
 
 
Table 2.2: Five-point hedonic scale, and corresponding word anchors used for PRO evaluation. 
Facial scale 
     
Corresponding 
word scale 
Extremely 
comfortable 
Somewhat 
comfortable 
Neither 
comfortable 
nor 
uncomfortable 
Somewhat 
uncomfortable 
Extremely 
uncomfortable 
 
 
Participants were also asked to answer a multiple choice question on whether the sample 
disintegration time was less than one minute, between one and three minutes, or more 
than three minutes. After the assessment of all four samples, participants were asked to 
rank the ODFs from the least to the most sticky. Participants’ comfort/discomfort, 
perceived stickiness intensity ranking, and perceived disintegration time assessment 
were considered Participant-Reported Outcomes (PROs).   
A semi-structured interview was conducted after the assessment of each sample. 
Questions are listed in Tab. 2.3. 
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Table 2.3: Semi-structured interview conducted after each sample's assessment. 
 Semi-structured interview 
Q1 Is there anything you would like to change in this sample? 
Q2 If so, what would it be? 
 
2.2.7.5 Data analysis 
 
RRO were assigned on three items, each one that could receive a score from 0 (least 
acceptable) to 2 (most acceptable). The median scores, and interquartile range (IQR) 
assigned to each of the three items by all the twenty-four participants were calculated for 
each sample, and in each session. For each participant, the scores assigned to each of 
the three items were then summed together, and the total median MAS score, and IQR 
of all participants was calculated for each sample and in each session [71]. Sample 
comfort/discomfort PROs were converted into numerical values (1 = extremely 
uncomfortable; 2 = somewhat uncomfortable; 3 = neither comfortable nor uncomfortable; 
4 = somewhat comfortable; 5 = extremely comfortable) [70], and treated as ordinal 
variables. The median PRO values, and IQR assigned by the twenty-four participants 
were calculated for each analysed attribute, and for each session. Samples with a 
median PRO value above 3 were considered acceptable [35]. Results of the multiple 
choice question on samples disintegration time were analysed by frequency for each 
session. The stickiness ranking exercise was also interpreted by assigning numerical 
values (1 = least sticky, 4 = most sticky), and by analysing them as ordinal variables 
[116].  
Results of the semi-structured interview were analysed by counting the number of 
participants giving the same answer. 
If samples received significantly different median acceptability scores (PROs and RROs) 
for a specific ODF attribute, such attribute was considered key for its potential influence 
on the end-user acceptability. 
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To evaluate the overall end-user acceptability of the test samples, the willingness of the 
participants to take the sample was interpreted based on all the median PROs obtained 
for all attributes, and the median RROs assigned on facial expression, and the ability to 
take the sample was interpreted based on the median total scores of the jaw movements, 
and intake performance RROs.  
 
2.2.7.6 Statistical analysis 
 
Differences among sample scores were analysed using the Friedman’s test for the 
analysis of variance followed by Dunn’s post hoc test for multiple comparisons (Prism 7, 
GraphPad Software Inc., La Jolla, CA, U.S.) [122]. Sample-related effects were analysed 
using Spearman’s rank correlation coefficient (dumb variables were assigned for 
polymer types and molecular weights). 
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2.3 Results and discussion 
 
2.3.1 Selection of film-forming polymers 
 
2.3.1.1 Selection criteria for polymers 
 
Polymers most frequently used for oral film preparation were identified by literature 
search [76,78,87,98,111,123–125]. Only the polymers meeting the following criteria were 
selected to enable the human panel study, and tested for solution pourability and film-
forming capability: 
 
• Availability of a range of specified molecular weights 
• Availability of full toxicity data for short-term, and long-term animal and human 
studies, and specification of non-observed adverse effect levels (NOAEL), and 
acceptable daily intake (ADI) values 
• Availability of excipient-grade raw materials 
 
PVOH, CMC, HPMC, and PVP met the above criteria, and were assessed for solution 
pourability. 
 
2.3.1.2 Solution pourability assessment 
 
All polymer solutions were prepared using a range of different concentrations that were 
either found in the literature, or recommended by the manufacturer. Solution 
concentrations and pourability results are summarised in Tab. 2.4. 
 
 72 
Table 2.4: Pourability test of polymeric solutions. Solutions were evaluated either a) appears as a solid, does 
not pour; b) viscous liquid, pours very slowly; or c) fluid, pours readily. 
Polymer Molecular weight/grade Concentration (w/v) Pourability 
PVOH 39 KDa 1% c 
  2.5% c 
  5% c 
  7% c 
 197 kDa 1% c 
  2.5% c 
  5% b 
  7% b 
CMC 395 kDa 0.5% c 
  1% c 
  2% b 
 725 kDa 0.5% c 
  1% b 
  2% a 
HPMC 65SH 2% c 
  4% c 
 90SH 2% c 
  4% b 
PVP 30 kDa 2% c 
  5% c 
 90 kDa 2% c 
  5% b 
 
 
For the purpose of solvent casting ODF manufacturing in a non-industrial setup, only 
solutions appearing as solids, and therefore identified as non-pourable from the syringe, 
were excluded from film-forming capability testing. 
 
 
 
 
 73 
2.3.1.3 Film-forming capability 
 
The results of film-forming capability assessment are summarised in Tab. 2.5. Of all the 
polymers and grades tested, only PVOH, and CMC could form films with acceptable  
flexibility, homogeneity, and ease of peeling, and adhesion to substrate, however only at 
the concentration of 1% w/v. Lower and higher concentrations resulted in films that were 
poorly elastic and brittle. HPMC 65SH, at a concentration of 4% w/v formed a 
homogeneous, flexible film as opposed to other HPMC grades and concentrations, 
where the formation of lumps was often observed. However, the drying time of 4% HPMC 
65S was much longer than that of other polymers, and less suitable for experimental 
testing. Moreover, only one HPMC grade was found to possess film-forming capability, 
therefore, the comparison with different molecular weights/grades was not possible. PVP 
90 kDa 5% produced a film that was difficult to peel off due to the high adhesion of the 
polymer to the PVC sheet. Other PVP molecular weights and concentrations resulted in 
brittle films. 
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Table 2.5: Film-forming capability of selected polymers and molecular weight/grades. Films were assigned 
+ where the characteristic assessed was acceptable, and - where not acceptable (b = brittle; a = strong 
adhesion to the substrate). 
Polymer Molecular 
weight/grade* 
Concentration 
(w/v) 
Flexibility Homogeneity Ease of 
peeling 
PVOH 39 KDa 1% - + - (b) 
  2.5% - + - (b) 
  5% + + + 
  7% + - + 
 197 kDa 1% - + + 
  2.5% + + + 
  5% + + + 
  7% - - + 
CMC 395 kDa 0.5% - - - 
  1% + + + 
  2% - + - 
 725 kDa 0.5% - + - 
  1% + + + 
HPMC 65SH 2% + - - (b) 
  4% + + + 
 90SH 2% + - - (b) 
  4% - - - (b) 
PVP 30 kDa 2% - - - (b) 
  5% - - - (b) 
 90 kDa 2% - + - (b) 
  5% + + - (a) 
 
* HPMC molecular weight was not specified by the manufacturer, however, each grade is 
associated with a specific solution viscosity. In turn, solution viscosity depends on polymeric 
molecular weight, which is controlled during manufacturing. 
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2.3.2 Thickness  
 
The thickness of single-polymer ODF samples is reported in Table 2.6. PVOH, HPMC, 
and PVP-based films had average thickness values ranging between 69 and 77 µm, 
whereas CMC-based samples had a thickness comprised between 35 and 44 µm.  
 
Table 2.6: Thickness values of the polymeric films prepared with polymers selected for film-forming capability 
(n = 3). Results are expressed as mean and standard deviation. 
 Molecular weight/grade* Concentration (w/v) Thickness (µm) 
PVOH 39 KDa 5% 75.95 ± 4.62 
 197 kDa 5% 76.55 ± 6.82 
CMC 395 kDa 1% 34.26 ± 9.42 
 725 kDa 1% 30.05 ±10.02 
HPMC 65SH 4% 69.41 ± 6.98 
PVP 90 KDa 5% 75.83 ± 3.47 
 
 
2.3.3 Exploratory pilot study on the mouthfeel evaluation of ODF 
 
2.3.3.1 ODF sample composition for human panel 
 
Based on the film capability assessment of the single-polymer ODFs, PVOH, and CMC-
based films were selected for in vivo evaluation. The composition and coding of the four 
samples is summarised in Tab. 2.7. 
 
Table 2.7: Coding and composition of ODF samples selected for in vivo studies. 
 P1 P2 C1 C2 
PVOH (39 kDa) 5% (197 kDa) 5% - - 
CMC - - (395 kDa) 1% (725 kDa) 1% 
Solvent water water water water 
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Casting volume (mL) 7.5 7.5 15 15 
Thickness (µm) 74.4 ± 2.3 76.8 ± 6.4 24.2 ± 2.7 25.1 ± 4.3 
 
 
2.3.3.2 Demographics 
 
Twenty-four healthy young adults aged between 18 and 35 years took part to the study. 
Participants were divided in two groups, each taking the assessment in different days. 
Each participant assessed the same set of samples in a different order in three 
assessment days. Demographic data are summarised in Tab 2.8. Participants’ mean 
age of was 25.5, the 37.5% of participants were male, and 62.5% were female.  
 
Table 2.8: Demographic characteristics of study participants. 
Group N Age (Mean ± SD) Gender % 
Group 1 9 28.78 ± 4.66 
M = 44.5% 
F = 55.5% 
Group 2 15 23.53 ± 4.56 
M = 33.4% 
F = 66.6% 
Total 24 25.5 ± 5.19 
M = 37.5% 
F = 62.5% 
 
 
2.3.3.3 Participant Reported Outcomes 
 
During and after the study, participants did not report any adverse reaction related to 
samples intake or discomfort. The PRO and RRO median values and IQR relative to the 
four analysed samples and collected during the three sessions are summarised in Tab. 
2.8, and Fig. 2.3. Statistically significant differences between samples and among 
sessions are tabulated in Tab. 2.9. 
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Table 2.9: PRO and RRO median and IQR values for each sample presented by attribute. 
                PROs 
 P1 P2 C1 C2 
 S1 S2 S3 S1 S2 S3 S1 S2 S3 S1 S2 S3 
                             Attributes perceived on handling 
Size 5  
(1) 
5 
(1) 
5 
(1) 
5 
(1.75) 
5 
(1) 
5 
(1) 
4 
(1.75) 
5 
(1) 
4.5 
(1) 
5 
(1) 
4 
(1) 
5 
(1) 
Thickness 4 
(1) 
5 
(1) 
4.5 
(1.75) 
4 
(2) 
4 
(1) 
4 
(1.75) 
4 
(1) 
4 
(1.75) 
4.5 
(1) 
5 
(1) 
5 
(1) 
5 
(1) 
Stickiness 5 
(1) 
5 
(1.75) 
5 
(1) 
5 
(2) 
5 
(1) 
5 
(1) 
5 
(1) 
4 
(1.75) 
5 
(1) 
5 
(2) 
5 
(1.75) 
5 
(1) 
 Attributes perceived on intake 
Size 5 
(1.75) 
5 
(1) 
4 
(1) 
4 
(1.75) 
4 
(1) 
4 
(2) 
5 
(1) 
5 
(1) 
5 
(1) 
5 
(1) 
4.5 
(1) 
5 
(1) 
Thickness 4 
(2) 
4.5 
(1) 
4 
(2) 
3.5 
(2.5) 
3 
(2) 
3 
(2) 
4.5 
(1) 
4.5 
(1) 
4 
(1) 
4 
(1) 
4 
(1) 
4 
(2) 
Stickiness 5 
(1.75) 
4.5 
(1) 
4 
(1.75) 
2 
(2) 
2.5 
(2) 
3 
(2) 
3 
(2) 
3 
(2) 
2 
(2) 
2 
(2) 
3 
(2) 
2 
(1.75) 
Disintegrati
on time 
5 
(1) 
5 
(0) 
4 
(2) 
2 
(1) 
2 
(2) 
2 
(1.75) 
3 
(2) 
4 
(1.75) 
4 
(2) 
3 
(2) 
2.5 
(2) 
2 
(1) 
 Attribute intensity 
Stickiness  1 
(1) 
1 
(1) 
1 
(1.75) 
3 
(2) 
3 
(1.75) 
2.5 
(2) 
3 
(2) 
2.5 
(1) 
3 
(1) 
3 
(2) 
3 
(1) 
3 
(2) 
                RROs 
 P1 P2 C1 C2 
 S1 S2 S3 S1 S2 S3 S1 S2 S3 S1 S2 S3 
Facial 
expression 
1 
(1) 
1 
(1) 
1 
(1) 
1 
(1) 
1 
(0.25) 
1 
(1) 
1 
(0) 
1 
(0) 
1 
(0.25) 
1 
(1) 
1 
(0) 
1 
(1) 
Jaw 
movements 
1 
(1.25) 
1.5 
(2) 
1 
(1) 
0 
(0) 
0 
(0) 
0 
(1) 
1 
(1) 
1 
(1) 
1 
(1) 
1 
(1) 
1 
(2) 
0 
(0) 
Sample 
intake 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
RRO total 4 
(1) 
4 
(1) 
4 
(1) 
3 
(1) 
3 
(0.75) 
3 
(2) 
4 
(2) 
4 
(1) 
3.5 
(1) 
3.5 
(1) 
4 
(2) 
3 
(1.75) 
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 Attributes perceived on handling PROs 
 Session 1 Session 2 Session 3 
Size 
   
Thickness 
   
Stickiness 
   
 
 Attributes perceived on intake PROs 
 Session 1 Session 2 Session 3 
Size 
   
Thickness 
   
Stickiness 
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Figure 2.3: Box and whiskers plot of PROs and RROs presented by ODF sample and session. The line in 
the middle indicates the median, yellow rectangles represent 95% confidence interval, lower and upper 
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margins of the boxes represent the 25th and 75th percentile, and bars indicate the maximum and minimum 
values. Statistical differences between samples are indicated by the horizontal bars, and p-values are 
represented by the asterisks. 
 
Table 2.10: Statistical differences between samples and among sessions of PROs and RROs. 
         PROs 
 Session 1 Session 2 Session 3 
 Perceived ODF size  
 P2 C1 C2 P2 C1 C2 P2 C1 C2 
P1 - - - - - - - - - 
P2  - -  - - - - - 
C1   -   - - - - 
 Perceived ODF thickness 
 P2 C1 C2 P2 C1 C2 P2 C1 C2 
P1 - - - p<0.05 - - p<0.01 - - 
P2  p<0.05 -  p<0.05 -  - - 
C1   -   -   - 
 Perceived ODF stickiness  
 P2 C1 C2 P2 C1 C2 P2 C1 C2 
P1 p<0.01 - p<0.01 p<0.01 p<0.05 p<0.05 - p<0.001 p<0.001 
P2  - -  - -  - - 
C1   -   -   - 
 Perceived ODF disintegration time 
 P2 C1 C2 P2 C1 C2 P2 C1 C2 
P1 p<0.0001 - p<0.01 p<0.0001 - p<0.0001 p<0.001 - p<0.001 
P2  p<0.01 -  p<0.01 -  p<0.001 - 
C1   -   -   p<0.001 
 Perceived ODF stickiness intensity 
 P2 C1 C2 P2 C1 C2 P2 C1 C2 
P1 p<0.05 p<0.01 p<0.01 p<0.05 p<0.05 p<0.0001 p<0.05 p<0.05 p<0.05 
P2  - -  - -  - - 
C1   -   -   - 
 RROs 
 P2 C1 C2 P2 C1 C2 P2 C1 C2 
P1 p<0.01 - - p<0.001 - - p<0.05 p<0.01 - 
P2  p<0.001 p<0.05  p<0.001 -  - - 
C1   -   -   - 
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2.3.3.3.1 Attributes perceived on handling 
 
Among all the ODF characteristics analysed, size perceived on handling, thickness 
perceived on handling, and stickiness perceived on handling were all evaluated 
somewhat comfortable by the participants, with no significant differences between ODF 
samples (Tab. 2.9, Fig. 2.3). 
 
2.3.3.3.2 Negative control attribute: perceived ODF size on intake 
 
The size perceived on intake (Tab. 2.9, Fig. 2.3) was evaluated between somewhat 
comfortable, and extremely comfortable by participants, with no significant differences 
among samples (Tab. 2.10). The size of all the test ODF samples was 6 cm2, and was 
kept constant in all samples. This attribute was therefore treated as a negative control to 
evaluate the reliability of the test method, and to confirm that the magnitude of the 
stimulus perceived by participants was fairly constant for identical administered stimuli.  
 
2.3.3.3.3 Positive control attribute: perceived ODF thickness on 
intake 
 
The ODF sample thickness perceived on intake was evaluated between somewhat 
comfortable to extremely comfortable in all samples except for sample P2, which was 
evaluated between neither comfortable nor uncomfortable and somewhat comfortable 
(Tab 2.9, Fig. 2.3). Significant differences were found between samples C1 and P2, only 
in the first and second session (Tab. 2.10).  
There was a difference in actual thickness between the CMC-based ODF samples 
(approximately 20 µm), and PVOH-based ODF (approximately 70 µm) samples, with C1 
being the thinnest, and P2 the thickest. Therefore, a difference in thickness perceived 
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between such samples was expected. However, due to the in-house ODF manufacturing 
method, the actual thickness of the samples for human panel was subjected to 
inhomogeneity, potentially explaining differences in perceived thickness such as those 
reported for samples P1 and P2 in session 2 and 3 (Tab. 2.10). Moreover, the differences 
in perceived thickness among samples were not reported in all the sessions, further 
confirming the potential role played by the inhomogeneity of samples thickness. 
Results of the semi-structured interview also evidenced the different perception in 
thickness between samples made of the two polymeric species reported by participants 
(Tab 2.11). An average of 5.0, and 8.7 participants complained about the high thickness 
of samples P1 and P2 respectively, whereas 5.3, and 2.7 participants on average 
reported that the thickness of samples C1 and C2 needed improvement, but for the 
opposite reason. This observation was often associated with reports of high levels of 
stiffness for samples P1 and P2, but not for C1 and C2. Therefore, observed sample 
characteristics such as high stiffness, high thickness, and inhomogeneity might have 
been all reflected in the perceived thickness PRO. Overall, the perceived thickness of 
the four ODF samples was considered between somewhat comfortable and extremely 
comfortable except for sample P2, however a difference in the perceived thickness 
among the two polymeric species was identified in the semi-structured interview. These 
findings suggested that the perceived thickness was probably not the most appropriate 
attribute to be used as positive control under the current manufacturing method, as its 
comfort/discomfort did not correspond with the actual thickness of the samples. An 
improvement in the manufacturing conditions might reduce variability or a different 
acceptability attribute should be chosen as positive control for the in vivo method.  
  
 83 
2.3.3.3.4 Perceived ODF stickiness on intake 
 
With regards to the stickiness perceived in the mouth sample P1 was evaluated between 
somewhat comfortable and extremely comfortable. Samples C1, C2, and P2 were 
considered between neither comfortable nor uncomfortable, and somewhat 
uncomfortable (Tab. 2.9; Fig. 2.3). Significant differences were found between C1 and 
P1, between C2 and P1, and between P1 and P2 (Tab. 2.10). 
Only the difference between C2 and P1 was reported by participants in all the three 
sessions, and was therefore considered a robust outcome.  
The most sticky sample in terms of intensity was C2, followed by C1, P2, and P1 (Tab. 
2.9, Fig. 2.3). Significant differences were found between C1 and P1, between C2 and 
P1, and between P1 and P2 (Tab. 2.10). 
Perceived stickiness PROs were further confirmed by the semi-structured interview, 
where between 12 and 19 participants pointed the need for improvement with regards to 
the stickiness of samples P2, C1, and C2, and between 2 and 4 participants for sample 
P1 (Tab. 2.11).  
The resulting PROs on ODF sample perceived stickiness suggested that the higher was 
the perceived stickiness of the sample, the lower was its acceptability score, with the 
exception of sample C1, which acceptability varied among sessions. However, an 
average of 14 or 15 participants per session indicated that the stickiness of C1 required 
improvement, further pointing to the sample’s low acceptability. 
The stickiness perceived in the mouth is also described as mucoadhesion in the literature 
[126–128], and its mechanisms are mediated by various theories [128], but no conclusive 
research to elucidate the mucoadhesive interaction has been conducted. It appears that 
mucoadhesion phenomena are mostly mediated by surface and interfacial properties 
[126,128], and are less likely to be influenced by the inhomogeneity of polymer 
concentration in the ODF volume compared to other ODF attributes. 
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Adhesion to the oral cavity surface is a desired and essential attribute for buccal films in 
order to favour the permeability of the API through the oral mucosa, to the point that its 
adhesive properties are often evaluated in vitro [127–133]. ODF or oral films not 
necessarily exhibit adhesive properties, and the strength of the adhesion is potentially 
linked to the molecular weight range of the film-forming polymer used [76]. The impact 
of adhesion on the ODF end-user acceptability has not been thoroughly explored. In a 
study conducted by Visser and colleagues, the poor adhesion of ODFs to the tongue or 
palate was associated with poor acceptance in adults [99]. The present study showed, 
on the contrary, that low stickiness was associated with high acceptability in the adult 
population, although due to the limited number of tested samples, a conclusive 
correlation could not be ruled out. Nevertheless, the very different methodology, and 
testing ODFs samples could potentially explain the different results obtained in the two 
studies.  
Because the perception of ODF stickiness differed among the tested samples in the 
present study, such attribute could potentially influence on the end-user acceptability.  
 
2.3.3.3.5 Perceived ODF disintegration time 
 
The disintegration time of the test ODF samples was considered between neither 
comfortable nor uncomfortable and extremely comfortable for C1 and P1, and somewhat 
uncomfortable for C2 and P2, suggesting the influence of the polymeric molecular weight 
on the perception of film disintegration time (Tab. 2.9; Fig. 2.3). Significant differences 
were found between C1 and C2, C1 and P2, C2 and P1, and P1 and P2 (Tab. 2.10).  
All the differences among samples were found in all the three sessions with the exception 
of C1 vs. C2, suggesting that also the perceived disintegration time has the potential to 
influence the end-user acceptability.  
Sample P1 was reported to disintegrate in less than 1 minute by participants in sixty-
eight tests, between 1 and 3 minutes in four tests, and more than 3 minutes in zero tests 
 85 
(Fig. 2.3). C1 disintegrated in less than 1 minute in fourty-nine tests, between 1 and 3 
minutes in twenty-three tests, and more than 3 minutes in zero tests. C2 disintegrated in 
less than 1 minute in nineteen tests, between 1 and 3 minutes in fourty-six tests, and 
more than 3 minutes in seven tests. P2 disintegrated in less than 1 minute in eight tests, 
between 1 and 3 minutes in fourty tests, and in more than 3 minutes in twenty-four tests.  
Around twelve participants reported the need to improve the disintegration time of 
samples P2 and C2, while only three participants reported so for sample C1, and none 
for sample P1 (Tab. 2.11). Taken together, all PROs collected on disintegration time 
suggested that the shorter the disintegration time, the higher its acceptability, and that 
low-molecular weight polymeric films were considered more acceptable than their high-
molecular weight counterparts. 
Disintegration time is a key attribute to the ODF platform performance. ODF 
disintegration time is often measured in vitro for quality assurance purposes, and it is 
mentioned in the European Pharmacopoeia as the identification criterion of 
orodispersible formulations [100]. Few literature works evaluated the disintegration of 
oral dosage forms in vivo [119,134–137], and almost exclusively in terms of quantitative 
rather than qualitative terms. The disintegration time of ODFs should ideally be shorter 
than 3 minutes [100]. Links between the oral processing time of foods and the 
intensity/dominance of other attributes such as flavour, stickiness, grittiness, and its 
dependence on the physicochemical properties of the food was reviewed extensively by 
Foster and colleagues [138]. The disintegration/dissolution time of solid dosage forms 
was indicated as critical acceptability attribute in the paediatric population [6], however 
little is known about the direct relationship between processing time and palatability of 
medicines in the oral cavity.  
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2.3.3.4 Semi-structured interview 
 
Additional ODF attributes emerged from the participants’ feedback obtained by semi-
structured interview (Tab. 2.11). ODF taste is notoriously known to affect the end-user 
acceptability, especially in the paediatric patient population [6,78]. Ideal ODF film-
forming polymers are supposed to have a neutral taste that does not contribute to the 
overall mouthfeel. Surprisingly, the taste of the CMC-based ODF samples was reported 
to require improvement, although no API or flavours were added to the formulation. Also 
the CMC-based ODF samples were reported to have a “drying” effect on the tongue, and 
to thicken the participants saliva during dissolution. Such characteristics agreed well with 
the reported water retention, and thickening characteristics of CMC [139]. Other 
characteristics of the test ODF samples that were pointed by participants were the 
tendency of almost all samples to form aggregates or lumps during disintegration, and 
their inhomogeneity. In particular, inhomogeneity was referenced to the tendency of one 
part of sample P2 to dissolve faster than the rest, confirming the thickness inhomogeneity 
issues arising due to in-house manufacturing process. 
 
Table 2.11: Semi-structured interview results expressed as number of participants who gave the same 
answer. 
Participants 
comments 
P1 P2 C1 C2 
Session S1 S2 S3 S1 S2 S3 S1 S2 S3 S1 S2 S3 
Stiffness needs 
improvement (sharp 
edges) 
6 7 5 5 5 5 - - - - - - 
Disintegration time 
needs improvement 
- - - 9 12 14 4 2 4 10 11 11 
Taste needs 
improvement 
2 2 - 1 1 6 6 6 4 5 3 3 
Stickiness needs 
improvement 
4 3 2 14 12 12 14 15 15 18 13 19 
Thickness needs 
improvement 
6 5 4 11 8 7 6 7 3 3 2 3 
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Size needs 
improvement 
2 1 - 1 - 1 1 1 - 1 - - 
It has a thickening 
effect on saliva 
- - - - 2 3 7 4 5 9 8 3 
Brittleness needs 
improvement 
- - - - - - 2 1 2 - 2 - 
Tendency to 
fold/form lumps 
- 4 4 5 5 8 1 2 1 8 5 11 
Inhomogeneity (one 
part dissolved 
faster) 
- 1 2 6 5 3 2 - 1 1 - 1 
It dries the mouth - - - - - 1 1 1 2 2 2 4 
It feels rough - - - - - - - - - - 1 - 
Shape needs 
improvement 
- 1 - 1 1 - - - - - - - 
 
 
2.3.3.5 Researcher Reported Outcomes and overall acceptability 
 
RROs and MAS median values are reported in Tab. 2.9, and graphed in Fig. 2.3. 
The maximum total MAS score per sample was 6. The highest total MAS scores of 4 
was assigned to sample P1, followed by C1, C2, and P2. Friedman’s and Dunn’s multiple 
comparisons tests on total MAS scores showed significant differences in acceptability 
between C1 and P2, between C2 and P2, between P1 and P2, and between C2 and P1 
(Tab. 2.10). Only the difference between P1 and P2 was significant in all the three 
sessions. Almost all samples received the maximum score (2) for sample intake 
performance, indicating that participants did not encounter any difficulty in taking the 
samples as instructed. With regard to the facial expression, a score of 1 was assigned 
to all samples with little variability, whereas the jaw movements determined the 
difference in MAS scores between the analysed samples. Overall, sample P1 was 
deemed the most acceptable, with the highest MAS score, and highest PROs scores, 
whereas P2 received the lowest PRO and RRO scores. Sample C2 also received low 
PROs with regards to perceived stickiness and disintegration time acceptability, but 
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higher MAS scores, whereas C1 was the most variable in terms of acceptability 
assessment.  
 
2.3.3.6 Identification of polymer type, and molecular weight effects on 
perceived stickiness and perceived disintegration time 
 
The Spearman r correlation coefficient was calculated in order to identify any polymer 
type or molecular weight effect on the perceived stickiness in the mouth, perceived 
disintegration time, and perceived stickiness intensity PROs. Results divided by session 
are reported in Tab. 2.12.  
 
Table 2.12: Spearman correlation coefficients of polymer type and polymeric molecular weight with 
perceived stickiness, perceived stickiness intensity, and perceived disintegration time PROs (n = 96). 
PRO Effect Session 
  S1 S2 S3 
Perceived stickiness 
Polymer type +0.284 
(p<0.01) 
+0.223 
(p<0.05) 
+0.394 
(p<0.0001) 
 
Molecular weight -0.365 
(p<0.001) 
-0.302 
(p<0.01) 
-0.200 
(n.s.) 
Perceived stickiness 
intensity 
Polymer type -0.354 
(p<0.001) 
-0.242 
(p<0.05) 
-0.205 
(p<0.05) 
 
Molecular weight +0.354 
(p<0.001) 
+0.326 
(p=0.001) 
+0.242 
(p<0.05) 
Perceived 
disintegration time 
Polymer type -0.071 
(n.s.) 
+0.086 
(n.s.) 
+0.047 
(n.s.) 
 
Molecular weight -0.635 
(p<0.0001) 
-0.623 
(p<0.0001) 
-0.607 
(p<0.0001) 
 
 
The type of polymer used to prepare the test ODF samples showed a weak positive 
monotonic correlation with the reported perceived stickiness acceptability, and stickiness 
intensity PROs, and no monotonic correlation with the perceived disintegration time 
PROs, with very low probability that the correlation exists. The polymeric molecular 
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weight showed a weak negative and positive monotonic correlation with perceived 
stickiness acceptability, and stickiness intensity respectively, and a strong negative 
monotonic correlation with the perceived molecular weight PROs. The correlation 
between polymer dissolution and molecular weight has been reported in the literature 
[140]. Phenomena such as polymeric chain disentanglement, availability of substitution 
groups to hydrogen bonding, and swelling properties of the polymers might have 
determined such correlation [141,142]. The weaker correlation between molecular 
weight and perceived stickiness acceptability, and intensity suggested the influence of 
other manufacturing variables or attributes.  
The Friedman’s test conducted on PROs assigned by participants to the same attribute 
showed that there was no significant difference between the three sessions. A difference 
between sessions 2 and 3 (p < 0.05) was found in the evaluation of the perceived 
disintegration time acceptability of sample P1. It must be noted that the lack of significant 
difference between sessions must not be taken as an indication of the reliability of the 
method.  
 
2.4 Conclusions 
 
Four excipient-grade polymers available in different molecular weights were used to 
prepare casting solutions at different concentrations, and tested for solution pourability. 
Out of 22 solutions, 21 were also assessed for film-forming capability. Of those, only 
PVOH (39 kDa, and 197 kDa), CMC (395 kDa, and 725 kDa), HPMC 65 SH, and PVP 
90 kDa solutions produced films with acceptable flexibility, homogeneity and ease of 
peeling. HPMC, and PVP were excluded from further analyses due to the lack of possible 
comparison between different molecular weights, therefore two CMC-based ODF 
samples were tested, together with two PVOH-based ODF samples, for in vivo 
acceptability. A single-blind, single centre, exploratory pilot human panel was conducted 
on twenty-four young healthy adults. Participants evaluated the acceptability of several 
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ODF attributes by taking orally the four single-polymer ODF samples, and by answering 
a computerised questionnaire and participating in a semi-structured interview. The 
sample perceived thickness, perceived stickiness in the mouth, and the perceived 
sample disintegration time received different acceptability scores in dependence of the 
sample analysed, and were considered attributes having the potential to influence the 
end-user acceptability of ODFs. Questionnaire results suggested that the perceived 
stickiness acceptability could be inversely correlated with the perceived stickiness 
intensity assessed by participants. Similarly, the perceived disintegration time 
acceptability seemed to show inverse correlation with the disintegration time measured 
by stopwatch. The acceptability assessment made by participants on the four samples 
was further confirmed by the researchers’ evaluation of the participants’ reaction to the 
sample, and intake performance. From the semi-structured interview, other potential 
attributes with influence on the end-user acceptability were identified. Among them, the 
thickening effect on saliva, the tendency to form lumps during disintegration, and, 
expectedly, the taste. A strong negative correlation was found between the molecular 
weight of the film-forming polymer and the acceptability of the disintegration time.  A 
weak negative correlation was found between polymeric molecular weight and the 
perceived stickiness acceptability, and a weak positive correlation between molecular 
weight and perceived stickiness intensity. Although it was not possible to assess the 
reliability of the method due to limited dataset, no significant differences on the overall 
acceptability scores assigned were found among panel sessions. Future work will entail 
the identification and optimisation of in vitro methods capable of predicting the 
acceptability of perceived stickiness and disintegration time of ODF acceptability. 
 
* Part of the data presented in chapter 2 has been published in Scarpa et al., 2018 [120]. 
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Chapter 3.  In vitro methodology assessment for the 
acceptability testing of orodispersible film attributes 
 
This chapter describes the assessment of existing in vitro methods for their predictive 
capability towards the end-user acceptability of orodispersible films (ODFs). Texture 
analysis and dynamic mechanical analysis were assessed to quantify in vitro adhesive 
characteristics and predict perceived stickiness of ODF samples. Petri dish method, drop 
method, and a mechanical oral cavity model were assessed for the in vitro quantification, 
and prediction of the acceptability of perceived ODF sample disintegration time. The in 
vitro/in vivo correlation of the data obtained informed on the potential of the in vitro 
methods to serve as a decision-supporting tool for the design of ODF formulations with 
regards to the optimisation of perceived stickiness and perceived disintegration time. 
Strengths and limitations of the assessed methods are also discussed. 
 
Aims:  
- To explore the predictive capability of existing or adapted in vitro methodologies 
for key ODF acceptability attributes based on human panel data. 
- To develop new in vitro methodologies for the prediction of key ODF acceptability 
attributes. 
Objectives: 
- To test a set of ODF samples differing in in vivo-perceived stickiness by texture 
analysis. 
- To test a set of ODF samples differing in in vivo-perceived disintegration time by 
petri dish and drop methods. 
- To adapt a mechanical oral cavity model and dynamic mechanical analyser for 
the assessment of ODF disintegration and tack respectively, and to optimise a 
novel method. 
 
 92 
3.1 Introduction 
 
The human panel to assess the end-user acceptability allowed the identification of ODF 
perceived stickiness and disintegration time as key acceptability attributes. In vitro 
methods capable of predicting the end-user acceptability of key ODF attributes should 
bring together the ability to quantify the intensity of perceived stickiness or perceived 
time to disintegration, and offer an outcome measure that correlates with the 
acceptability scores measured in vivo.  
 
3.1.1 In vitro analysis of ODF perceived stickiness 
 
3.1.1.1 The six theories of mucoadhesion 
 
In order to assess the perceived stickiness od ODFs, the test samples needed to be 
formulated with polymers with different degrees of adhesiveness [76]. 
The stickiness perceived by participants of the human panel study was referred to the 
tendency of the ODF sample to adhere to the hard palate. Such adhesive behaviour is 
likely to be mediated by the adhesive properties of the film-forming polymers used for 
ODF sample preparation [143]. The adhesion of a material to biological tissues is defined 
as bioadhesion, whereas adhesion to mucosal tissue is regarded as mucoadhesion 
[126]. Several theories proposed to explain the underlying causes of mucoadhesive 
phenomena, and a combination of such theories could actually govern mucoadhesion, 
depending on the adhesive system analysed. There are six theories of mucoadhesion. 
The electronic theory applies when there is a transfer of electrons across the adhesion 
surface of two materials. The transfer occurs because of the difference in electronic 
structure between materials, resulting in the formation of an electric double layer at the 
interface, and therefore to attractive forces [126]. The wetting theory applies to the ability 
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of liquids to spontaneously spread onto a surface. This phenomenon is regarded as a 
prerequisite for the formation of an adhesive bond [126]. The adsorption theory describes 
the adhesive bond formation as a consequence of hydrogen bonds or van der Waals 
forces between surfaces [126]. The diffusion theory describes adhesion as a 
phenomenon mediated by the interdiffusion of polymeric chains and mucins, high-
molecular weight glycoproteins present on mucosal surfaces [126]. The mechanical 
interlocking theory suggests that mucoadhesion may occur because of interlocking 
mechanisms between a liquid, and the irregularities of the mucosal surface [126]. Finally, 
the fracture theory uses the measurement of the force applied to detach two surfaces as 
indication of the adhesive bond [126]. This is the most used theory to explain adhesion 
occurring between surfaces. Every theory can be validated or disqualified for the specific 
system analysed by using specific methodologies. For example, the wetting theory can 
be tested by measuring the contact angle of the adhesive material, if the last exposes a 
solid surface. The mechanical interlocking theory can be tested by measuring the 
roughness of the adherent surface, if the adhesive is in a liquid form. However, not all 
theories can be applied to every system. 
 
3.1.1.2 Hypothesis on mucoadhesive mechanisms involved in hard 
palate/ODF adhesion 
 
Before the selection of the experimental methods to test, it is important to build a 
hypothesis based on the characteristics of the adhesive bond between ODF and hard 
palate occurring in vivo. The human hard palate is covered by a keratinized epithelium 
constituting a masticatory mucosal surface of approximately 0.2 mm thickness [144]. The 
superficial layer of the hard palate mucosa is characterised by a stratified squamous 
epithelium composed of dead cells rich in cytoskeletal elements, where keratin can 
constitute up to 85% of the total protein content [145]. Both acidic and basic or neutral 
keratin variants are expressed in hard palate keratinocytes [145], making difficult to 
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estimate the net surface charge of the palate. Little information is available on the surface 
roughness of the hard palate epithelium, however tongue surface roughness was 
reported to be high [146]. Moreover, a low salivary flow rate, and a limited presence of 
salivary proteins were noticed on the hard palate in comparison with other oral surfaces 
[147]. Surface and electrochemical properties of the palate surface can provide basic 
information on which mucoadhesion theory is more likely to explain the adhesive 
phenomena observed in ODF samples, and consequently, which techniques/methods to 
use for the assessment of ODF adhesion. In particular, mechanical interlocking is 
unlikely to be involved in the adhesive bond between ODF and palate because the 
participants to the human panel reported that films tended to adhere to the palate instead 
of the rougher surface of the tongue [71,148]. If mechanical interlocking was involved, 
ODFs would have probably adhered to the tongue instead. The diffusion theory is also 
unlikely to be responsible for ODF/palate adhesion because of the reduced salivary 
protein concentration, probably including mucins, on the palate surface compared to 
other regions of the oral cavity [147]. In some cases, despite the hypothesis of the 
involvement of a specific mucoadhesion theory could not be rejected, the method to test 
such hypothesis could not be applied to the analysed system. The measurement of water 
contact angle might have provided information on the tendency of a hydrophilic liquid 
medium such as saliva or mucus to adhere to the ODF surface, and therefore to mediate 
adhesion according to the wetting theory. However, the highly hydrophilic nature of the 
ODF samples, made impossible to obtain a stable image of the contact angle formed by 
the liquid drop deposited onto the film surface. Remaining plausible theories that could 
explain the observed ODF adhesion are therefore the fracture, electronic, and adsorption 
theories. Fracture theory was tested first. 
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3.1.1.3 Fracture theory and testing methods 
 
The most used theory in mucoadhesive phenomena is the fracture theory [126,149]. It is 
based on the mechanical measurement of the force required to separate two surfaces 
after adhesion occurs [126,150]. The force (!") is expressed as the normalisation by 
the adhesive area (#0) of the maximum detachment force (%") measured in a test for 
resistance to rupture [128], in accordance with Equation 3.1. 
 
Equation 3.1: 
 
!" =	%"#0  
The adhesive force !", can be linked to the fracture energy, and Young’s modulus 
measured by rheological methods [128], however multiple-component systems can be 
more complicated to analyse this way. Considering that the observed ODF adhesion to 
the palate is a two-component system, a simple tensile testing-type method might be 
more suitable to provide a descriptor of ODF adhesive properties.  
Various in vitro methods have been used to test mucoadhesion. In vitro/ex vivo tensile 
testing methods constituting of compressed disks of porcine mucins [151], excised 
porcine mucosa [150], or rat intestinal mucus [152], and a universal tensile tester or a 
texture analyser were employed. Other methods aimed to measure the shear strength 
of a parallel polymer/mucus sample [153]. Both perpendicular and shear stresses are 
likely to be applied to the ODF sample in the oral cavity. Non-ex vivo methods for the 
measurement of perpendicular force will be assessed first, in order to maintain the 
testing conditions as simple as possible, and avoid variability potentially introduced by 
the utilisation of animal tissue.  
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3.1.2 In vitro analysis of ODF perceived disintegration time 
 
Disintegration time is defined by the United States Pharmacopoeia as “the state in which 
any residue of the unit, except fragments of insoluble coating or capsule shell, remaining 
on the screen of the test apparatus is a soft mass having no palpably firm core” [154], 
and such definition also applies to orodispersible films. However, ODFs become soft and 
impalpable very quickly after hydration due to their polymeric nature. Hence, it might be 
complicated to identify an appropriate definition of disintegrated status for ODFs, and 
consequently, to determine a disintegration endpoint [155], and acceptability criteria.  
The perceived disintegration time was quantitatively and qualitatively evaluated by 
participants of the human panel study. Both time to disintegration and acceptability of 
the disintegration time were assessed. Whereas the disintegration time is easy to 
quantify, and can be measured using a stopwatch, its acceptability may not depend on 
time alone, and might be difficult to predict. However, in vivo disintegration time 
measurement and acceptability scores seemed to show a certain degree of 
proportionality. Therefore, a simple method for the measurement of disintegration time 
might also provide information on its acceptability in ODF samples. There is a good 
availability of in vitro methods for the quantitative measurement of disintegration time. 
According to the European Pharmacopoeia guidelines, orodispersible formulations such 
as films, should disintegrate in less than 180s, and any suitable method can be used to 
test the disintegration time [100]. Campbell and co-authors highlighted the importance 
of assessing disintegration in a system mimicking physiological conditions as closely as 
possible, in order to achieve proportionality between in vitro and in vivo rates [156]. Since 
no method is currently specified, several research groups have presented biorelevant 
methods [98,107,157–159] for disintegration testing of solid dosage forms. Such 
apparatuses, however, enable the measurement of disintegration time based on the 
ODF sample’s interaction with the disintegration medium, and applies mechanical 
stresses that do not reflect those applied in in vivo conditions. First, two “conventional” 
 97 
in vitro methods were chosen for disintegration time testing, and assessed for in vivo/in 
vitro correlation. Petri dish and drop methods differ between each other in volume of 
disintegration medium, and presence or absence of mechanical stress applied to the 
sample [107].  
 
3.1.2.1 Adaptation of in vitro mechanical oral cavity model for the 
assessment of ODF disintegration time   
 
In order to assess the disintegration time of ODF samples by application of a mechanical 
stress mimicking the in vivo condition more closely than in the petri dish method, an oral 
cavity model previously developed by the University College London Department of 
Mechanical Engineering was adapted and tested. The model was originally intended for 
the study of the flow properties  
of thickening agents during the swallowing process, and its design is shown in Fig. 3.1 
[160].  
 
Figure 3.1: Design of the mechanical oral cavity model (figure from Redfearn and Hanson, 2017). [161] 
 
As both dimensions and mechanical characteristics of the materials of the artificial mouth 
reflect the in vivo characteristics of the oral cavity, the model could be adapted to the 
study of the disintegration behaviour of ODFs. The device is composed of two fixed and 
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one mobile metallic plates capable of travelling upwards on four threaded rods by tailspin 
movement. A piece of moulded silicone with specific dimensions is accommodated on 
top of the mobile plate and secured to it. On full compression, the silicone tongue 
completely adheres to an upper acrylic plate (parallel to the mobile metal plate) 
representing the hard palate, and applies a specific pressure at different points on the 
sagittal axis. The pressure can therefore be regulated by adjusting the position of the 
mobile plate. Motion control is regulated manually by an Arduino Uno microcontroller 
equipped with buttons, a rotary knob, and a digital display, or electronically, by a 
compression cycle program purposely created using Matlab (MathWorks, Natick, MA, 
USA).   
 
3.2 Materials and methods 
 
3.2.1 ODF samples 
 
Unless specified otherwise, four drug-free single-polymer ODF samples were prepared 
in house by solvent casting as described in chapter 1. Listerine PocketPacksâ breath 
strips was purchased from Johnson & Johnson (New Brunswick, New Jersey, U.S.). The 
simulated salivary fluid was composed of potassium dihydrogen phosphate (Fisher 
Scientific, Loughborough, Leics, UK), EMSURE Ò sodium chloride (Merck-Millipore, 
Darmstadt, Germany), calcium chloride (Merck-Millipore, Darmstadt, Germany), and 
sodium hydroxide (Fisher Scientific, Loughborough, Leics, UK). 
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3.2.2 Tack measurement of ODF samples by texture analysis 
 
ODF sample tack was measured by texture analysis by adaptation of a previously 
optimised method [162,163]. A TA.XT Plus (Stable Microsystems Ltd., Godalming, 
Surrey, U.K.) equipped with a 30 Kg load cell, and a 6 mm cylindrical poly(methyl 
methacrylate) (PMMA) probe was used. ODF samples were cut to a 1 x 1 cm2 area, and 
attached to a microscope slide (Thermo Scientific, Braunschweig, Germany) with non-
conductive double-sided adhesive tape (SPI supplies, West Chester, Pennsylvania, 
U.S.). The microscope slide was then placed beneath the probe, and 200 µL of pre-
warmed distilled water (37°C) was deposited on top of the test ODF sample. The probe 
was set to lower at a speed of 0.4 mm/s, and to apply a force of 2.308 N for 12 s. The 
retraction speed was 1 mm/s. Data were analysed using Exponent software (Exponent 
v6, Stable Microsystems Ltd., Godalming, Surrey, U.K.). 
 
3.2.3 Tack measurement of ODF samples by DMA 
 
The adhesive force profile of ODF samples was measured using a Q800 Dynamic 
Mechanical Analyser (DMA) (TA Instruments Delaware, US) operating in controlled force 
mode. A set of 15 mm diameter steel compression clamps were installed and the 
instrument calibrated. ODF samples were cut to 15 mm diameter discs, and attached to 
the lower disk of the compression clamps using a non-conductive double-sided adhesive 
tape (SPI supplies, West Chester, Pennsylvania, U.S.). The clamps were kept separated 
by applying a negative force of -0.8 N until the equilibration temperature of 37 °C was 
reached. 0.45 mL of pre-warmed deionised water was deposited on top of the ODF 
sample surface, as shown in Fig. 3.2. 
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Figure 3.2: ODF adhesive force measurement experimental setup. 
 
The clamps were brought to contact by applying a force of +2.649 N (compression = 
0.015 MPa), and then immediately withdrawn by ramping the force at -25 N/min to -8 N. 
The data obtained were analysed using Universal Analysis 2000 v.4.5A (TA Instruments 
Waters LLC, Delaware, US) software by plotting the static force and displacement 
signals vs. time. The adhesive force value was taken at the intersection between the 
ordinate of the onset point of the displacement ramp and the static force curve. An 
example of resulting plot is shown in Fig. 3.3. 
 
 
Figure 3.3: Example of a sample's adhesive force calculation on the displacement and static force vs. time 
plot. 
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The adhesive force measurement was taken after 10s, 60s, 120s, and 180s from drop 
deposition. 
 
3.2.4 Measurement of the disintegration time of ODF samples by petri dish 
and drop methods 
 
For the petri dish method, ODF samples were cut to 3 x 2 cm rectangles and placed in 
a 9 cm petri dish in a 37 °C water bath under gentle shaking (70 rpm). Pre-warmed 
distilled water or simulated salivary fluid (SSF) [164] (2 mL) was deposited on top of the 
film [107] and the time to disintegration was taken when the film was observed breaking 
from the viewing area [155]. For the drop method, a piece of ODF sample was secured 
between two metallic plates with a semi-circular hole on one side, in order for part of the 
film surface to be exposed on both sides. The sandwich was positioned at 1 cm height 
and parallel to the ground. A drop of 200 µL [107] pre-warmed (37 °C) water or SSF was 
deposited on the upper surface of the film, and time was taken until the drop formed a 
hole, and fell down, as shown in Fig. 3.4. 
 
 
Figure 3.4: Example of disintegration time measured by drop method. 
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3.2.5 Measurement of the disintegration time of ODF samples by mechanical 
oral cavity model 
 
3.2.5.1 ODF sample composition for disintegration assessment by oral 
cavity model 
 
Four single-polymer orodispersible films were prepared by solvent casting following the 
method described in chapter 1. Two carboxymethylcellulose (CMC) (395 and 725 KDa), 
and two poly(vinyl) alcohol (PVOH) (31 and 197 KDa) solutions were prepared as 
described in chapter 1. A 1% v/v red food colouring agent (Waitrose Ltd, UK) was added 
to the polymeric solutions before casting. Listerineâ strips (Johnson & Johnson Inc., 
Skillman, NJ, U.S.) were also analysed.  
3.2.5.2 Adaptation of the experimental conditions for disintegration time 
measurement 
 
A swallowing frequency of one compression every 60.8 s. was initially calculated using 
the equation developed by Rudney and Larson [165]. However, a faster cycle was later 
adopted in order to avoid system overload. The compression cycle and inter-
compression lag, were set by modifying the existing Matlab code to 660 ms, and 2,000 
ms respectively. A compression distance of 16.5 cm was calculated in order to apply a 
pressure of 30 kPa at the median section of the artificial palate [166]. The artificial oral 
cavity internal volume was 12 mL prior to compression, and 0 mL on full compression. A 
Canon (Sony RX100M4) camera recording at 25 fps was installed above the artificial 
palate facing downwards so that the framing included the whole surface of the silicone 
tongue on full compression. Controlled lighting conditions were applied.  
Each test ODF sample was positioned on the surface of the silicone tongue as shown in 
Figure 3.5.  
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Figure 3.5: ODF sample position in the oral cavity model (figure from Redfearn et al., 2019) [167]. 
 
Recording was started and compression cycle sequence initiated. After the first 
compression, simulated salivary fluid (composition in Tab. 3.1) [168] was sprayed in the 
artificial oral cavity, and the procedure was repeated every two compressions, in order 
to achieve a simulated salivary flow rate of 1.5 mL/min [169]. Upon film disintegration, 
the device was switched off and the recording stopped. 
 
Table 3.1: Artificial salivary fluid (SSF) composition according to Guhmann et al., 2012. 
Component Concentration 
Potassium dihydrogen phosphate 12 mM 
Sodium chloride 40 mM 
Calcium chloride 1.5 mM 
Sodium hydroxide To pH 7.4 
Demineralised water To 1 L 
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3.2.5.3 Video data analysis 
 
The obtained video file was then analysed using a program developed in Matlab 
environment (MathWorks, Natick, MA, USA). A video frame was extracted after exactly 
2320 ms. from the beginning of every compression cycle (Fig. 3.6). This was to ensure 
that the extracted frame corresponded to the film’s most distant position from the palate. 
 
Figure 3.6: Compression and retraction cycle of the oral cavity model. 
 
The number of frames extracted depended on the length of the video. A “crop” function 
allowed selecting the area corresponding to the silicon tongue from the first extracted 
frame. Then, the area corresponding to the ODF sample was selected using a second 
“crop” function (Fig. 3.7).  
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Figure 3.7: Crop function for background and sample area selection of the oral cavity model video analysis 
method. 
 
The program calculated the intensity of the three Red (R) Green (G), and Blue (B) colour 
channels for each pixel, and extracted the highest and second highest intensity channel 
(RG for the analysed ODF samples, and GB for Listerineâ) from the selected film area 
(Fig. 3.8 a,b). A manual thresholding was conducted in order to exclude any pixels 
belonging to the selected background (tongue) area from the ODF area calculation. 
Subsequently, the R and G signals were summed together and the result subtracted 
from the background signal intensities for each extracted frame (Fig. 3.8 c). The resulting 
values were plotted against time. The data was then normalised based on the resulting 
RG values of the first extracted frame (at time 0) and smoothed (Fig. 3.8 d).  
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Figure 3.8: Example of frame sample signal calculation (a,b,c), and normalisation (d) of the oral cavity model 
video analysis method. 
 
An alternative method for data analysis was also developed. Instead of selecting the two 
highest signal channels from the film area of the extracted frames, the computer program 
considered all the three RGB channels intensities for comparison with the background. 
This method was named “Difference” method, as opposed to the method previously 
described that was named “Red-Green” method. 
 
3.2.5.4 Thickness calibration 
 
The signal intensity was measured on a strip of ODF samples with varying thickness 
using the two methods. The real film thickness was measured using a microcaliper and 
plotted against the signal intensity obtained by the computer program. This calibration 
was then used to predict the thickness of the strip image using the two video data 
analysis methods described before. Therefore, the ODF sample disintegration data 
represented the film volume (ODF area multiplied by ODF thickness) compared to the 
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first extracted frame, when the film had not started to disintegrate. The resulting 
disintegration curves represented the % of the ODF initial volume over time, and 
indicated its progressive volume reduction. 
 
3.3 Results and discussion 
 
3.3.1 Tack assessment of ODF samples 
 
3.3.1.1 Adhesive force measurement of ODF samples by texture analysis 
 
The adhesive force profiles of the ODF samples are represented in Fig. 3.9. 
Samples P1 and P2 reached their maximum adhesive force values of 0.430 ± 0.005 
N/mm2 and 0.478 ± 0.063 N/mm2 respectively after 10s of hydration time. Then it 
decreased in both samples to 0.200 N/mm2 and 0.290 N/mm2 respectively at 60s, and 
stabilised around these values. The adhesive force of sample C1 was 0.157 ± 0.006 
N/mm2 after 10 s, and maintained stable adhesion until 240s. Sample C2 reached a 
similar value (0.105 ± 0.001 N/mm2) at 10s and maintained it to 240s. 
 
 
Figure 3.9: Adhesive force profile of the four tested ODF samples by texture analysis (n = 3). 
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The two PVOH-based films maintained adhesive force values always above 0.180 
N/mm2, whereas CMC-based samples showed adhesive force always below 0.200 
N/mm2. The Kruskal-Wallis test followed by Dunn’s multiple comparison test showed 
significant difference in adhesive force existing between P2 and C1 (p < 0.001), and 
between P2 and C2 (p < 0.05). The texture analyser showed discriminative capability 
towards different polymer types after the first 10s of hydration, but not afterwards. It was 
not discriminative towards different polymeric molecular weights or degrees of 
substitution. The adhesive properties of partially hydrolysed PVOH are well known, and 
the polymer is widely utilised in the adhesives industry [170]. CMC is mainly used as a 
thickener in the food industry [171], however it has been used in pharmaceutical 
preparations as a disintegrant, stabilising, suspending, emulsifying, gel-forming, and 
viscosity-regulating agent [172]. Bioadhesive applications of PVOH and CMC were also 
explored due to their high biocompatibility, and their abundance in hydroxyl and 
carboxylic groups respectively [76,143], therefore a certain level of adhesion of the 
polymeric ODF samples was expected. Differences in adhesive behaviour between 
polymeric adhesives differing in molecular weight were described by Weiss [173]. The 
effect of polymeric molecular weight of PVOH on its adhesion to different materials was 
described [174], and so was the effect of CMC molecular weight and degree of 
substitution on adhesion to Li4Ti5O12 anodes [175]. Consequently, it was reasonable to 
expect a difference in adhesive behaviour between different molecular weight-polymeric 
films, when measured by in vitro methods showing potential predictive power. Different 
perceived stickiness intensities of ODF samples were also reported by human 
volunteers, especially in correlation with PVOH molecular weight. The missing 
correlation between sample type/molecular weight and adhesive properties of polymers 
measured by texture analysis might be attributable to the material properties of the 
cylindrical probe utilised. PVOH was reported to adhere and adsorb to PMMA [176,177], 
and CMC was also observed to influence the adhesion of polyisobuthylene to PMMA 
[178], however the influence of polymeric molecular weight, and any differences in 
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adhesive force strength between the two polymer types were not reported in the 
literature. 
 
3.3.1.2 Adhesive force measurement of ODF samples by DMA 
 
The developed DMA method allowed measuring the maximum force required to detach 
the hydrated film from a stainless steel plate as a description of the tack properties of the 
polymeric species analysed. The adhesive force was measured at different time points 
in order to obtain a profile of the adhesive behaviour of each film over time. The adhesive 
force profile of the four ODF samples, and Listerineâ is shown in Fig. 3.10. 
 
 
Figure 3.10: Adhesive force profile of the four tested ODF samples, Listerine (R) and Niquitin (R) films 
analysed by DMA (n = 3). Figure from Scarpa et al., 2018 [120]. 
 
The adhesive force profiles of the four placebo ODFs and commercial films differed 
between samples and over time. The highest adhesive force value was exhibited by the 
low molecular weight CMC sample (395 KDa – C1), which increased to 0.0370 ± 0.0010 
N/mm2 at 10s, reached a maximum peak of 0.0443 ± 0.0003 N/mm2 after 60s, and 
dropped to 0.0147 ± 0.0002 N/mm2 at 180s. Listerineâ had the lowest adhesive force 
values, that reached 0.0089 ± 0.0001 at 10s, decreased to 0.0019 ± 0.0000 N/mm2 at 
120s, and stabilised around similar values until 180s. The low molecular weight PVOH 
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sample (39 KDa - P1) increased its adhesive force to 0.0091 ± 0.0007 N/mm2 at 10s, and 
maintained similar values until 180s, when it dropped to 0.0054 ± 0.0011 N/mm2. The 
high molecular weight PVOH-based film (197 KDa – P2), reached 0.0108 ± 0.0010 
N/mm2 at 10s, increased to 0.0217 ± 0.0013 N/mm2 at 60s, and then it decreased to 
0.0167 ± 0.0012 N/mm2 at 180s. The high molecular weight CMC-based sample (725 
KDa – C2) increased its adhesive force to 0.0244 ± 0.0013 N/mm2 at 10s, then it 
decreased to 0.0165 ± 0.0006 N/mm2 at 60s, increased to 0.0212 ± 0.0024 N/mm2 at 
120s, and decreased again to 0.0288 ± 0.0007 N/mm2 at 180s. Listerineâ is a 
commercially available healthcare breath freshener strip product in the form of ODF, that 
was estimated to be used by 8.86 million Americans within one month in 2018 (Census 
data and Simmons National Consumer Survey) [179], and hence selected for 
comparison purposes in the study. When tested for tack, Listerineâ showed the lowest 
adhesive force profile compared with all the other samples analysed. The role of water 
as solvent in the adhesion process observed is fundamental, as dry films did not adhere 
to the metallic plate. Polymeric molecular weight may also affect adhesion, especially in 
relation to the mobility of the polymeric chains, and thus influence their ability to diffuse, 
adsorb, improve surface wetting, and form electrically charged double layers [143]. This 
might explain the difference between the adhesive force profiles observed in PVOH-
based samples differing in molecular weight. The adhesive force values of sample C1 
increased during the first 120s, and then decreased considerably until 180s. The specific 
CMC polymers used in the experiment have different degrees of substitution (DS), and 
different molecular weights (DS 0.7 for 725 KDa, and DS 1.2 for 395 KDa). A high DS 
means that more carboxylic groups are present in the molecule [180]. Carboxylic groups 
are involved in the bioadhesive properties of CMC, alongside hydroxylic groups [143], 
and might also determine the cohesive properties of the molecule [181], potentially 
explain the higher tack exhibited by sample C1 compared to sample C2, in spite of its 
lower molecular weight. A cohesive dominance effect was suggested to be responsible 
for the adhesive properties of thick polymeric coatings made of polyelectrolyte 
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multilayers mediated by disentanglement processes [182], and an increase in cohesion 
as a result of CMC addition to foods [183] and biomass pellets [184] was also reported. 
However, the DS of CMC added to low-fat frankfurters was not observed to influence the 
cohesiveness of the product [185]. Moreover, CMC molecular weight and DS were found 
to influence its adhesion to Li4Ti5O12 anodes, but in an inverse relationship compared to 
the adhesion behaviour to stainless steel observed in the present study [175]. Therefore, 
it is difficult to determine whether the adhesive behaviour of high-DS sample C1 could 
be attributed to strong cohesive forces between the polymeric chains that subsequently 
failed after the first two minutes of hydration. Also, it is not clear as to whether the inverse 
adhesive force relationship observed by Lee and co-workers [175] can be attributed to 
the specific binding material (Li4Ti5O12 anodes or stainless steel) or to other reasons. A 
high degree of polymeric chain packing was reported for high molecular weight PMMA 
films by Linossier and colleagues [142]. In turn, chain packing was responsible for the 
limited access of binding sites for water. Considering the involvement of water in wet 
adhesion phenomena, and if the same chain packing process occurs in high molecular 
weight CMC films, then the lower adhesion of sample C2 compared to sample C1 could 
be explained by the limited interaction of water molecules and C=O groups, thus causing 
reduced tack. The strong affinity of C=O groups for water could also potentially explain 
the similarity in adhesive force values between samples P2 and C2, despite their 
difference in molecular weights. Highly packed long polymeric CMC chains might hide 
water binding sites compared to shorter PVOH chains, therefore resulting in the reduced 
tack of sample C2. Chain entanglement mechanisms may also play a role in the 
observed phenomenon [186]. Considering the different nature of PVOH and CMC, it is 
reasonable to hypothesise that the entanglement/disentanglement behaviour of the two 
polymeric species during a dissolution process might differ as well, potentially affecting 
the adhesive properties observed in vitro. Furthermore, surface properties might be 
involved in the adhesive bond occurring between polymers and metallic plates. Stainless 
steel materials are known to form a protective chromium oxide layer on their surface 
[187]. Chromium oxide surfaces can be further functionalised by coating using materials 
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containing specific functional groups [187]. Depending on the type and functionalisation 
of the steel, the surface energy changes as well. For example, the Lifschitz/Van der 
Waals polar part of freshly polished (grade AISI 304) stainless steel surface energy 
measured by contact angle was higher (38-39) than its basic (2.1 – 7.2), and acidic (0) 
parts [188], meaning that the surface is more likely to chemically interact with polar 
materials. The type and grade of stainless steel of the DMA metallic plates might differ 
from that analysed by Hedberg and colleagues, however, a potential hypothesis 
explaining the adhesive bond observed between ODF samples and DMA clamps might 
involve the formation of polar interactions between the -OH, and -COOH groups of the 
polymers, and the stainless steel surface. However, other mechanisms related to the 
molecular structure or other physicochemical properties of the polymer might be involved 
in the adhesion mechanism between ODFs and DMA plates, hence the type of DMA 
equipment (e.g. material used for DMA plates) should be considered.  
 
3.3.1.3 In vivo/in vitro correlation of ODF samples tack assessment 
 
Texture analysis did not evidence differences in the adhesive properties of different 
molecular weight polymeric films, whereas the dynamic mechanical analysis did. 
Considering that a molecular weight effect for PVOH samples was also observed in vivo, 
the texture analyser did not show promising predictive capability with respect to adhesive 
properties of ODF samples, as the DMA did. The low perceived stickiness intensity 
reported by human volunteers was reflected in the low adhesive force profile of sample 
P1 analysed by DMA. However, DMA data interpretation for in vitro/in vivo correlation 
purposes is complicated by the fact that adhesive force changes of ODF samples are 
studied over time, making them difficult to compare to numerical scores assigned by 
panel participants. The identification of a specific reference time point for in vivo/in vitro 
data comparison is also not advisable, as the stickiness perception depends on the time 
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the ODF resides in the oral cavity, and therefore, on its disintegration time. A different 
approach to DMA data interpretation must then be adopted. 
 
3.3.2 Disintegration time assessment of ODF samples 
 
3.3.2.1 Disintegration time measurement of ODF samples by petri dish 
and drop methods 
 
The disintegration of samples C1, P1, P2 and Listerine® measured by petri dish method 
was much faster than sample C2 (Tab. 3.2). Only the difference in disintegration time 
between samples C2 and P1 was significant (p<0.05). Measurements carried out by drop 
method seemed to slightly overestimate the disintegration time of PVOH-based samples, 
and to overestimate that of CMC-based films, and Listerineâ compared to the petri dish 
method. There was no significant difference in disintegration time measured in water or 
SSF (data not shown). The molecular weight of the film-forming polymer seemed to 
influence the disintegration time of the ODF samples, as opposed to what was reported 
by Chan, Hao, and Heng in 1999 for low-hydrolysis degree PVOH [189]. On the other 
hand, a correlation between molecular size of CMC and drug release by erosion or matrix 
relaxation mechanisms was found for other orally disintegrating dosage forms [190]. 
Moreover, the type of film-forming polymer also seemed to influence the disintegration 
of ODF samples, probably due to the presence of COOH groups. Strong hydrogen 
bonding is likely to occur between carboxylic groups and water, however, long polymeric 
chains may lead to high molecular packing, and therefore, to a limited availability of 
binding sites [142], potentially explaining the slower disintegration time of sample C2 
compared to sample C1.  
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Table 3.2: Average disintegration time of ODF samples measured by petri dish and drop methods. Results 
are expressed in seconds (n = 3). 
 
Sample P1 P2 C1 C2 Listerineâ 
Petri dish 
method 
7.2 ± 0.8 55.8 ± 2.8 25.4 ± 0.2 262.0 ± 11.2 12.9 ± 0.6 
Drop 
method 
14.6 ± 1.0 113.3 ± 20.0 19.3 ± 3.0 202.6 ± 10.9 14.9 ± 0.3 
 
3.3.2.2 Disintegration time measurement of ODF samples by oral cavity 
model 
 
An oral cavity model previously developed by the UCL Department of Mechanical 
Engineering was adapted for the in vitro assessment of ODF disintegration. 
 
3.3.2.2.1 Correlation between video signal intensity and ODF 
thickness 
 
The two video data analysis methods were compared and the method giving the least 
data deviation from the fitted curve was selected. The best curve fitting of the calculated 
vs. measured thickness data corresponded to an exponential curve for both the methods 
analysed (Fig. 3.11).  
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Figure 3.11: Measured vs. calculated thickness curve fitting for a) RG method, b) Difference method, c) both 
methods in the oral cavity model video analysis (courtesy of Dr Andrew Redfearn). 
 
In the RG method, the largest data deviation was observed for real film thickness values 
between 50 to 150 µm, however, for higher film thickness values, the data dispersion 
reduced (Fig. 3.11 a). In the Difference method, on the other hand, the data deviation 
was significant in all the real thickness range (Fig. 3.11 b). This difference was also 
observable when the calculated thickness with both methods, and the real thickness 
measured by micrometer were plotted against the distance along the film strip (Fig. 3.11 
c). The deviation from the real thickness (black line), and the Difference method (blue 
line) was more pronounced across the whole length of the strip, whereas the RG method 
predicted thickness values closer to the real thickness, especially in the central part of 
the strip. The purpose of the analysis was to predict the disintegration time and observe 
the disintegration behaviour of ODF, therefore an accurate detection of the film thickness 
and, consequently, of the calculated film volume was a key requirement. This 
observation provided the rationale for the selection of the RG method to analyse the 
video data of ODF disintegration time. 
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3.3.2.2.2 Disintegration time measurement of ODF samples by 
mechanical oral cavity model 
 
The disintegration of four red-coloured single-polymer ODFs and a Listerine â strips was 
measured. The data representing the percent of film volume reduction over time is shown 
in Fig. 3.12.  
 
 
Figure 3.12: Percent volume reduction at 180s of ODF samples (n = 3). Standard deviation is represented 
by the dashed lines (figure from Redfearn et al., 2019) [167]. 
 
The method presented and tested in this work was able to measure film volume (relative 
to initial volume) for five different ODF formulations, including a commercial film, during 
mechanical and chemical degradation. A clear difference between characteristic volume 
reduction curves for each ODF sample was found. During the disintegration process all 
ODF samples tested adhered to the acrylic palate after the first compression cycle. 
The European Pharmacopoeia indicates a cut-off disintegration time of 3 min. for a 
dosage form to be considered orodispersible [100]. Therefore, 180s was selected as a 
reference time to compare the analysed formulations. Sample P1, and Listerineâ 
reached complete disintegration in less than 3 min., whilst the % volume reduction of the 
other films at 180s was approximately 90%, 50%, and 39% for samples C1, P2, and C2 
respectively. The low molecular weight polymeric films disintegrated faster than the high 
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molecular weight polymeric films within the same polymer species, with P1 being the 
fastest dissolving film, and the C2 being the slowest. The molecular weight of PVOH was 
reported not to influence its solubility at low hydrolysation degrees [189], however other 
authors reported the molecular weight influence on the disintegration of other polymeric 
species [112,113]. In the present study, a molecular weight effect was observed within 
ODF samples made of the same polymeric species, and that could depend on the higher 
entanglement density present between high-molecular weight polymeric chains. 
Interestingly, the curve fitting of the film volume vs. time plot was linear for samples P1 
and Listerineâ, and became non-linear as the polymeric molecular weight increased. 
The presence of the two non-linear regions of the sigmoid curves could be explained by 
the disentanglement behaviour of the polymeric chains in solution. Also, the different 
curve fitting might depend on the interaction between water molecules and the 
substitution groups in the two polymeric species analysed [142]. According to Linossier 
and colleagues, a hydration lag was observed in PMMA films having the same thickness, 
but different molecular weight. This was attributed to the limited bonding sites 
accessibility due to high chain packing in high molecular weight polymers. If the same 
reasoning can be applied to CMC and PVOH polymers, this could explain the lag in 
hydration, and therefore in the consequent erosion process observed in the higher 
molecular weight ODF samples, and corresponding to the non-linear region of the curve 
at the beginning of the experiment. The low-molecular weight CMC film disintegrated 
faster than the high-molecular weight PVOH film, despite their difference in molecular 
weight. This could have occurred because, at pH 7.4, carboxyl groups are ionised 
whereas hydroxyl groups are not. Therefore, as CMC has carboxyl substitution groups, 
we could expect it to exhibit negative charges that can favour dissolution. The non-linear 
region at the end of the disintegration curve might be explained by the interfacial 
interaction between films and the acrylic plate. Adhesive behaviour between ODF 
sample and the PMMA rigid surface was observed during the experiment. This adhesion 
could have determined a temporary limitation of the polymeric chains mobility, and 
therefore prevent water molecules to access hydrogen bonding sites to untangle the 
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polymeric matrix. In support of this observation, absorption phenomena, and potentially 
bonding between PVOH and PMMA was reported in the literature [176,177]. In addition 
to erosion processes mediated by hydration mechanisms, the recurrent compression 
applied to the samples by the oral cavity model may have favoured the elimination of the 
solubilised polymeric chains by pushing the SSF out of the posterior side of the artificial 
oral cavity. 
 
3.3.2.2.3 Disintegration behavior of ODF samples 
 
The oral cavity model not only provided information on the disintegration rate of the test 
ODF samples, but also on their disintegration behaviour over time (Fig. 3.13).  
 
 
Figure 3.13: Extracted frames of the dissolving ODF samples at different time points (figure from Redfearn 
et al., 2019) [167]. 
 
It was possible to appreciate the tendency of the PVOH-based films to break into pieces 
as opposed to the proneness of CMC-based films to a more homogeneous breakdown 
pattern by forming a thickened fluid during their dissolution. CMC is widely used as a 
thickener in many pharmaceutical and food preparations due to its excellent water 
retention properties. Water solubility of CMC is a function of its degree of substitution, 
with higher degrees of substitution, corresponding to more carboxylic groups per 
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monomer, exhibiting higher solubility [191]. Moreover, low DS CMC was associated with 
the thixotropic behaviour of the molecule in solution [191]. The different disintegration 
patterns were observed in the two CMC-based ODF samples as a result of their different 
DS. Also, if the polymeric solubility is increased by the presence of C=O groups, this 
could explain the different disintegration behaviour observed between the C=O 
containing CMC-based and non-C=O containing PVOH-based films. The breakdown 
behaviour of ListerineÒ was similar to that of the CMC-based films, although its 
disintegration time was much faster. ListerineÒ strips do not contain CMC, however 
other polysaccharides such as pullulan, carrageenan, locust bean gum, and xanthan 
gum are present in the list of excipients. As the specific characteristics of the polymers 
used in ListerineÒ are not specified, it was difficult to understand the relationship 
between attributes such as polymeric molecular weight with the strips disintegration time 
and behaviour. However, similarities in the molecular structures such as the presence of 
repeated monosaccharide units, might have determined the similar breakdown 
behaviour observed between CMC and ListerineÒ samples. 
 
3.3.2.3 In vivo/in vitro correlation of ODF samples disintegration time 
assessment 
 
The disintegration time measured by petri dish and drop methods reflected the 
disintegration time duration reported by panel volunteers, with the exception of a slight 
overestimation for sample C2. Only in the petri dish method, the disintegration time of  
sample P2 was slightly underestimated compared to in vivo data. The discrepancy 
between in vitro/in vivo results might depend on the different nature and intensity of 
mechanical stresses applied to the samples compared to in vivo conditions, besides the 
relatively limited volume of disintegration medium used in the experiment, which was 
considered biorelevant [124]. This provided the rationale for attempting the design of a 
new disintegration apparatus integrating the concept of a different type of mechanical 
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stress applied to the sample, in order to mimic more closely the natural conditions of the 
human oral cavity. 
The disintegration data obtained by artificial oral cavity model tended to overestimate the 
disintegration time measured by other in vitro methods, and in vivo. In the in vivo study, 
the disintegration time of all samples analysed was reported to be much faster, with P1, 
and C1 disintegrating in less than 1 min., and P2, and C2 disintegrating between 1 and 
3 mins (Fig. 2.6). A potential explanation for the observed difference could lie, once 
again, in the type of mechanical stress to which samples are exposed during the 
experiment in the oral cavity model. In fact, the oral cavity model was designed to apply 
a recurrent perpendicular pressure to the film sample [160,192]. The perpendicular 
pressure has been proven a relevant component in the design of oral cavity models 
aimed at investigating the breakdown and bolus formation of foods in bulk food samples 
[192], however in the case of thin films, like the ones analysed in the present study, 
friction forces could represent a more significant stress component in mimicking human 
oral function [193,194]. Therefore, future studies will be aimed at investigating the role 
of friction in the breakdown and degradation of ODFs in the mouth, and to upgrading the 
oral cavity model with the capability of reproducing both the force components. The ODF 
sample volume reduction rate ordered from the fastest to the slowest-dissolving film was 
P1 > Listerine â > C1 > P2 > C2, in agreement with the disintegration times ordered 
from fastest to slowest measured by drop method. In the petri dish method, however, 
Listerine â dissolved faster than P1. The disintegration time of sample P1 was the only 
one that was considered acceptable by panel participants (Fig. 2.3) in the ODF 
acceptability study, whereas Listerine â was not tested in vivo. This might suggest that 
the feeling of a solid or a viscous liquid present in the mouth for too long might be related 
to the discomfort expressed by the panel participants in vivo. Such discomfort might 
originate from the inconsistency between the absence of particles and the perception of 
a solid/highly viscous object in the mouth. In normal circumstances (solid food) the 
chewing and salivation processes are aided by the tongue to achieve a specific particle 
size [192], and bolus viscosity before swallowing. When the food takes too long to 
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achieve the target viscosity, it can trigger an uncomfortable feeling. Moreover, the 
adhesion of the ODFs to the palate, further interferes with the ability to break the film 
structure into pieces. The real time cut-off beyond which an ODF is considered 
uncomfortable might not correspond to 180s in vivo, however, this disintegration time 
could be adopted as a convention to predict uncomfortable disintegration time in vitro, 
making the oral cavity model a potential tool for the in vitro prediction of the end user 
acceptability of ODF disintegration time in the healthy young adult population. 
The qualitative evaluation of ODF disintegration evidenced the different behaviour of 
PVOH- and CMC-based films, with CMC films forming a thickened fluid. This observation 
corroborates the feedback of the panel participants, who reported in a semi-structured 
interview that the two CMC-based films had a marked thickening effect on the saliva. 
 
3.4 Conclusions 
 
Two in vitro methods were assessed for ODF tack measurement, and three in vitro 
methods were used for the measurement of ODF disintegration time. DMA showed 
promise as a descriptive method for the quantitative and qualitative evaluation of the 
adhesive properties of ODFs, and as a predictive methodology for the assessment of 
ODF tack. However, the nature of the adhesive interaction between polymeric film and 
the stainless steel surface of the DMA clamps needs to be further elucidated. The 
accurate selection of an extended series of test ODF samples might inform on the 
underlying adhesion theory behind the observed phenomenon. Also, a new data 
interpretation approach must be adopted in order to enable in vitro/in vivo comparison 
between DMA adhesive force profiles and perceived stickiness intensity and 
acceptability scores assigned by volunteers.  
All the in vitro techniques explored for the measurement of ODF disintegration time 
showed discriminative power for both polymer type and polymeric molecular weight of 
the ODF samples analysed. The disintegration time of ODF samples measured by petri 
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dish and drop methods correlated better than the disintegration time obtained by oral 
cavity model with human panel data, however the order in which the ODF samples 
reached complete disintegration was maintained in both in vitro methods. Further 
optimisation of the mechanical oral cavity model is therefore required in order to achieve 
a better predictive power over disintegration time measurement. On the other hand, a 
new concept of ODF disintegration characterisation was presented. Instead of 
measuring the time to disintegration only, the mechanical oral cavity model made 
possible for the first time to explore the concept of ODF volume reduction over time, as 
an indication of ODF disintegration behaviour. This analysis holds potential to provide 
information to better understand ODF dissolution mediated by erosion mechanisms. 
 
* Part of the data presented in chapter 3 has been published in Scarpa et al., 2018 [120]. 
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Chapter 4.  Mechanisms involved in the ODF tack 
quantification by Dynamic Mechanical Analysis  
 
The following chapter describes a new approach to the data analysis of the in vitro tack 
measurement of orodispersible films (ODFs) as a method to predict the acceptability of 
ODF perceived stickiness. In order to understand the mechanisms involved in the 
physicochemical interaction between ODF and dynamic mechanical analysis (DMA) 
plates, an extended range of ODF samples differing in their composition such as 
molecular weight, charge, hydrophobicity of the polymer, and addition of active 
pharmaceutical ingredient (API) and excipients, were tested. Placebo, and drug-loaded 
ODF formulations were optimised by mechanical properties prior to the tack test. The 
results of the in vitro study provided useful information on the physicochemical 
interaction potentially mediating the adhesive bond responsible for the measured tack, 
and on the mucoadhesion theories potentially involved.  
 
Aims: 
- To optimise a data analysis method of the tack results obtained by DMA to 
achieve the prediction of in vivo perceived ODF stickiness 
- To analyse an extended set of ODF samples by DMA in order to elucidate the 
adhesion mechanisms involved in the ODF tack quantification 
Objectives 
- To consider the contribution of disintegration time to the perception of ODF 
stickiness in the data interpretation of the DMA analysis conducted in chapter 2 
- To formulate ODFs with different pharmaceutical (excipients, API) and chemical 
(charge, polarity) properties to investigate the adhesion mechanisms between 
ODFs and DMA plates.  
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4.1 Introduction 
 
The fracture theory of mucoadhesion provided a potential, although partial explanation 
of the nature of the adhesive bond forming between ODFs and human palate. One of 
the most used experimental methods based on the fracture theory for the measurement 
of bulk adhesion was adopted. A DMA method was optimised according to the principles 
of fracture theory testing, and proved to represent a good methodology for the 
measurement of ODF tack. As ODFs dissolve in the mouth, and change their physical 
properties, ODF sample tack was measured at several time points for each sample. The 
resulting data allowed the identification of an adhesive force profile that described how 
ODF tack changed over time (chapter 3). However, the goal of the present study was to 
identify an in vitro method that could predict the end-user acceptability of the perceived 
ODF stickiness. In this respect, the adhesive force profile taken as it was, could not 
provide information on acceptability. In order to investigate the correlation between tack 
data and acceptability of the perceived ODF stickiness, the selection of a specific time 
point on the adhesive force profile would not be ideal. 
 
4.1.1 The contribution of residence time to the oral perception of stickiness 
 
In a study conducted by Hutchings and colleagues on food processing, several 
volunteers were presented with samples of whole and blended cashew nuts. Volunteers 
were asked to chew, and rate the stickiness intensity of the samples over time on a 9 
points score system [195]. Hutchings found that the stickiness intensity of whole cashew 
samples rose over time and was rated less intense, on average, than the blended 
cashew samples. In addition, the total duration of the assessment (mastication time) was 
significantly shorter for blended cashews. Based on Hutchings’ data, an existing 
relationship seems to exist between stickiness perception, degree of oral processing, 
and processing time. In broad terms, the perception of the physical and rheological 
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properties of foods changes over time, and the perception of food texture, and palatability 
should be always assessed in relation to time [138]. In particular, the adhesiveness of 
foods changes over time during mastication [196]. Very likely, ODFs are no exception to 
this rule, and disintegration time might play a significant role in the perception of ODF 
stickiness in vivo. For this reason, ODF disintegration time was introduced as a variable 
in the calculation of perceived ODF stickiness acceptability. 
 
4.1.2 Other mucoadhesion theories potentially involved in the adhesion 
between ODF and DMA plates 
 
The fracture theory might not be the only theory of mucoadhesion explaining the ODF 
adhesion phenomenon. The impossibility to carry out some testing method to verify 
some mucoadhesion theories (e.g. wetting theory) was discussed in chapter 3. Other 
mucoadhesion theories can be excluded from influencing the ODF/DMA plates system. 
For example, the diffusion theory describes how the adhesive bond forms because of 
the interdiffusion and interaction of molecular chains between two surfaces [126]. Unless 
intentionally functionalised, the surface of stainless steel does not normally have long 
molecular chains attached to its surface, therefore making the interdiffusion process 
impossible. There might be a certain degree of diffusion of the polymeric chains on the 
ODF side, however the type of interaction with the metallic plate must be different. Also, 
mechanical interlocking mechanisms are unlikely to be involved, as the surface of the 
stainless steel plates is very smooth and non-porous. Differences in the electronic 
structure of the two surfaces may play a role in the adhesive bond formation, as could 
the formation of hydrogen bonds and van der Waal’s forces. Therefore, the electronic 
and adsorption theories are worth exploring.  
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4.1.3 Testing of the adsorption and electronic theories in the DMA system 
 
Since no experimental methods have been specified for the testing of the adsorption and 
electronic theories, a method was designed and implemented. In order to understand 
what type of chemical bonds/interactions were involved in the ODF/DMA plate adhesion 
phenomenon, polymeric films with different molecular weights, charges, polar properties, 
excipients, and amounts of loaded drug were tested.  
 
4.1.3.1 Assessment of potential chemical bonds involved in ODF samples 
adhesion 
 
A set of two polymeric species, each in two molecular weight variants were tested in 
chapter 3, in order to assess the suitability of the DMA and other methods for tack 
measurement, and end-user acceptability prediction. Such set of polymeric ODF 
samples suggested that a potential correlation between ODF tack and polymeric 
molecular weight existed. A confirmation of such finding could suggest that the strength 
of the adhesive bond increases with the length of the polymeric chain, and could 
therefore be dependent on the type and number of substitution groups specific to the 
polymeric species analysed. In turn, this could mean that there is a cohesive component 
involved in the adhesive bond, which strength could depend on the number of 
substitution groups interacting with each other [197], assuming that the number of 
substitution groups interfacing with the metallic plate is the same, regardless of the chain 
length. If only one substitution group is present in the polymeric species, it would 
theoretically be possible to understand the contribution of such group in both 
intermolecular and interfacial forces. An ideal polymer for such test would be the 
poly(vinyl) alcohol (PVOH) because of its availability in a range of molecular weight at 
the same degree of substitution, and because of the presence of hydroxyl groups only. 
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4.1.3.2 Assessment of the role of polymeric charge in ODF samples 
adhesion 
 
In order to assess the role of charged molecules in ODF adhesion, two polymers of 
opposite charges should be tested. Several polymers are known to be positively 
charged, however their solubilisation could be challenging, and their film-forming 
capability is not always good. Eudragit E POâ is a good film-forming, cationic polymer 
that is soluble in acidic solutions, and is often used as coating and taste masking agent 
(manufacturer recommendations). It was therefore chosen as a positively-charged 
polymer, after full ionisation was induced. Carboxymethylcellulose is a negatively-
charged derivative of cellulose, however its net charge depends on the solution it is 
dissolved in. Fully ionised carboxymethylcellulose (CMC) can be obtained by 
appropriately increasing the pH of the solution. A direct comparison between negatively-
charged CMC, and positively-charged Eudragit E POÒ ODF samples could further 
inform on the contribution of polymeric charge on ODF adhesion. 
 
4.1.3.3 Assessment of the role of polymeric polar properties in ODF 
samples adhesion 
 
Hydrophobic polymers can also be used as film-forming agents to load poorly soluble 
drugs in the ODF platform [198]. Testing a hydrophobic polymer, in comparison with a 
hydrophilic polymer could provide useful information as to whether hydrophobic 
interactions contribute to the adhesive bond. However, the addition of hydrophilic 
excipients is required for the film to form [198]. Therefore, the comparison could only be 
performed between ODF samples having the same composition, but differing in the 
presence or absence of the hydrophobic component. Kollicoat SR 30Dâ is a suspension 
of polyvinyl acetate (PVAc), polyvinylpyrrolidone (PVP), and sodium lauryl sulfate (SLS) 
that is frequently used for tablet coating (manufacturer instructions). If combined with a 
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PVOH polymeric solution, a film could be obtained, and compared with a second film 
only containing PVOH, PVP, and SLS. 
 
4.1.3.4 Effect of the addition of excipients and drug on ODF samples 
adhesion 
 
Poly(vinyl) alcohol proved to be a good film-forming polymer, and received different 
acceptability feedback from panel participants based on types differing in their polymeric 
molecular weight. Low molecular weight films were considered highly acceptable, 
whereas high molecular weight films received negative acceptability scores. Films made 
with both high, and low molecular weight PVOH can be optimised as placebo, and drug-
loaded formulations by adding increasing concentrations of a model active 
pharmaceutical ingredient (API), in order to see how the additions have an effect on ODF 
tack. The optimisation of the formulations should be done in order to ensure acceptable 
mechanical properties, so that the films are capable to withstand the stresses related to 
manufacturing and handling. 
 
4.2 Materials and methods 
 
4.2.1 Materials 
 
EMPROVEâ PVOH 8-88 (83 kDa), and 18-88 (130 kDa), glycerol and sucralose were 
purchased from Merck Millipore (Darmstadt, Germany). Eudragit E POâ was provided 
by Evonik (Essen, Germany), whereas Kollicoat SR 30Dâ, and SLS (PVP 30 kDa) were 
kindly donated by BASF (Ludwigshafen, Germany). 4-Hydroxy-2,5-dimethyl-3(2H)-
furanone (strawberry furanone), and glycerol were purchased from Sigma (Gillingham, 
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Dorset, UK). The composition of the simulated salivary fluid (SSF) is summarised in Tab. 
3.1. 
 
4.2.2 ODF sample preparation 
 
An extended set of ODF samples were prepared by solvent casting. The formulation 
composition of samples is summarised in Tab. 4.1.  
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  Table 4.1: ODF sample composition for tack analysis. 
Sample code P1 P3 P4 P2 E1 C1 C2 C3 H1 H2 
PVOH (39 kDa) 5% (83 kDa) 5% (130 kDa) 5% (197 kDa) 5% - - - - (39 kDa) 5% (39 kDa) 5% 
EudragitÒ E PO - - - - (150 kDa) 3.66% - - - - - 
CMC - - - - - (395 kDa) 1% (725 kDa) 1% (395 kDa) 1% - - 
PVP - - - - - - - - (30 kDa) 0.9% (30 kDa) 0.9% 
SLS - - - - - - - - 0.10% 0.10% 
PVAc - - - - - - - - 9% - 
Glycerol (v/v) - - - - - - - - - - 
Sucralose - - - - - - - - - - 
4-Hydroxy-2,5-dimethyl-
3(2H)-furanone - - - - - - - - - - 
PSP (mg/film) - - - - - - - - - - 
Solvent water water water water 
water 
(8.46%) + 
hydrochloric 
acid (91.54 
%) 
water water 
water (77.12%) 
+ sodium 
hydroxide 
(22.8%) 
water water 
Casting volume (mL) 7.5 7.5 7.5 7.5 7.5 15 15 15 7.5 7.5 
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                Table 4.1: (Continued). 
 
 
Sample code F1 F2 F3 F4 F5 F6 F7 F8 
PVOH (197 kDa) 5% (197 kDa) 5% (197 kDa) 5% (30 kDa) 5% (30 kDa) 5% (30 kDa) 5% (197 kDa) 5% (197 kDa) 5% 
EudragitÒ E PO - - - - - - - - 
CMC - - - - - - - - 
PVP (30 kDa) 1.26% (30 kDa) 1.26% - (30 kDa) 0.63% (30 kDa) 0.63% (30 kDa) 0.63% (30 kDa) 1.26% (30 kDa) 1.26% 
SLS - - - - - - - - 
PVAc - - - - - - - - 
Glycerol (v/v) 0.25% 0.25% 0.25% 0.25% 0.30% 0.30% 0.25% 0.25% 
Sucralose 0.10% - 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 
4-Hydroxy-2,5-
dimethyl-3(2H)-
furanone 
0.10% - 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 
PSP (mg/film) - - - - 1 5 1 5 
Solvent water water water water water water water Water 
Casting volume (mL) 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 
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PVOH-based samples with molecular weights 39 and 197 kDa were re-analysed by 
DMA, and compared with two intermediate molecular weights (83, and 130 kDa) to 
better understand the influence of molecular weight on ODF tack.  
Fully-ionised positively-, and negatively-charged polymers were also analysed by DMA, 
in comparison with high- and low-molecular weight CMC films in order to understand 
the role of charged molecules in the adhesive bond. EudragitÒ E PO is a cationic 
copolymer that can be solubilised in acidic solvents [199,200], whereas CMC is 
negatively charged, and it is not fully-ionised in water, however an increase in 
ionisation can be obtained in alkaline solvents [201]. To carry out a comparison, the 
same number of positive and negative charges per film area should be obtained. The 
number of charges per clamp area was approximately estimated by calculating the 
mass of polymer present on the clamp area, and then by dividing the polymeric mass 
by the molecular weight of the repeating unit (and the result multiplied by the degree of 
substitution (DS) for CMC [202]), in order to obtain the total number of moles of 
charges/clamp area. Then, the corresponding number of moles of acid or base were 
calculated in order to obtain full ionization of the charged substitution groups, and the 
corresponding volume of hydrochloric acid (HCl) or sodium hydroxide (NaOH) was 
added to the solvent.  
To understand whether hydrophobic interactions also played a role in the adhesive 
bond between film and DMA clamp, two film formulations differing only in the presence 
of the hydrophobic polymer PVAc [203] were prepared.  
The influence of a loaded drug on the tack of a fully optimised formulation was 
assessed by testing both high- and low-molecular weight PVOH formulations in their 
placebo version, and after the incorporation of 1, and 5 mg of the model drug 
Prednisolone Sodium Phosphate (PSP). Full-composition formulations were optimised 
by mechanical properties before being tested by DMA.  
Taste, smell, and other attributes can have a significant influence on the perception of 
other mouthfeel characteristics [115]. Therefore, to assess whether the in vivo 
perceived stickiness of formulations containing sweetener and flavour, differed from 
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that of films mainly composed of polymers, ODF formulations F1, F2, and F3 (Tab. 4.1) 
were compared in vitro and in vivo for perceived stickiness acceptability. 
 
4.2.3 Optimisation of the ODF sample formulation by mechanical properties 
 
ODF sample tensile strength, elongation at break, and Young’s modulus were measured 
using an Instron Universal Tester 5567 (Instron Ltd., Wycombe, UK), equipped with a 
500 N load cell, and 1 kN capacity pneumatic grips. The ODF sample was cut to a 
specific type 3 dumbbell shape according to the international Standard EN ISO 37, and 
EN ISO 527 [204,205], with the following dimensions: overall length, 50 mm; length of 
the narrow portion, 16 mm; width of the wide ends, 8.5 mm; width of the narrow portion 
4 mm [206]. The thickness of each sample was measured by microcaliper (Mahr Plc., 
Milton Keynes, UK), and entered as measurement parameter. Samples were positioned 
so that the distance between the grips was 16 mm (Figure 4.1), and the experiment was 
carried out by applying an uniaxial stress at a crosshead speed of 50 mm/min [207].    
 
 
Figure 4.1: Sample positioning between the tension grips of the universal testing instrument. 
 
A stress versus strain curve (Figure 4.2 a), and resulting parameters were visualised 
using Bluehill software v. 3 (Instron Ltd., Wycombe, UK).  
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Figure 4.2: Example of a stress vs. strain curve obtained by testing a PVOH 197 kDa ODF sample (a). 
Interpretation of the stress/strain curve (b). 
 
Tensile strength is the maximum tensile stress recorded at the sample breaking point 
[204,205] (Fig. 4.2 a,b). It is calculated with Equation 4.1 [78], where !"#$ is the 
maximum load applied, and % is the cross-sectional area of the film. The elongation at 
break is the change in sample length, or deformation, at the breaking point expressed in 
percentage, and it is calculated using Equation 4.2 [78], where Δ' is the difference 
between the initial and final length of the sample, and '( the initial length. The Young’s 
modulus is an indication of the elasticity of the sample, and corresponds to the slope of 
the linear region of the stress/strain curve [78] (Fig. 4.3 b), and it is obtained by resolving 
Equation 4.3, where ! is the force applied at corresponding strain, and ) is the strain. 
 
Equation 4.1 
 
*+,-./+	-12+,31ℎ	(67) = 	!"#$%  
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Equation 4.2 
 
%	;/<,3=1.<,	()7) = 	Δ''( 	× 	100 
 
Equation 4.3 
 
A<B,3C-	D<EB/B-	(;) = 	!% 	×	1) 
 
4.2.4 In vitro tack assessment of ODF samples by DMA analysis 
 
ODF sample tack was analysed using the same method described in chapter 3, with a 
slight modification. The liquid medium with which ODF samples were hydrated prior to 
tack measurement was a simulated salivary fluid (SSF), which composition was also 
described in chapter 3. Also, the adhesive force was measured more frequently at 10s, 
30s, 60s, 90s, 120s, and 180s. 
 
4.2.4.1 Analysis of data obtained from DMA-measured ODF samples 
adhesive force profiles for the calculation of the Area Under the 
Curve (AUC) 
 
The adhesive force profiles of the four PVOH- and CMC-based single-polymer ODF 
samples could not be directly compared with in vivo data on perceived stickiness 
acceptability collected by human panel, as in vitro adhesive force was measured for the 
duration of the adhesive interaction between 0 and 240 seconds. Therefore, the Area 
Under the Curve (AUC) for adhesive force vs. time figure was calculated based on the 
disintegration time measured in vitro by drop method. X-axis values for AUC calculation 
were approximated to the closest time point assessed in the DMA experiment. For 
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instance, in the case of sample C1, the in vitro-measured disintegration time was 52 
seconds, and hence the AUC was calculated between 0 and 60 s on the x axis (Fig.4.3).  
 
 
Figure 4.3: Example of AUC calculation of ODF samples. Integration was calculated for x values between 0 
and the disintegration time measured in vitro by drop method (yellow area). 
 
4.2.5 In vitro disintegration time assessment of ODF samples by drop method 
 
The drop method was identified in chapter 3 as the most suitable in vitro method to 
measure ODF disintegration time, because the resulting data collected for samples P1, 
P2, C1, and C2 were the closest to the in vivo measurement compared to other in vitro 
methods. Therefore, the same experimental protocol was maintained with the only 
difference being the use of SSF instead of deionised water as disintegration medium. 
 
4.2.6 Data analysis 
 
Datasets were analysed using GraphPad Prism 7 (GraphPad Software Inc., La Jolla, 
US.). AUC was calculated using the approximated trapezoid rule. A One-way analysis 
of variance (ANOVA) followed by Tukey’s multiple comparison post hoc test was 
conducted in order to identify statistically significant differences among sample AUCs. 
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Other normally distributed, continuous datasets were analysed using one-way ANOVA 
followed by Tukey’s post hoc test. Linear regression was performed using the ordinary 
least squares method. 
 
4.3 Results and discussion 
 
4.3.1 Formulation optimisation of ODF samples by mechanical properties 
 
Poly(vinyl) alcohol 197 kDa, and 39 kDa were respectively selected based on previously 
obtained in vivo, and in vitro data as examples of poorly-, and highly-acceptable film-
forming polymers, and developed into full ODF formulations in order to understand how 
the addition of excipients, and different concentrations of API, influenced the in vitro 
predicted stickiness acceptability, and in vivo perceived stickiness acceptability (only 
placebo formulations were tested in vivo). Mechanical properties are very often 
measured as a quality control parameter when a new ODF formulation is developed 
[208], and are key quality discriminative parameter in the industrial setting ensuring that 
the ODF product is able to withstand mechanical stresses. The concentrations of the 
excipients were optimised based on the ODF sample mechanical properties, in order to 
satisfy the acceptable ranges specified by Visser et al., 2015, and Borges et al., 2016 
[207,209]  (Tab. 4.2). 
 
Table 4.2: Acceptable ranges of ODF mechanical properties published by Visser et al., 2015, and Borges et 
al., 2016. 
Mechanical property Visser et al., 2015 Borges et al., 2016 
Tensile strength (MPa) >2 15-35 
Elongation at break (%) >10 5-40 
Young’s modulus (MPa) <550 100-1500 
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4.3.1.1 Thickness measurement of ODF samples 
 
The thickness of the optimised formulations did not significantly differ between samples, 
and it maintained values between 90 and 105 µm. Single-polymer ODF samples had a 
thickness of 76-77 µm. Results are summarised in Tab. 4.3 
 
Table 4.3: Thickness of single-polymer PVOH ODF samples, and optimised formulations (n = 3). 
 
Sample Thickness (µm) 
P2 76.33 ± 6.63 
F1 91.92 ± 3.61 
F7 90 ± 3.99 
F8 92 ± 5.97 
P1 77.5 ± 2.36 
F4 105 ± 7.56 
F5 98.33 ± 4.49 
F6 97.33 ± 7.43 
 
4.3.1.2 Tensile strength 
 
Tensile strength, elongation at break, and Young’s modulus of ODF samples are 
presented in Figure 4.4 a, b, and c. 
 
 
 
a) 
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Figure 4.4: Tensile strength (a), Young's modulus (b), and elongation at break (c) of the optimised ODF 
formulations are compared with single-polymer ODFs (n = 3). Asterisks refer to statistical significance in 
comparison with the correspondent single-polymer ODF (F1, F7, F8 compared with P2; F4, F5, F6 compared 
with P1). 
 
The highest tensile strength values were exhibited by the high-molecular weight single 
polymer PVOH (P2), followed by F1, with 41.36 ± 0.41 MPa, and 32.72 ± 0.89 MPa 
respectively. The lowest value of 15.82 ± 1.72 MPa belonged to sample F6. The tensile 
strength is an indicator of the robustness of the film in response to mechanical tensile 
stresses. P2 and P1, corresponding to high- and low-molecular weight single polymer 
PVOH films, differed considerably in tensile strength (p<0.001), suggesting that 
increasing molecular weight of the film-forming polymer can confer higher resistance to 
load. This behaviour has been observed by Nunes and colleagues, who explained that 
for molecular weights higher than 105 Da, the polymeric chains showed enough 
entanglement to exhibit a rubbery behaviour, therefore acquiring resistance to load [210] 
compared to lower molecular weights, however, the glass transition temperature (Tg) of 
b) 
c) 
 140 
PVOH ranges between 70 and 90 °C. Significant differences were found between P2, 
and samples F7 (p<0.001) and F8 (p<0.0001), whereas no significant difference was 
observed with sample F1. The lack of difference in tensile strength between samples P2 
and F1 suggests that the addition of plasticiser, known for its ability to lower the tensile 
strength of films [211,212], did not have a significant effect, or its influence was likely 
mitigated by other excipients, most likely of polymeric nature. On the contrary, the 
addition of PSP decreased significantly the tensile strength in a concentration-dependent 
way, in accordance to what observed by Visser [61]. There was no significant difference 
between P1, and F4, F5 or F6. The addition of excipients, and API seemed to have little 
effect on the tensile strength of the low-molecular weight PVOH samples. This might be 
due to the low-molecular weight of the film-forming polymer and the already poor ability 
of its chains to entangle with each other [210]. Visser, and Borges both published ranges 
of acceptable mechanical properties for orodispersible films [207,209] (Tab. 4.2), based 
on a quality-by-design study in the first case, and on measurements conducted on 
commercial products in the second.  According to the tensile strength values reported in 
Borges et al., 2016, only sample P2 was outside the acceptable range, whereas all 
samples’ tensile strength would be acceptable according to Visser et al., 2015. The value 
ranges reported in the two articles refer to marketed ODF formulations, including one or 
a blend of film-forming polymers, plasticiser(s), API(s), and possibly other excipients. It 
is therefore acceptable for the tensile strength of sample P2 to fall outside the acceptable 
limits. It is possible to affirm that all the placebo and drug-loaded formulations were 
successfully optimised according to tensile strength.  
 
4.3.1.3 Young’s modulus 
 
The Young’s modulus of single-polymer ODF samples was very high, indicating non-
ideal elastic properties. The highest modulus of 5,551.0 ± 5.4 MPa was measured in 
sample P1, and the lowest modulus of 213.6 ± 54.2 MPa in sample F1. A considerable 
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difference was noticeable between single-polymer, and optimised samples, indicating 
that the addition of excipients, particularly the plasticiser, decreased the Young’s 
modulus and improved elasticity [212]. Significant differences were observed between 
F1, and F7, F8, suggesting that PSP slightly increased the modulus, in accordance with 
the effect of PSP observed on different ODF formulations [61]. However, PSP loading 
seemed to have no influence on the Young’s modulus of optimised formulations 
prepared from low-molecular weight PVOH. The Young’s modulus is a measure of the 
recoverable deformation of a material, indicating the ability to re-gain the original shape 
after a stress is applied [213]. This property is tightly dependent on the properties of the 
material analysed, and does not necessarily correlate with other mechanical properties 
[210]. However, it depends on the flexibility of the polymeric atoms to move in 
dependence on the bonds with other atoms, and the empty space available around them 
[214]. As long as polymeric chains are prevented to slide past each other, and do not 
break bonds, the polymeric structure will recover its shape [214]. In this respect, the 
molecular interaction between long or short polymeric chains, and plasticiser and API, 
and the order in which the excipients were added to the mixture could have determined 
the difference observed between samples F1 and F4. In support of this finding, glycerol 
added to PVOH was reported to reduce the interactions between polymeric chains [212].  
According to the mechanical property ranges specified by Borges (Tab. 4.2), all the 
moduli of the optimised formulations were acceptable, whereas those of single-polymer 
ODF samples were not. On the contrary, only the Young’s modulus of formulation F1 
would be acceptable if the more restrictive parameters reported by Visser were 
considered.  
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4.3.1.4 Elongation at break 
 
A % elongation at break of 142.89 ± 6.89% was reached by sample F4, and it was the 
largest deformation detected among the analysed samples. The smallest deformation of 
1.667 ± 0.33%  was exhibited by sample P1. The % elongation of single-polymer films 
was very small, indicating brittleness, and poor resistance to deformation. Significant 
differences in elongation at break were found between F1 and P2 (p<0.001), between 
F7 and P2 (p<0.05), and between F4 and P1 (p<0.0001), F5 and P1 (p<0.001), and F6 
and P1 (p<0.01). The % elongation at break is calculated from the strain at which a 
material breaks [215], and represents the ability of the material to resist changes without 
cracking, with high % values corresponding to highly deforming materials. The addition 
of excipients increased considerably the elongation of optimised formulations [212] in 
comparison with the single-polymer films, as opposed to the drug loaded formulations, 
where the addition of API that decreased the deformation [61] in a concentration-
dependent manner. An anti-plasticising effect of drug-loaded API was reported by Buanz 
and colleagues [216]. The % elongation at break of none of the ODF formulations, except 
P2 would be acceptable according to Borges, whereas the deformations of all samples 
except P1 would be considered acceptable according to Visser.  
 
4.3.1.5 Comparison with literature data 
 
Solvent-cast PVOH films (DS 95.5%) 10% (w/v) were reported to have a tensile strength 
of 20 MPa, a % elongation of 300%, and a Young’s modulus of 2,000 MPa [217]. A 150 
µm thick, 10% w/v PVOH (133 kDa, DS 98%) film was reported to have a tensile stress 
of 105 MPa, a % elongation at break of approximately 100%, and a Young’s modulus of 
2,500 MPa [218]. A 78 kDa 5% (w/w) PVOH film (DS 87-89%) was reported to have a 
tensile strength of 14 MPa, and a % elongation at break of approximately 210% [219]. 
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Mechanical properties data found in the literature differed from those exhibited by the 
tested PVOH-based formulations. A potential explanation could involve the lower 
concentrations, thickness, and potentially different polymeric molecular weights used in 
the present study compared to those used in the other literature works. In particular, the 
elongation at break and Young’s modulus of samples P1 and P2 appeared outside the 
range reported in the literature data. This difference might be attributed to the lack of 
plasticising effect, which have prevented brittleness, and improved the elastic 
deformation component.  
 
4.3.2 Tack assessment of ODF samples by DMA analysis 
 
4.3.2.1 ODF samples AUC calculation and in vivo/in vitro correlation with 
perceived stickiness acceptability data 
 
The calculation of the AUC led to the identification of a correlation with in vivo 
perceived stickiness acceptability scores assigned by pilot human panel participants. 
Results are shown in Fig. 4.5.  
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Figure 4.5: AUC values of four single-polymer ODF samples (a) (n = 3), compared with in vivo perceived 
stickiness PROs (b) (session 1), and linear regression of the two datasets (c). (R2=0.903; PRO data are 
from three sessions). 
 
 AUC values were calculated for the four single-polymer ODF samples. Statistically 
significant differences were identified between all samples (Fig. 4.5 a). An inverse 
correlation seemed to relate the hedonic rating on perceived stickiness reported by pilot 
human panel participants with the calculated AUC values. The higher the acceptability 
scores, the lower the AUC values (Fig. 4.5 a,b,c). The highest acceptability assigned to 
sample P1 also had the lowest AUC (5 ± 0.87, and 0.19 ± 0.12 respectively), whereas 
the lowest acceptability scores were assigned to samples P2 and C2 (2 ± 1.00), and the 
AUC values were 3.21 ± 0.92, and 4.46 ± 0.59 respectively. In this case the reliability of 
the linear regression model for the identification of an inverse correlation must be taken 
with care for two main reasons: the number of samples analysed was very little, and the 
two datasets were very different in nature, with the PROs scores being a categorical 
ordinal variable, and the AUC a continuous variable with residues not perfectly normally 
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distributed. Although this has not been identified as a precluding factor for using the 
Ordinary Least Squares (OLS) method to calculate linear regression [220], there are 
conflicting opinions on the topic. However, the preliminary regression analysis on the 
four single-polymer ODF samples paved the way towards a more extensive analysis that 
includes a higher number of samples. The identification of a correlation between 
perceived stickiness acceptability scores and AUC values also confirms the potential 
influence of disintegration time on the perception of ODF stickiness, as previously 
hypothesised.  
 
4.3.2.2 Tack assessment of an extended set of ODF samples by DMA 
analysis 
 
The extended set of samples was tested by DMA analysis in the same experimental 
conditions that were described in chapter 3, with the only different factor being the use 
of SSF instead of deionised water. 
 
4.3.2.2.1 Effect of PVOH molecular weight on ODF samples tack 
 
First, single-polymer, PVOH-based ODF samples were tested, in order to better 
understand the molecular weight effect on ODF tack. Results are presented in Figure 
4.6. 
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Figure 4.6: Adhesive force profile of PVOH 39 kDa (P1), 78 kDa (P3), 139 kDa (P4), and 197 kDa (P2) 
single-polymer ODF samples (n = 3). 
 
The adhesive force of sample P1 in SSF immediately increased to 0.0058 ± 0.0005 
N/mm2 after 10s of hydration, and maintained the same values until the end of the 
assessment. Samples P2 and P3 increased to higher values at 10s (0.0123 ± 0.0003 
N/mm2, and 0.0136 ± 0.0005 N/mm2 respectively), decreasing slightly to 0.0106 ± 
0.0004 N/mm2, and 0.0106 ± 0.0005 N/mm2 from 60s until the end of the experiment. 
Sample P4 reached an adhesive force of 0.0106 ± 0.0002 N/mm2, and maintained 
similar values until 180s. From the results obtained it appeared that the molecular 
weight of PVOH only influenced ODF tack above a certain threshold, while for 
molecular weights lower than 78 kDa, the force of the adhesive bond was relatively 
limited. A linear correlation between polymeric molecular weight and adhesion was 
reported by Gurney and colleagues, who assessed adhesion between styrene-
butadiene copolymers, in wet conditions, and for contact times shorter than 10s [221], 
however, there is no information about a linear relationship existing between molecular 
weight and adhesion in PVOH. A difference in adhesive force values was also detected 
when samples P1, and P2 were tested in deionised water, however in that case, the 
values were consistently higher, potentially indicating that the presence of salts 
dissolved in the hydration medium could lower adhesion between polymer and steel 
plate [222]. 
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4.3.2.2.2 Effect of polymeric charge on ODF samples tack 
 
A fully-ionised Eudragit E PO â positively-charged, a fully-ionised CMC negatively-
charged, and high and low-molecular weight CMC ODF samples were tested in order 
to assess the involvement of charges in the adhesive bond between ODFs and DMA 
plates. Adhesive force profiles are plotted in Figure 4.7. 
 
 
Figure 4.7: Adhesive force profiles of ionised Eudragit E PO (R) (E1), low-molecular weight CMC (C1), high-
molecular weight CMC (C2), and fully-ionised, low-molecular weight CMC (C3) ODFs (n = 3). 
 
The adhesive force of Eudragit â film was characterised by an almost repulsive force, 
reaching negative values until 100s. Higher adhesive force values were exhibited by 
both fully-ionised CMC (max. adhesive force 0.0231 ± 0.0002 N/mm2), and low-
molecular weight CMC (max. adhesive force 0.0342 ± 0.0003 N/mm2), with a decrease 
of the fully-ionised CMC adhesive bond strength after 60s of hydration. Takehara and 
Fukuzaki explored the adsorption behaviour of charged and unionised pectin on 
untreated and treated stainless steel [223]. They discovered that stainless steel 
treatment incrementing the availability of basic hydroxyl groups on the steel surface, 
favoured the adsorption of unionised pectin by bonding with pectin polar groups (-
COOH, and -OH). They also found that the degree of ionisation of pectin influenced its 
affinity for the steel surface. The adsorption of ionised pectin molecules to the stainless 
steel surface was predominantly mediated by the formation of ion pairs at the contact 
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region, however, adsorption was pH dependent. At higher pH, ionised pectin molecules 
tended to develop intermolecular repulsive forces, preventing the formation of 
intermolecular hydrogen bonds, and thus the formation of compacted structures able to 
adhere to stainless steel by both adhesive and cohesive mechanisms [223]. The lack in 
cohesion might have negatively affected the strength of the adhesive bond. A similar 
event might have taken place in the present study. The low-molecular weight CMC was 
more free to establish hydrogen bonds with the stainless steel clamp, whereas its fully-
ionised counterpart might have initially established ion pairs, in addition to the available 
hydrogen bonds. When the film began disintegrating, and the charged molecules 
became free to move in a high-pH environment, the more prominent repulsion between 
charges of the fully-ionised CMC and the consequent weakening of intermolecular 
cohesion might have caused the observed decrease in adhesive strength. It must be 
noticed how the standard error of the low-molecular weight CMC film adhesive force 
widens considerably at 180s. A potential explanation for this could be that the SSF 
used in the experiment has a pH of 7.4. This could mean that, as soon as the SSF gets 
in contact with CMC carboxyl groups, the lasts ionise, and the film decreases in 
cohesion, and thus in tack, due to the mechanisms previously explained. Moreover, the 
difference in adhesive force profiles between high- and low-molecular weight CMC 
films that was observed during the first DMA study (chapter 3) was confirmed, with an 
overall reduction of adhesive force values, and a delay in the peak adhesive force in 
sample C1. This difference could be attributed to the presence of dissolved salts in the 
SSF utilised.   
 
4.3.2.2.3 Effect of hydrophobic polymers on ODF samples tack 
 
Two ODF samples, one with, and one without the presence of the hydrophobic polymer 
PVAc were assessed by DMA. Adhesive force profiles are reported in figure 4.8. 
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Figure 4.8: Adhesive force profiles of ODF sample containing PVAc (H1), and ODF sample without PVAc 
(H2) (n = 3). 
 
The two ODF formulations differed only in the presence of PVAc. The adhesive force of 
both films tended to slightly increase over time, and to decrease at initial values at 
180s. However, consistently higher adhesive force values were exhibited by the 
hydrophilic film, suggesting that the presence of hydrophobic excipients weakened the 
adhesive bond between films and steel plate. Stainless steel is considered hydrophilic, 
with contact angles of approximately 90° [224]. It is no surprise, then that hydrophobic 
interactions are unlikely to be involved in the adhesive bond between ODFs and DMA 
plates. It is therefore possible that the hydrophobic component of sample H1 had 
contributed to decreased adhesion by reducing the area of the hydrophilic polymer 
available to form hydrogen bonds with the stainless steel surface. 
 
4.3.2.2.4 Effect of excipients on ODF samples tack 
 
No significant difference was observed when the adhesive force profile of a placebo 
optimised formulation containing a combination of two polymers, plasticiser, sweetener, 
and flavour was compared with that of the same formulation deprived of sweetener and 
flavour, or deprived of part of the polymeric component (Fig. 4.9).  
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Figure 4.9: Adhesive force profile of PVOH (high m.w.) optimised formulation (F1), polymers and plasticiser 
ODF sample (F2), PVOH, plasticiser, sweetener, and flavour ODF sample (F3) (n = 3). 
 
The adhesive force values of all three samples were in the range of 0.010 N/mm2, and 
did not change significantly for the whole experiment. The adhesion profile was also 
consistent with that of the single-polymer ODF samples prepared with high-molecular 
weight PVOH (P2) (Fig. 4.6). The rationale behind this experiment was to assess 
whether any difference in adhesion behaviour was observable in vitro among the three 
samples, and if the presence or absence of palatability-enhancing excipients such as 
sweetener and flavour could influence the perception of ODF stickiness in in vivo 
experiments. The relevant results will be given in chapter 5. 
 
4.3.2.2.5 Effect of drug loading on ODF samples tack 
 
Optimised placebo formulations were compared with correspondent formulations drug-
loaded with 1mg or 5mg PSP. The formulations were optimised from the highly-
acceptable film-forming polymer (PVOH 39 kDa), and the poorly acceptable film-
forming polymer (PVOH 197 kDa), based on the participant-reported outcomes (PROs) 
obtained from the pilot human panel. Adhesive force profiles are presented in Fig. 4.10. 
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Figure 4.10: Adhesive force profile of PVOH 197 kDa placebo formulation (F1), and drug-loaded with 1mg 
(F7), and 5mg (F8) PSP; and adhesive force profile of PVOH 39 kDa placebo formulation (F4), and drug-
loaded with 1mg (F5), and 5mg (F6) PSP (n = 3). 
 
The adhesive force values of both the formulation families did not change significantly 
over time, and were consistent with the profiles of the corresponding single-polymer 
ODF samples (Fig. 4.6). Only sample F7 seemed to deviate from the adhesive force 
profile of samples F1, and F8, with values increasing more slowly over time. However 
difference with F1, and F8 were not significant. The addition of excipients (samples F1 
and F4), and of increasing concentrations of API did not seem to affect the tack of ODF 
samples in any way, underlining the relevance of the appropriate selection of the main 
film-forming polymer for the development of highly-acceptable ODF products. 
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4.3.3 In vitro assessment of ODF samples disintegration time 
 
The disintegration time of the analysed ODF samples was assessed by drop method. 
Results are summarised in table 4.11. 
 
 
Figure 4.11: In vitro ODF samples disintegration time measured by drop method (n = 3). 
 
The in vitro disintegration time of the single-polymer PVOH-based ODF samples 
increased according to molecular weight, however only the difference between P1 and 
P2 was statistically significant (p<0.01), and both disintegration times were similar to 
those reported in chapter 3. Sample E1 quickly broke where the drop was located, 
however the SSF did not form a round-shaped hole as it did for other samples. A 
potential explanation for this behaviour could reside in the insolubility of Eudragit E PO 
â at high pH. Probably, the SSF (pH 7.4) was able to dissolve the film only until the pH 
of the film was sufficiently concentrated, allowing just the time to break the surface in 
its weakest points. As soon as the SSF neutralised the pH, Eudragit E PO â was no 
longer solubilised, and the erosion process was halted. Samples C1 and C2 differed 
considerably in disintegration time (p<0.0001), and even though the disintegration time 
of sample C2 was similar to that reported in chapter 3, sample C1 disintegrated slightly 
faster. Sample C3 disintegrated almost as fast as sample C1, which was expected 
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since the two ODF samples were made with the same polymer. Sample H1 
disintegrated in 25.1 ± 1.3 s, however the drop could fall because the surface of the 
film was broken in correspondence of the drop without the typical round-shaped 
erosion front formation. Such observation could be explained by the formation of areas 
of the ODF surface more concentrated in hydrophilic polymer, and functioning as 
“tunnels” for the passage of liquids. Thus, instead of the concentric progression in 
surface erosion typical of hydrophilic polymers, a cut through the surface was observed 
instead. H2 disintegrated faster than H1, thanks to the lack of hydrophobic polymer. F2 
disintegrated much slower than F1, and F3, however the difference in disintegration 
time was significant only against sample F3 (p<0.01). It appeared that the presence of 
polyvinylpyrrolidone (PVP) and absence of sucralose and furanone had the effect of 
prolonging F2 disintegration time. No significant difference was observed between F1, 
F7, and F8, and between F4, F5, and F6, indicating that the addition of API did not 
affect the disintegration time. 
 
4.4 Conclusions 
 
The calculation of the AUC represented a quantitative predictive method to estimate 
the perceived stickiness acceptability of ODFs. A linear correlation was found between 
AUC and acceptability scores assigned by participants to four single-polymer ODF 
samples assessed in vivo and in vitro in chapter 2 and 3 respectively. An extended set 
of ODF samples were formulated, and some of them optimised by mechanical 
properties before their adhesive force profiles were studied by DMA. The molecular 
weight of the film-forming polymer, as well as the addition of the model drug 
prednisolone sodium phosphate (PSP) affected the tensile strength and elongation at 
break of ODF samples, however only the addition of excipients and PSP influenced the 
Young’s modulus. With regards to the type of interactions contributing to the adhesive 
bond forming between ODF samples and the stainless steel plate of the DMA 
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equipment, hydrophobic interactions were excluded, and negatively and positively-
charged polymers were found to inhibit, or even impairing adhesion. The addition of 
increasing concentrations of PSP did not influence the strength of the adhesive bond, 
although the molecular weight of PVOH seemed to determine the tack of the ODF 
sample, regardless the presence of other excipients. This suggested that, by 
appropriately selecting the film-forming polymer, it might be possible to determine the 
stickiness acceptability of the final ODF product. There was no linear relationship 
between PVOH molecular weight and ODF tack, but rather a threshold-dependent 
mechanism, where below a certain molecular weight (39 kDa), the adhesion of ODFs is 
limited. Disintegration time of the analysed ODF samples was measured by the drop 
method, in order to serve as parameter for the calculation of the AUC. As expected, the 
disintegration time of PVOH samples increased according to the polymeric molecular 
weight. A marked difference between high, and low-molecular weight partially-ionised 
CMC samples was confirmed from the previous in vitro study, whereas fully-ionised 
polymers disintegrated relatively fast. The hydrophobic component caused the sample 
to become insoluble, as opposed to its hydrophilic counterpart. The addition of API only 
influenced the disintegration time of ODF samples based on high-molecular weight 
PVOH, but not those based on low-molecular weight polymer. The addition of 
plasticiser, sweetener, and flavour tended to shorten the disintegration time of ODF 
samples. Considered together, all the DMA study pointed to the importance of polar 
interactions in the adhesion between ODFs and DMA plates, confirming that the 
adsorption theory, in addition to the fracture theory, is one of the adhesion mechanisms 
more likely to describe the observed ODF tack phenomenon. Phenomena explained by 
the electronic theory seemed, on the other hand, to have a limited influence on the 
bonding between negatively-charged fully-ionised CMC, and metallic plate, and no 
influence at all in the case of positively-charged polymers. In order to confirm that the 
calculation of AUC from DMA adhesive force profiles can in fact predict in vivo 
perceived stickiness acceptability, some samples that were tested in vitro will be 
assessed in vivo by a second human panel. Unfortunately, some key ODF samples 
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such as those made from fully-ionised positively, and negatively-charged polymers 
were characterised by an extreme pH, making them not suitable for human 
consumption. Thus, such samples cannot be further analysed in vivo by a human 
panel. However, differences in adhesive characteristics between DMA and human 
mouth will be assessed, with regards to the role of polar interactions, hydrophobic 
interactions, and the effect of excipients in the perception of stickiness, in chapter 5. 
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Chapter 5.  Assessment of the in vitro/in vivo correlation of 
ODF perceived stickiness acceptability 
 
This chapter describes the in vitro/in vivo correlation between the area under the curve 
(AUC) values calculated from the tack data previously collected on an extended set of 
orodispersible films (ODF) samples, and the perceived stickiness Participant-Reported 
Outcomes (PROs) obtained by a second human panel. The extended set of samples 
tested included single-polymer films made with four poly(vinyl) alcohol (PVOH) 
molecular weights, one sample with the hydrophobic polymer polyvinyl acetate (PVAc), 
and one having the same composition except PVAc. Furthermore, an optimised 
placebo ODF formulation, and its corresponding high polymer/excipients ratio, and low 
polymer/excipients ratio were tested. Healthy adults were recruited and were asked to 
assess ODF samples perceived size, perceived thickening effect, perceived thickness, 
perceived stickiness, and perceived disintegration time. The same study design was 
maintained from the pilot human study in chapter 2, whereas the intensity of the ODF 
sample perceived thickening effect, and perceived ODF sample stickiness intensity 
was measured on a five-point score system. In vivo/in vivo correlation was calculated 
between the comfort/discomfort, and intensity PROs of the perceived thickening effect 
and perceived stickiness attributes. The AUC of the tested samples was calculated 
from the tack data previously collected by DMA, and using the disintegration time 
measured in vitro by drop method. Subsequently, the in vitro/in vivo correlation with the 
perceived stickiness PROs was calculated. The correlation resulted non-linear, and the 
PROs from other attributes, and from the semi-structured interview suggested the 
existence of a potential influence of other ODF attributes on stickiness perception. The 
utilisation of in vitro-measured disintegration time by drop method for the calculation of 
AUC values showed an underestimation of the latest, indicating that a more accurate in 
vitro disintegration time method needs to be optimised. 
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Aims: 
- To confirm in vitro/in vivo correlation between predicted and perceived ODF 
disintegration time and stickiness acceptability. 
- To identify the influence of other acceptability attributes in the perception of 
ODF stickiness 
Objective: 
- To conduct a second human panel to evaluate in vivo the acceptability 
attributes of the extended set of ODF samples previously assessed in vitro in 
chapter 4. 
 
5.1 Introduction 
 
5.1.1 Selection of ODF samples for in vivo assessment by a second human 
panel 
 
In the previous chapter, a correlation was found between the AUC calculated from the 
samples’ adhesive force profile measured over time, and the perceived stickiness 
PROs of the pilot human panel. The number of samples tested was limited, and in 
order to explore the adhesion mechanisms involved in the DMA experiment, purposely-
formulated ODF samples needed to be analysed. Four different molecular weights of 
PVOH, a fully-ionised carboxymethylcellulose (CMC), and Eudragit E POâ-based ODF 
samples were analysed for tack by DMA. In addition, the tack of an ODF sample 
containing the hydrophobic polymer PVAc and its corresponding formulation without 
PVAc, of two complete ODF formulation loaded with different concentrations of 
prednisolone sodium phosphate (PSP), and of a complete ODF formulation with and 
with different polymer-to-excipient ratios was also analysed in vitro. In this chapter 
some of the samples that were assessed for adhesive force by DMA are also selected 
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for acceptability assessment in a second human panel, in order to confirm whether an 
in vivo/in vitro correlation exists between the calculated AUC and PROs for ODF 
perceived stickiness. Due to safety reasons, some of the samples analysed by DMA 
could not be assessed in vivo, preventing from formulating a hypothesis on the 
mucoadhesion theories most likely to contribute to the adhesion between ODFs and 
human palate. Due to the extreme pH and the presence of corrosive material, the fully-
ionised positively, and negatively-charged ODF samples were not given to the panel 
participants. CMC-based ODF samples were also not given to participants because 
they were already tested in the pilot human panel, and thus they would have 
represented an unnecessary burden. Due to the presence of an active pharmaceutical 
ingredient, also the drug-loaded ODF formulations were not given to participants. 
The remaining samples eligible for in vivo administration corresponded to the four single-
polymer PVOH-based samples, the two samples with and without a hydrophobic 
polymeric component, and the optimised high-molecular weight PVOH samples 
containing all the excipients, or with a high or low polymer-to-excipients ratio.  
 
5.1.2 Selection of ODF attributes to be investigated based on the results of 
the pilot human panel 
 
From the results of the pilot human panel conducted on 24 healthy adult volunteers, 
key ODF acceptability attributes, and manufacturing variables influencing the end-user 
acceptability were identified. The main attributes potentially influencing the end-user 
acceptability were tested for acceptability, and intensity where possible, by using a five-
point hedonic facial scale, and a four-point ranking system respectively. The 
acceptability of the perceived ODF thickness, perceived stickiness, and perceived 
disintegration time varied among the four samples, and were therefore identified as 
potentially influencing attributes. The same attributes were investigated in the second 
human panel on a different set of samples. Perceived size was also analysed as a 
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negative control attribute. More information on ODF attributes affecting acceptability 
was collected by means of a semi-structured interview conducted at the end of each 
sample assessment. In addition to samples perceived thickness, stickiness, and 
disintegration time, attributes such as taste, a “drying”, or thickening effect on saliva, 
stiffness, brittleness, tendency to fold/form lumps, and sample thickness inhomogeneity 
were reported by participants as requiring improvement. Samples’ thickness 
inhomogeneity could have been related to the in-house manufacturing method lacking 
of a levelling knife, while the tendency to fold and form lumps could have been an 
intrinsic characteristic of polymeric thin films, and the result of ODF manipulation in the 
mouth. On the other hand, the stiffness, the brittleness, the drying and thickening 
effects could represent relevant attributes for their potential to influence the end-user 
acceptability. The drying effect was not specifically investigated in this chapter because 
of the small number of volunteers who reported it in the pilot panel interview. The 
perceived thickening effect was investigated for its comfort/discomfort and intensity in 
the second human panel, although from the pilot semi-structured interview, only CMC-
based samples seemed to receive reports of such effect. Perceived thickening effect 
was investigated in the second panel, despite the absence of CMC-based ODF 
samples, because the use of other film-forming polymers or the addition of excipients 
to PVOH-based formulations could have contributed to such mouthfeel attribute. 
Similarly, the perceived ODF stiffness seemed to only affect PVOH-based samples. 
Perceived ODF stiffness is an attribute directly related to the mechanical properties of 
a material [225], rather than to its physicochemical properties. Assuming that fully 
optimised formulations accessing the market should meet certain standards in terms of 
mechanical properties, it is probable that their perceived stiffness should also be 
optimised. As a consequence, perceived stiffness was not specifically assessed in the 
second panel. In order to obtain more information on the tested ODF samples, a semi-
structured interview was carried out in a similar structure as that used in the pilot 
human panel.  
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5.1.3 Expected findings from the selected set of ODF samples 
 
The in vitro/in vivo correlation for the comfort/discomfort response, and the intensity of 
the perceived thickening effect and perceived stickiness, and perceived disintegration 
time should inform whether a direct correlation exists between the two variables or if 
there is an influence of other parameters/attributes.  
An important outcome expected from the second human panel would be the verification 
of whether an in vitro/in vivo correlation exists between the calculated AUC values, and 
PROs on ODF sample perceived stickiness. The AUC values will be calculated using the 
adhesive force profiles measured by dynamic mechanical analysis (DMA), and the 
disintegration time measured in vitro by drop method.  
Another potential source of information regards the suitability of existing in vitro methods 
for the measurement of ODF disintegration time, and consequently, for the calculation 
of AUC without the need of obtaining human data. The drop method proved to be the 
best methodology to accurately measure ODF disintegration time in vitro of the four 
samples analysed in chapter 2. The same method was used to calculate the AUC values 
of the extended set of samples in the present chapter. AUC values obtained with samples 
disintegration time measured by drop method  will be compared with the AUC values 
obtained from the real disintegration time measured in vivo in order to evaluate the 
suitability of the drop method for AUC calculation.  
Due to the limitations in the number of ODF samples that can be tested in vivo, it is likely 
that the role of positive or negative charges in the adhesion between ODF and human 
palate will not be investigated. Instead, the role of hydrophobic interactions are aimed to 
be investigated. 
Finally, the influence of flavouring and sweetening agents added to the ODF formulation 
on the perception of stickiness and overall acceptability will be assessed [226,227]. 
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5.2 Methods 
 
5.2.1 Human panel on healthy young adults 
 
5.2.1.1 ODF acceptability study 
 
A second single-centre, single-blind human panel was conducted on healthy young 
adults. The study was conducted in a single session, as no substantial difference in 
PROs was observed between the three sessions in the pilot human panel (chapter 2). 
However, samples containing sweetener and flavour, and unsweetened, unflavoured 
samples were presented to participants in separate days. Therefore, participants were 
asked to attend both days. The study was approved by the University College London 
Research Ethics Committee (REC ID 8249/002) on 29th November 2016 (Annex 2). 
Data collection, handling, and storage were conducted in accordance with the Data 
Protection Act 1998, after permission was obtained by the University College London 
Data Protection Office (Data Registration Number: Z6364106/2016/10/51). Volunteers 
were informed about the study details and potential hazard/risks involved by receiving 
the Participant Information Sheet (PIS), and, verbally, immediately before the study. 
Informed consent was signed by all participants prior to the assessment (Annex 2). 
 
5.2.1.2 Sample size, and inclusion/exclusion criteria 
 
Healthy volunteers aged between 20 and 49 years (median age 25 years) were 
recruited. Of  24 participants recruited, 18 were females, and 6 were males. The 
sample size was estimated by nomogram-assisted calculation based on the data 
obtained from the pilot human panel, according to the method described by Jones and 
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co-workers [228]. The sample size for a 95% confidence level and a power of 0.9 was 
estimated to be between 20 and 24 participants (depending on the item assessed). A 
power level of 0.9 was selected to ensure avoidance of type II error considering that 
the study: 
 
• Did not involve any drug-related safety trial or evaluation of efficiency of a 
medical-related screening method. Hence the selected power level could exclude 
the most restrictive parameters such as 0.95 or 0.99.  
• The statistical tests used were non-parametric, therefore the power level should 
have been increased compared to parametric analyses.  
 
It was concluded that a sample size of 24 was sufficient for the parameters specified. 
Inclusion/exclusion criteria were maintained identical from the pilot human study. Male 
and female volunteers able to understand and speak English could take part to the 
study. Volunteers were excluded if they had received dental care in the 15 days 
preceding the study, or anaesthetics into the mouth in the 24 hours preceding the 
study. Also, volunteers taking medicines altering salivation, or with any known 
hypersensitivity to excipients, or affected by sensory disorders of the mouth were 
excluded. 
 
5.2.1.3 Study design and data collection 
 
The study design, and flow chart were maintained similar to those of the pilot human 
panel, with slight modifications to the questionnaire. Each participant received six ODF 
samples in the first session (P1, P2, P3, P4, H1, and H2), and three in the second 
session (F1, F2, and F3) in a randomised order (Tab. 5.1). Comfort/discomfort 
assessment was carried out by participants for attributes such as size perceived in the 
mouth, thickness perceived in the mouth, stickiness perceived in the mouth, perceived 
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disintegration time, and thickening effect perceived on saliva, on a five-point hedonic 
facial scale, and data was collected as PROs. The intensity of the perceived stickiness, 
and thickening effect were evaluated by participants on a five-point scale ranging from 
non-sticky/thickened to extremely sticky/thickened. A multiple choice question was 
used to ask participants whether the ODF sample disintegrated in less than one 
minute, between one and three minutes, or in more than three minutes, however 
participants were also required to report the precise disintegration time as it appeared 
on the stopwatch display. Researcher-Reported Outcomes (RROs) were obtained by 
researchers using the same method and score point system adopted for the pilot 
human panel (chapter 2). Briefly, during sample intake, researchers assessed the 
facial expression, jaw movements, and intake performance of the participants, on a 2-
point score system. A semi-structured interview after the assessment of each sample 
was carried out, and the same questions of the pilot human panel were asked. In 
addition, participants were asked about their willingness to take the assessed sample 
every day, if it was a medicine. 
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Table 5.1: Codes and composition of ODF samples for human panel study. 
 
Sample code P1 P3 P4 P2 H1 H2 F1 F2 F3 
PVOH (39 kDa) 5% (83 kDa) 5% (130 kDa) 5% (197 kDa) 5% (39 kDa) 5% (39 kDa) 5% (197 kDa) 5% (197 kDa) 5% (197 kDa) 5% 
EudragitÒ E PO - - - - - - - - - 
CMC - - - - - - - - - 
PVP - - - - (30 kDa) 0.9% (30 kDa) 0.9% (30 kDa) 1.26% (30 kDa) 1.26% - 
SLS - - - - 0.10% 0.10% - - - 
PVAc - - - - 9% - - - - 
Glycerol (v/v) - - - - - - 0.25% 0.25% 0.25% 
Sucralose - - - - - - 0.10% - 0.10% 
4-Hydroxy-2,5-
dimethyl-3(2H)-
furanone 
- - - - - - 0.10% - 0.10% 
PSP (mg/film) - - - - - - - - - 
Solvent water water water water water water water water water 
Casting volume (mL) 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 
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5.2.1.4 Data and statistical analysis 
 
Hedonic scale, and Medicines Acceptability Scale (MAS) data were converted, and 
analysed as in the pilot human panel with the exception of the ODF perceived 
stickiness, and thickening effect intensity evaluation. The intensity of the perceived 
ODF sample stickiness, and thickening effect were converted into numerical values 
with non-sticky/thickened = 1, and extremely sticky/thickened = 5, and analysed as 
categorical ordinal variables (Tab. 5.2). 
 
Table 5.2: Five-point score system used for the in vivo assessment of the perceived thickening effect 
intensity, and perceived stickiness intensity of ODF samples. 
Word scale for 
perceived 
thickening effect 
intensity 
Not 
thickened 
Slightly 
thickened  
Moderately 
thickened 
Strongly 
thickened 
Extremely 
thickened 
Word scale for 
perceived 
stickiness 
intensity 
Non-sticky Slightly sticky 
Moderately 
sticky 
Strongly 
sticky 
Extremely 
sticky 
Corresponding 
assigned 
score 
5 4 3 2 1 
 
The actual disintegration time was treated as continuous variable. The yes/no answer 
about the willingness of participants to take the ODF sample every day was analysed 
as frequency distribution. Friedman’s test followed by Dunn’s multiple comparisons 
post hoc test (Prism 7, GraphPad Software Inc., La Jolla, US.) was used to calculate 
differences between samples for categorical variables, whereas one-way analysis of 
variance (ANOVA) followed by Tukey’s multiple comparison post hoc test was used to 
assess differences among samples (Prism 7, GraphPad Software Inc., La Jolla, US.). 
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5.2.2 Data analysis for in vivo/in vitro, and in vivo/in vivo correlation 
 
AUC values were calculated from the DMA data obtained in chapter 4, and analysed 
using the same method. In vitro/in vivo correlation, and in vivo/in vivo correlation were 
assessed by linear regression calculation using the ordinary least squares method, and 
by Spearman r correlation coefficient (Prism 7, GraphPad Software Inc., La Jolla, US.). 
 
5.3 Results and discussion 
 
5.3.1 Human panel on the mouthfeel evaluation of ODF 
 
A second human panel was conducted on 24 young healthy volunteers with the 
purpose of verifying the predictive capability of the DMA method on perceived ODF 
stickiness, and to assess the effect of palatability-enhancing excipients on stickiness 
and other mouthfeel attributes’ perception. During and after this human panel study, no 
discomfort or adverse reactions were reported. Results are summarised in Tab. 5.3, 
and Fig. 5.1. 
 
Table 5.3: PRO and RRO median and IQR values for each ODF sample presented by attribute (n = 24). 
                PROs 
 P1 P3 P4 P2 H1 H2 F1 F2 F3 
                             Attributes perceived on intake 
Size 4 
(1) 
4 
(1) 
4 
(1.75) 
4 
(1) 
4 
(1.75) 
4.5 
(1) 
4 
(1.75) 
5 
(1) 
5 
(1) 
Thickness 4 
(2) 
4 
(2) 
3 
(2) 
4 
(2) 
3 
(2) 
4 
(1) 
5 
(1) 
4 
(1) 
5 
(1) 
Thickening 
effect 
4 
(1.75) 
3.5 
(1) 
3 
(1) 
4 
(1) 
3 
(1) 
4 
(2) 
4 
(1.75) 
3 
(1) 
3.5 
(1.75) 
Stickiness 4 
(1) 
3 
(2) 
2 
(1) 
3 
(1) 
3.5 
(2.75) 
3.5 
(1.75) 
3.5 
(2) 
3 
(2) 
3 
(1) 
Disintegrati
on time 
4 
(1) 
4 
(1) 
2 
(1) 
2 
(2) 
1.5 
(1.75) 
5 
(1) 
3.5 
(2.5) 
2.5 
(2) 
3.5 
(2) 
 Attribute intensity 
Thickening 
effect 
1.5 
(1) 
2 
(0) 
2 
(2) 
2 
(2) 
1 
(1) 
2 
(1.75) 
2 
(0.75) 
2 
(1.75) 
2 
(2) 
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Stickiness 2 
(1) 
3 
(1) 
3 
(1) 
3 
(2) 
2 
(1.75) 
3 
(1) 
3 
(1) 
3 
(1.75) 
3 
(1.75) 
                RROs 
 P1 P3 P4 P2 H1 H2 F1 F2 F3 
Facial 
expression 
1 
(0) 
1 
(0) 
1 
(0.75) 
1 
(0) 
0 
(1) 
1 
(0) 
1 
(0) 
1 
(0) 
1 
(0.75) 
Jaw 
movements 
2 
(2) 
1 
(1) 
1 
(1) 
1 
(1.75) 
0 
(0) 
2 
(1) 
1 
(2) 
1 
(2) 
1 
(1.75) 
Sample 
intake 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
2 
(0) 
RRO total 5 
(2) 
4 
(2) 
3.5 
(1) 
4 
(1.75) 
2 
(1) 
4.5 
(1) 
4 
(1.75) 
4 
(2) 
4.5 
(1) 
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 Attributes perceived on intake PROs 
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Figure 5.1: Box and whisker plot of PROs and RROs presented by ODF sample and by attribute. The 
horizontal line in the middle of the boxes indicates the median, Yellow rectangles behind the boxes represent 
95% confidence intervals, lower and upper margins of the boxes represent the 25th and 75th percentile, and 
bars indicate the maximum and minimum values. Statistical differences between samples are indicated by 
the top horizontal bars, and p-values are represented by the asterisks. A hedonic rating of 3 and above on 
5-points scales was considered acceptable according to Mistry et al., 2017 [6]. In correlation graphs vertical 
and horizontal bars are indicated. For categorical variables, bars correspond to the interquartile range, 
whereas for continuous variables, bars represent the standard deviation. 
 
5.3.1.1 Perceived size and perceived thickening effect of ODF samples 
 
As expected, the control attribute represented by the perceived ODF size was 
evaluated between somewhat comfortable, and extremely comfortable in all samples 
by the majority of participants, with no significant differences among sample PROs 
(Tab. 5.3; Fig. 5.1).  
In the case of the ODF thickening effect and its perceived intensity, no significant 
difference was reported among samples (Tab. 5.3; Fig. 5.1). This result was not 
surprising, as none of the administered ODF samples was made with polymers with 
known thickening effect. A poor correlation was found between the perceived 
thickening effect comfort/discomfort, and the thickening effect intensity PROs 
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(R2=0.06452; r=0.122, n.s.), most likely due to the lack of thickening effect variability 
among the analysed samples (Fig. 5.1). 
 
5.3.1.2 Perceived thickness of ODF samples 
 
Participants reported differences in the acceptability scores of the ODF thickness, 
particularly between sample H1, and other ODF samples (Tab. 5.3; Fig. 5.1).  
Sample H1 was characterised by the presence of PVAc, a hydrophobic polymer that 
was combined with the other hydrophilic excipients by means of an emulsifying agent 
(sodium lauryl sulfate – SLS). After the drying process, the obtained film resulted of a 
high, non-uniform thickness, and had a very brittle consistency. Moreover, once placed 
in the mouth, sample H1 resided for a long time without thinning. Therefore, the 
perception of a highly thick sample reported by participants is reasonable for sample 
H1. No significant difference was found between the thickness acceptability scores of 
samples F1, F2, and F3, indicating that the presence or absence of sweetener and 
favour did not alter participants’ thickness perception. 
 
5.3.1.3 Perceived stickiness of ODF samples 
 
PROs on perceived stickiness are summarised in Tab. 5.3, and in Fig. 5.1. 
Sample P1 was reported to be a highly acceptable ODF with a low perceived stickiness 
intensity, receiving a median acceptability score of 4, and a median stickiness intensity 
score of 2. Significant differences were found with samples P4 (p<0.01), and P2 
(p<0.05) in both perceived stickiness acceptability, and intensity (p<0.05), whereas no 
significant difference was observed with sample P3. A low median stickiness intensity 
score (2) was reported for sample H1, significantly different from sample P4 (p<0.01), 
P2 (p<0.05), and H2 (p<0.05). 
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A high acceptability score for sample P1 compared to sample P2, corresponding to 
low, and high stickiness intensity scores respectively, were also reported by the 
participants of the pilot human panel, confirming the relationship between the tack of 
high-and low-molecular weight PVOH polymers. However, from the results of the 
second human panel, such relationship turned out to be non-linear, with sample P2 
(197 kDa) receiving higher median acceptability scores than sample P4 (130 kDa), 
although the difference was non-significant.  
Interestingly, the stickiness acceptability, and stickiness intensity scores of samples F1, 
F2, and F3 were very similar, indicating that the presence of palatability-enhancing 
excipients had no effect on the stickiness perception.  
There was a poor correlation between the perceived stickiness acceptability and 
intensity PROs (Fig. 5.3 c). The absence of a direct correlation suggests that the 
evaluation of the ODF perceived stickiness acceptability does not depend exclusively 
on the intensity of the stimulus, confirming previous findings (chapter 2). Most likely, 
other sensory attributes might be determining the samples end-user acceptability.  
 
5.3.1.4 Perceived stickiness intensity as indicator of in vivo ODF tack 
 
In the absence of a quantitative method to evaluate the strength of ODF adhesion to 
the human palate, the perceived stickiness intensity represents the best indicator of the 
in vivo ODF tack. In this respect, a low stickiness intensity was reported for samples 
P1, and H1, whereas the rest of the samples were evaluated moderately sticky. The 
threshold of 39 kDa as the PVOH molecular weight determining lower tack, in 
comparison to the higher-molecular weight polymeric counterparts was confirmed. The 
stickiness intensity of sample H1 was evaluated as lower than that of sample H2, again 
confirming the in vitro data. Finally, samples F1, F2, and F3 had similar perceived 
stickiness intensity, also reflecting the adhesive force profiles measured by DMA. As a 
result, it can be hypothesised that hydrophobic interactions are likely not involved in the 
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ODF adhesion in both the in vitro and in vivo systems. On the other hand, it cannot be 
excluded that polar interactions might be mediating the adhesive bond between ODFs, 
and both DMA plates and human palate.  
 
5.3.1.5 Perceived disintegration time of ODF samples 
 
Perceived disintegration time was assessed by participants, and its comfort/discomfort 
and real time as appeared on the stopwatch display were reported (Tab. 5.3; Fig 5.1). 
Similarly to the pilot human panel, an inverse correlation between perceived 
disintegration time acceptability and span was observed. The perceived disintegration 
time of sample H2 was considered extremely comfortable, whereas the disintegration 
time of samples P1 and F1 were evaluated between somewhat comfortable and 
extremely comfortable. Differences between sample P1, and P4 (p<0.001) and P2 
(p<0.001) were confirmed by statistical analyses, and so was the difference with H1 
(p<0.0001), and F2 (p<0.01), confirming the poor acceptability of samples P4, P2, and 
H1 with regards to the perceived disintegration time. There also was a significant 
difference in disintegration time acceptability between H1, and H2 (p<0.0001). A 
decrease in disintegration time acceptability was expected from P1, to P2 as a similar 
evaluation was reported in the pilot human panel. As disintegration time is supposed to 
be influenced by PVOH molecular weight, also the difference between P1, and P4 was 
foreseen, however, so was the difference between P1, and P3, which was, instead, non-
significant. Differences in acceptability between H1 and H2 was also not surprising 
because the presence in sample H1 of PVAc, a polymer which is insoluble in saliva, was 
characterised by a long permanence in the mouth, and could have made the formulation 
uncomfortable. Sample F2 was composed by two polymeric species and a plasticiser, 
and did not contain any sweeteners or flavours. On the contrary, samples F1, and F3 did 
contain such excipients, which seemed to have shortened the perceived disintegration 
time, and made it more acceptable. The perceived disintegration time acceptability 
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seemed to show some correlation with the real disintegration time measured by 
stopwatch (R2 = 0.7217; Spearman r = -0.8355, p<0.01) (Fig. 5.1). The linearity of the 
correlation improved if the set of flavoured samples was excluded from the calculation (R2 = 
0.9647), potentially indicating either the influence of taste in the acceptability of ODF 
disintegration time, or the different evaluation made by participants in the two assessment 
days. 
 
5.3.1.6 Researcher-Reported Outcomes 
 
The RROs were calculated as previously described in chapter 2, and results are 
summarised in Tab. 5.3, and Fig. 5.1 
Facial expression RROs did not evidence much variability among the samples, except 
for H1, which induced signs of distress in many of the participants. The same sample 
also had to be chewed, probably due to its insolubility. Samples P1 and H2 did not induce 
jaw movements, and also corresponded to samples characterised by a fast disintegration 
time. All other samples required 1 to 3 chews, or observed tongue movements before 
they were swallowed, however the IQR was wide, indicating a certain degree of 
variability. No sample loss was reported in any of the samples. Overall, samples that 
received the highest RROs were P1, H2, and F3, which were also characterised by either 
a fast disintegration time, or the presence of sweetener and flavour, and a reduced 
polymeric component. In general, participants did not encounter any difficulties hindering 
their ability to take the sample. 
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5.3.1.7 Semi-structured interview 
 
Like in the pilot human panel, a semi-structured interview was conducted in order to learn 
more about the participants’ experience. Answers are summarised in Tab 5.4. 
 
Table 5.4: Semi-structured interview results expressed as number of participants who gave the same 
answer. 
Participant 
comment 
P1 P3 P4 P2 H1 H2 F1 F2 F3 
Stiffness needs 
improvement (sharp 
edges) 
8 3 4 2 3 - - 1 - 
Disintegration time 
needs improvement 
1 2 8 7 9 3 5 8 8 
Taste needs 
improvement 
5 5 3 2 10 13 4 6 4 
Stickiness needs 
improvement 
1 9 9 9 8 3 5 7 5 
Thickness needs 
improvement 
1 1 3 4 1 2 2 3 4 
Size needs 
improvement 
2 - 1 1 - - - - - 
It has a thickening 
effect on saliva 
- 3 2 - - 1 - - 1 
Brittleness needs 
improvement 
1 - - - 2 1 - - 1 
Tendency to 
fold/form lumps 
1 1 2 - 2 1 2 3 1 
Inhomogeneity (one 
part dissolved 
faster) 
- 1 - 1 - 1 - 1 - 
It dries the mouth - - 1 - - 1 - - - 
It feels rough - - - - - - - - - 
Shape needs 
improvement 
1 - - - - - - - - 
Add colour 1 1 - - 1 1 - - - 
If feels like plastic 1 1  1 2 1    
Sweetness needs 
adjustment 
- - - - - - 4 - 2 
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High levels of stiffness and the presence of sharp edges were reported for samples P1, 
P2, P3, and P4, indicating that single-polymer ODF samples based on PVOH needed 
improvement in that direction. High stiffness was also reported by three participants for 
sample H1, which tended to lose its flexibility upon drying. Sample F2 was indicated as 
being stiff by one participant only. Compared to sample F1 and F3, F2 was characterised 
by the highest polymer/excipient ratio, probably reducing the flexibility of the resulting 
ODF.  
A shortening in disintegration time was required for samples P4 and P2, H1, F1, F2, and 
F3, as also confirmed by the perceived disintegration time acceptability (Fig. 5.1). P4 
and P2 corresponded to the highest molecular weight PVOH-based ODF sample, H1 
contained a part of hydrophobic insoluble polymer, and F1, F2, and F3 had high-
molecular weight PVOH as main film-forming polymer. All these samples, with the 
exception of H1, were also characterised by the longest disintegration time measured in 
vitro (Fig. 4.11 – Chapter 4). Fewer participants also indicated P1, P3, and H2 as 
samples requiring improvement with respect to disintegration time, however this result 
was not supported by in vitro disintegration data (Fig. 4.11 – Chapter 4), nor by other in 
vivo acceptability data (Fig. 5.1).  
Taste was a critical aspect addressed by panel participants. Sample H1, and H2 were 
reported having a bad taste by the majority of participants, and this could have been 
caused by the presence of SLS in both samples. In this respect, some complaints of 
“bitter aftertaste” were made. Taste was not considered acceptable, although by fewer 
participants, also for the PVOH-based sample, especially for P1, and P3. Surprisingly, 
four participants did not particularly like the taste of samples F1, and F3, indicating that 
they were too sweet, or too intensely flavoured, whereas F3 had no sweetener nor 
flavour, therefore an improvement in taste was deemed desirable by six participants.  
High stickiness levels were reported in samples P2, P3, P4, H1, F1, F2, and F3. Samples 
P2, P3, P4, F2, and F3 were associated with relatively low perceived stickiness 
acceptability (Fig. 5.1), whereas samples H1, and F1 received higher stickiness 
acceptability scores. There was a discrepancy between participants’ acceptability 
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scores, and their comments in the semi-structured interview for H1, and F1. With regards 
to sample H1, some comments indicated that the sample was indeed sticky in nature, 
but as it reminded participants of the consistency of a “candy”, it was deemed tolerable. 
In the case of sample F1, no additional comment helped to identify the reason for the 
different feedback. 
A desirable thickness improvement was suggested by a relatively low number of 
participants, with four people indicating samples P2, and F3 as “too thick”. Sample P2 
was considered thick also in the semi-structured interview conducted during the pilot 
human panel (Tab. 2.8 – Chapter 2). Participants commented that sample F3 became 
thick upon hydration with saliva, whereas samples containing a higher polymeric fraction 
did not. The in vivo perceived thickness was evaluated less comfortable for samples P4, 
and H1 (Fig. 5.1), which did not receive any comments in the semi-structured interview. 
The size of samples P1, P4, and P2 was considered unsuitable to two, and one 
participants respectively. It was also reported that this corresponded to the presence of 
sharp edges, therefore a reduction in size was proposed as potential solution. This could 
then explain the overall high acceptability of the ODF sample size obtained from the 
questionnaire (Fig. 5.1). Only the single-polymer PVOH-based samples received such 
comment.  
A thickening effect on saliva was indicated in samples P2, and P3 by two and three 
participants respectively, and by one participant for samples H2, and F3. Higher 
thickening effect intensity was reported for samples P2, P3, P4, H2, F1, F2, and F3, 
however only samples P4, H1, and F2 received lower, though non-significantly, 
acceptability scores (Fig. 5.1). The many inconsistencies in the evaluation of ODF 
sample thickening effect between hedonic scale evaluations, and interview suggested 
either the existence of a problem with how the questionnaire was phrased or explained 
to participants, or the influence of other factors in the perception of such attribute. On the 
other hand, the low number of participants who reported issues with the perceived 
thickening effect of samples in the semi-structured interview might justify the non-
significance of the differences in intensity and acceptability scores. The thickening effect 
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might have negatively influenced the perceived stickiness acceptability score of sample 
P4 considering that the perceived stickiness intensity scores of P2, P3, and P4 were very 
similar to each other, however this did not happen for samples H2, and F3.  
Brittleness was reported for samples P1, H1, H2, and F3, probably for a combination of 
short polymeric chains, and lack of plasticiser in samples P1, H1, and H2, and for the 
low polymer/excipient ratio in sample F3. 
The tendency to fold or form lumps was a widespread characteristic among the analysed 
ODF samples. All samples except P2 had at least one participant reporting this issue, 
which could be linked to the nature of PVOH.  
Very few participants reported the necessity for improvement in thickness homogeneity, 
drying effect, roughness, and shape. 
The addition of colour was suggested as improvement for the difficulty to visualise and 
picking samples P1, P3, and H2. Instead, sample H1 was easy to see and pick up, but 
its appearance was cloudy and the addition of a colouring agent was seen as an 
improvement.  
The feeling of a plastic material in the mouth was reported for samples P1, P2, P3, H1, 
and H2, and it could be explained by the absence of excipients intended to improve the 
mechanical properties of ODFs. 
Finally, the excessive sweetness of samples F1, and F3 resulted uncomfortable to 
participants, and it pointed out that the concentration of sweetener recommended by the 
manufacturer not always corresponds to acceptable palatability, especially if in 
combination with other excipients. 
During the interview, participants were asked if they were willing to take the ODF sample 
every day, if it was a medicinal product (Fig. 5.2). 
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Figure 5.2: Willingness to take the ODF sample every day (n = 24). 
 
Less than half participants were willing to take sample H1 every day, whereas the large 
majority of them were willing to take sample P1. Among the single-polymer PVOH-based 
samples P3, which had a lower molecular weight, a faster disintegration, and the same 
stickiness as samples P2, and P4, was considered to be taken daily by seventeen 
participants, and P2, and P4 by eighteen. Twenty-two participants would take the 
completely hydrophilic sample H2 daily. Twenty-one, nineteen, and twenty participants 
respectively were willing to take samples F1, F2 and F3 every day, indicating that, in the 
adult population, the addition of sweeteners and flavours had a limited influence on the 
overall willingness to take ODFs, whereas other attributes seemed to have a more 
prominent effect. Overall, all the samples analysed with the exception of sample H1 
would be taken every day, and without improvements by the majority of participants. This 
was also reflected in a total RRO score higher than 3, except in sample H1, and by 
perceived disintegration time acceptability scores higher than 2, whereas perceived 
stickiness acceptability scores were higher than 2 in all samples. This result suggests 
that the perceived disintegration time might have a prominent role in the willingness of 
end-users to take ODFs as medicines on a daily basis. 
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5.3.2 AUC calculation and in vitro/in vivo correlation of ODF samples 
perceived stickiness acceptability 
 
The AUC values for each sample were calculated as previously described in chapter 4. 
AUCs were therefore calculated using the disintegration time measured in vitro by drop 
method (Fig. 5.3 a), and differences with the AUC calculated using in vivo measured 
disintegration time (Fig. 5.4) were evaluated where possible. Disintegration times for 
AUC calculation were approximated to the closest time point at which ODF sample tack 
was measured in the DMA analysis.  
 
 
 
 
Figure 5.3: AUC calculated using the disintegration time measured by drop method (a) (n = 3), and 
correlation between AUC and perceived stickiness acceptability PROs (b). (R2 = 0.5151). Asterisks indicate 
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significantly different disintegration time compared with the corresponding in vivo disintegration time 
measured by participants. Vertical bars indicate standard deviation, whereas horizontal bars indicate the 
interquartile range. 
 
The AUC measured with in vitro disintegration data confirmed the existence of a certain 
degree of correlation with the perceived stickiness PROs (Fig.5.6 b), with low AUC 
values corresponding to high perceived acceptability scores. Nevertheless, the 
relationship between the two variables was not perfectly linear.  
 
5.3.2.1 Non-linearity due to data collection methods 
 
This could be due to two factors, also representing the major weaknesses of the 
developed method:  
 
• The number of response categories panel participants were required to choose 
among, in order to express their comfort/discomfort were few (5 points). In this 
respect, the utilisation of a 6 or 9 points hedonic scale, or a Visual Analogue 
Scale (VAS) for the assessment of ODF perceived stickiness could have resulted 
in a more accurate correlation with in vitro measurement. On the other hand, 
because the end-user population was not composed of trained panellists, panel 
participants might have encountered difficulties in using such scales, and results 
would have probably been too disperse. 
 
• The disintegration times used for the calculation of the AUC were rounded to the 
closest time point used to measure sample tack in the DMA analysis. This was 
done for purely practical reasons, in order to avoid the tack assessment of too 
many time points. By increasing the number of time points for tack assessment, 
the AUC values would probably correlate better with the perceived stickiness 
acceptability PROs. 
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Considering that the purpose of the method was to predict whether the formulation being 
developed would receive a positive acceptability feedback by the end-users, such 
degree of approximation could be considered acceptable. A good correlation was found 
in samples P1, P3, P4, and P2, indicating that linearity is maintained if ODFs are made 
of a single film-forming polymer. It is important to point out that the difference in perceived 
stickiness acceptability between samples P4, and P2 was non-significant, and the 
variability in the acceptability scores of sample P3, and P4 was wide. As a consequence, 
also the apparent inconsistency between AUC and perceived stickiness acceptability 
score of sample P3 might be non-significant. Sample H1 was also close to the resulting 
regression line. Low AUC values were found in sample H2, which was considered 
somewhat comfortable by participants. Also in the case of sample F1, F2, and F3 the 
AUC values were higher than expected compared to their acceptability assessment.  
Another potential cause of the poor linear correlation, could reside in the evaluation being 
carried out in two different days. Although in the pilot human panel, the evaluation of the 
four samples seemed to not differ among the three sessions, in the second human panel, 
the type of samples assessed differed between the assessment days. This might have 
caused a shift in the PROs because participants had different sets of samples to 
compare among. Reference samples have been used in some published works on the 
sensory evaluation of dosage forms, in order to provide a comparator for panellists 
[53,229]. If the reference sample changes, it is very likely that the outcome will be 
affected. 
 
5.3.2.2 Non-linearity due to the influence of other mouthfeel attributes 
 
The perceived disintegration time of ODFs is one of the parameters upon which the AUC 
is calculated, and it is one of the main contributors to the perception of ODF stickiness, 
as it was discussed before (chapter 4). 
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The thickness of samples P4, and H1 was evaluated less acceptable than the other 
samples, although this data was inconsistent with the participants comments in the semi-
structured interview. This might have contributed to further lower the perceived stickiness 
acceptability of sample P4, and to increase the AUC compared with other single-polymer 
ODF samples. During the interview, the highest number of participants (four) received 
comments related to the need to improve the thickness of samples P2, and F3.  
 
P4, H1, F2 had a poorer acceptability with regards to thickening effect, however it was 
difficult to determine whether the thickening effect was influencing the acceptability of 
the perceived stickiness.  
 
Samples H1 and H2, were indicated in the semi-structured interview as having a poor 
taste. 
Many participants reported that sample H1 struggled to dissolve, factor that should have 
negatively affected the perceived stickiness acceptability as reported in the previous 
study (chapter 4). Both poor taste and long disintegration time could have affected the 
stickiness perception of sample H1. Despite this, participants also admitted that the 
texture of sample H1 was familiar, and reminded them of candies, which might justify 
why the acceptability scores did correlated with the AUC. Another factor potentially 
contributing to the correlation between datasets for sample H1, could have been the 
lower perceived stickiness intensity. On the contrary, the poor taste of sample H2 was 
not compensated by a familiar consistency/texture, and might have resulted in poor 
acceptability with regards to stickiness. This might explain how the acceptability of H1 
was as expected despite its difficult disintegration, and the acceptability of H2 was lower 
than expected. 
With regards to sample F1, F2, and F3, there is the possibility that the presence of 
glycerol, which has a plasticising and sweetening effect, in the formulation might have 
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positively influenced not only the in vivo perception of stickiness acceptability, but also 
that of stickiness intensity. 
 
Different ODF attributes can have positive or negative effect on the perceived stickiness 
acceptability. A hypothesis on the potential relationship is summarised in Tab. 5.5. 
 
Table 5.5: Hypothesis on the potential effect of ODF attributes on perceived stickiness acceptability. (positive 
correlation =Ý ; negative correlation = ß). 
 
 
Perceived 
disintegration 
time 
Perceived 
thickness 
Perceived 
thickening 
effect 
Perceived 
good 
taste 
Perceived 
poor 
taste 
Effect on 
perceived 
stickiness 
acceptability 
ß ß ß Ý ß 
 
It was clear that several ODF attributes influenced participants’ perception of ODF 
stickiness, and therefore of its acceptability, however determining the dominance of one 
attribute over another, was not possible with the current dataset. To this end, a more 
detailed study to establish which sensory attribute is dominant, such as that described 
by Pineau et al., 2009 should be adapted to the set of attributes analysed, and carried 
out [230].  
 
5.3.2.3 Non-linearity due to the material properties of the in vitro 
equipment 
 
A second reason that could explain why the in vitro/in vivo correlation of samples AUC 
with human panel data was not linear could lie in the differences in materials between 
the DMA and the human mouth. The oral mucosa is characterised by an external layer 
of keratin, and by the presence of multiple protein species on its surface and solubilised 
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in saliva. The surface properties of the DMA stainless steel plate might exhibit some 
similarities with the human hard palate, therefore explaining the correlation between 
AUC, and the PROs on perceived stickiness of the first set of samples analysed. 
However, the absence of negatively-charged surface mucins might have prevented the 
Eudragit E POâ film from adhering, in contrast with what was observed when chitosan 
was used as mucoadhesive polymer [126]. Due to the extreme pH of the positively, and 
negatively-charged ODF samples, it was not possible to have a comparison between in 
vitro and in vivo stickiness evaluation. Differences in the materials of the DMA and 
human mouth could also be responsible for the inconsistency between perceived 
stickiness acceptability and AUC values of sample H1.  
 
5.3.3 ODF samples perceived stickiness acceptability in vivo/in vitro 
correlation with AUC values calculated using in vivo-measured 
disintegration time 
 
 
Figure 5.4: AUC calculated using the disintegration time measured in vivo by panel participants (n = 24). 
Asterisks represent statistically significant differences with the corresponding AUC values calculated using 
in vitro data. 
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Significantly higher values were found in the majority of the samples when the AUC was 
calculated with disintegration time measured in vivo (Fig. 5.4), except for samples H2, 
and P1, where the AUC was similar. This was an indication that the drop method was 
not the most suitable methodology for the measurement of in vitro disintegration time, 
and that other methods are required to accurately predict ODF perceived disintegration 
time.  
5.4 Conclusions 
 
A second human panel conducted on 24 healthy young adults on a set of nine samples 
was conducted. The acceptability of perceived size, and perceived thickening effect of 
the analysed ODF samples did not differ significantly among samples, although this 
could not always find confirmation in the outcomes of the semi-structured interview. 
The acceptability of the perceived thickness, perceived stickiness, and perceived 
disintegration time, on the other hand, varied among samples. With regards to the 
perceived stickiness acceptability, the molecular weight of the single-polymer ODFs 
seemed to confirm its influence, as previously identified by DMA, with the exception of 
sample P4. In this respect, the additional influence of other attributes might have 
occurred. Despite the difference in the perceived stickiness intensity between samples 
H1, and H2, there was no significant difference in their perceived stickiness 
acceptability. The acceptability of the perceived disintegration time was higher for 
lower-molecular weight single-polymer PVOH samples. A very low perceived 
disintegration time acceptability of sample H1 in comparison with sample H2 was 
noticeable, as well as a lower acceptability of the formulation with a high polymer-to-
excipients ratio. A linear relationship between perceived disintegration time 
acceptability and real disintegration time measured in vivo was found, and the 
correlation was better if flavoured samples were excluded. RROs evidenced a high 
overall sample acceptability with the exception of sample H1. The results of the semi-
structured interview showed for the first time the potential influence of attributes such 
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as colour, sweetness, and a “plastic” feeling on the acceptability of ODFs. Not all the 
feedbacks given by participants in the semi-structured interview agreed with the PROs 
given for the corresponding attributes on the five-point scale, although the number of 
participants suggesting sample improvement in the semi-structured interview was 
much smaller. All samples analysed would be taken by participants every day, except 
for sample H1, in agreement with the RROs. Overall, attributes including the perceived 
disintegration time, perceived thickness, perceived thickening effect, and perceived 
taste were found to have a potential positive or negative influence on the perception of 
ODF stickiness. Samples AUCs were calculated using both the disintegration time 
measured in vitro by drop method, and that reported by the panel participants. The 
AUC values calculated with in vitro-measured disintegration time were much lower than 
those calculated with the in vivo-measured disintegration time, however the method 
showed predictive capability of ODF perceived stickiness acceptability. The in vitro/in 
vivo correlation between the calculated AUC and the perceived stickiness PROs was 
non-linear, possibly due to the data collection method, to the influence of other 
mouthfeel attributes on stickiness perception, or to the material properties of the in vitro 
equipment. 
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Chapter 6.  General discussion, conclusions and future 
work 
 
In the present work, key acceptability attributes of the orodispersible film (ODF) 
platform contributing to the end-user acceptability were identified, and an in vitro 
method for the prediction of the perceived ODF stickiness acceptability was developed 
and evaluated. In this chapter, the experimental results, methodology strengths and 
limitations, and potential implications of the integration of the proposed strategy into the 
early drug development stage will be discussed. Future work involving further method 
optimisation and development will be described. 
 
6.1 Review of experimental results and methodology 
 
The assessment strategy for the oral dosage form attributes acceptability assessment 
was developed and tested for the first time, and it was proposed as an example to 
guide the acceptability assessment of all oral dosage forms. It is composed of various 
phases, each requiring a different methodology.  
 
6.1.1 Adoption of a new terminology use for the description of ODF attributes 
 
The very first step was represented by the identification of the most appropriate 
terminology for the description of oral dosage form acceptability attributes. In this 
approach, some of the terms used in the sensory evaluation of food were adapted to 
the assessment of oral dosage forms. This represents an advantage as it enabled the 
unambiguous description of the sensory aspects of relevant attributes of the dosage 
form analysed. On the other hand, a limitation of the adoption of such terminology is 
related to the knowledge and ease of use by the lay person. For thorough sensory 
analysis of orally administered medicinal products a partial training to the target patient 
 188 
population sample participating in acceptability assessment studies might add value. 
Such training does not need to be extensive, however it should provide panel 
participants with the sufficient knowledge and proficiency to ensure that all the sensory 
features of the sample contributing to the end-user acceptability are evaluated. 
 
6.1.2 Rationale behind the acceptability assessment of the ODF platform 
 
ODFs are considered patient-friendly dosage forms for a number of reasons. Proof of 
the high patient acceptability of ODFs has been provided in several literature works. 
Testing a new method for the assessment of patient acceptability on a dosage form 
platform that is already considered highly acceptable represents a “stress-test” for 
method robustness. If the method allows the identification of poorly acceptable 
attributes in a dosage form that is generally considered highly acceptable, it is likely 
that it will be able to work even better for dosage forms which patient acceptability is 
questioned.  
A potential pitfall of the method regards the fact that, although the acceptability of one 
or more attributes was considered poor, it did not significantly affect the willingness of 
the panel participants to take the ODF samples even every day, if it was a medicinal 
product, in the study population. This observation rebounds to the debate raised by the 
scientific community about the difference between medicine acceptability and 
preference [24]. Patient acceptability is supposed to have a significant impact on the 
adherence and success of the medicinal treatment, whereas preference is more 
related to the sensory satisfaction of a medicinal product. Where the first is an 
important aspect related to the safety and quality of life of an individual, the second 
does not represent a barrier, as sensory unpleasant products can be taken anyway 
when the benefits of the therapeutic effects exceed the sensory displeasure for the 
medicinal product. However, the boundaries between the two concepts are weak, since 
small children or uncooperative patients, not always can be easily convinced to take a 
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poorly tasting medicinal product. Therefore, depending on the target population, the 
acceptability criteria can change, and should be assessed. Thus, the poor acceptability 
of ODF attributes found in the healthy young adult population might not have the same 
impact on overall patient acceptability as in other patient populations, however the 
developed method proved to be capable of detecting it. 
 
6.1.3 Selection of ODF attributes for acceptability assessment 
 
ODF attributes were identified following consideration of the whole intake process, and 
the most appropriate ones were selected for pilot testing in vivo. Ease of packaging 
opening, ODF size, thickness, and stickiness perceived by the panel participants on 
handling, and size, thickness, stickiness, and disintegration time perceived during 
intake were evaluated for acceptability and, in some cases, intensity of the stimuli. The 
acceptability assessment of attributes perceived on handling did not differ among 
samples, whereas novel acceptability information was obtained from the packaging 
usability, and from the assessment of ODF attributes perceived during intake. The 
attribute selection process allowed the identification of some of the key acceptability 
attributes of the ODF platform. Other attributes such as taste and smell had a 
significant influence on the ODF end-user acceptability, however they were excluded 
from the study as they would require a dedicated project. A second set of mouthfeel 
attributes were not analysed because of the limitations related to terminology use by 
the panel participants, although they were identified, during the attribute identification 
process, as potentially influencing patient acceptability. Overall, the key acceptability 
attributes identification strategy led to the pre-selection of many relevant aspects of the 
dosage form for acceptability assessment. However, there is always the possibility that 
some relevant attributes were missed. In this sense, tools like face-to-face interview 
proved to facilitate the identification of additional relevant acceptability attributes 
directly from the end-user population.  
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6.1.4 Importance of conducting an in vivo acceptability assessment  
 
With respect to the identification of ODF acceptability attributes, the initial selection of 
the attributes to test for the ODF platform had left out some potentially relevant ones, 
which were reported by the same participants during the semi-structured interview. 
Although this can be seen as a limitation to the method employed, it also confirms how, 
without the direct feedback of the end-user, it is difficult to predict the acceptability of a 
medicinal product, and it underlines the need of appropriate methods for acceptability 
testing. 
 
6.1.5 Selection of the healthy young adult population for optimising the in vivo 
acceptability assessment method 
 
A small sample of the healthy young adult population was recruited for both the human 
panel studies carried out in this project. Such population was recruited because it was 
suitable not only for collecting acceptability data, but also to test the reliability of the 
method. It is reasonable to think that healthy adults are not likely to experience 
difficulties with ODF intake. Surprisingly, poor acceptability was detected in the 
perceived stickiness and disintegration time of some samples, potentially affecting the 
willingness of the participant to take the sample, if it was a medicinal product. Patient 
groups above or below certain age ranges, or affected by various pathological 
conditions are more likely to experiencing difficulties to handle and take ODFs due to 
poor manual dexterity, lowered sight, cognitive impairment, reduced saliva production, 
and other conditions.  
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6.1.6 Questionnaire design for in vivo acceptability assessment  
 
Information on the acceptability of individual ODF attributes was obtained by designing 
a questionnaire and an assessment protocol containing multiple scales and 
assessment modalities. This was done with the purpose of gathering as much 
information as possible, using the most versatile and appropriate approach that could 
be suitable for different study populations. Populations ranging from small 
children/neonates to the elderly were considered in the study design. Aspects such as 
the ability to use the assessment scales, the distribution of the data collected, the 
potential involvement or contribution of a third party (researchers or parent/carer), 
participant safety, the number of samples analysed, number of sessions, and the type 
and difficulty of the tasks were all carefully considered and integrated into the study 
design. For example, the use of a five-point scale was preferred to seven- or nine-point 
scales, as non-trained panellists might have difficulties evaluating sensory attributes 
using too many response categories, despite hedonic scales with more than four points 
were found to perform better with regards to discriminating power [231]. Similarly, 
hedonic facial scales were considered easier to use by children or other patient groups, 
therefore they were preferred to other types of scales. 
 
6.1.7 Selection of polymeric type and grade for ODF sample preparation, and 
limitations of the in-house ODF sample manufacturing method 
 
Some difficulties encountered before ODF sample preparation included the poor 
availability of polymers in different molecular weights, capable of yielding films with 
good mechanical properties (sometimes the mechanical properties had to be 
overlooked in favour of data collection). Also, limitations related to the poor 
manufacturability of some polymeric solutions were identified. Thickness 
inhomogeneity issues of the test ODF samples were encountered due to the in-house 
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manufacturing method adopted for film casting, whereas industrial-scale manufacturing 
methods should considerably reduce thickness variability. 
The advantage of testing single-polymer ODF samples for initial method validation was 
represented by the possibility to study individual formulation variables such as polymer 
type or molecular weight.  
 
6.1.8 Selection of ODF samples for in vivo and in vitro acceptability 
assessment  
 
The selection of ODF samples to test in the first part of the project (chapters 2 and 3) 
was carried out with the purpose of assessing whether formulation variables such as 
film-forming polymer type and molecular weight influenced the acceptability of different 
ODF attributes. Therefore, single-polymer ODF samples prepared with different 
polymer types, and molecular weights were tested. After a preliminary selection 
process involving the safety assessment for human intake, manufacturability 
assessment of the polymeric solutions, and film-forming capability assessment, two 
polymers in two different molecular weight variants were tested. A correlation was 
found between the in vivo acceptability assessment of ODF perceived stickiness, and 
the AUC calculated from the in vitro adhesive force measurement of the tested ODF 
samples. Then, an extended set of samples was prepared in order to elucidate the 
characteristics of the adhesion mechanisms responsible for the sample adhesion 
measured with the developed in vitro method, and for the stickiness perceived in vivo. 
Poly(vinyl) alcohol (PVOH) was available in a wide range of molecular weights, and it 
was suitable for further understanding the effect of polymeric molecular weight on ODF 
in vitro-measured tack and in vivo-measured perceived stickiness. More molecular 
weight variants of carboxymethylcellulose (CMC) were difficult to find, however the 
possibility to fully ionise CMC to obtain a negatively-charged ODF sample was 
possible, and a comparison with a fully ionised positively-charged Eudragit E POâ 
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ODF sample was carried out in vitro. This led to understand the role played by opposite 
ODF charges on the measured tack. Unfortunately, this set of samples could not be 
tested in vivo due to safety concerns. The testing of ODF samples with and without a 
hydrophobic polymeric component confirmed that hydrophobic elements reduce ODF 
tack in vivo and in vitro, but not the in vivo perceived stickiness acceptability. The 
formulation optimisation by addition of other excipients and active pharmaceutical 
ingredient (API) did not seem to substantially affect the ODF sample tack, which was 
determined by the film-forming polymer. Of the optimised formulations, only the 
placebo sweetened/flavoured or non-sweetened/non-flavoured ones could also be 
tested in vivo.  
 
6.1.9 The participant group can influence the identified acceptability 
attributes in human panel studies  
 
The ability to swallow ODFs has been previously defined as acceptability attribute for 
infants and children [71]. In the present study, the swallowability of ODF was not 
reported as an acceptability barrier by healthy young adults. This suggests how the 
perception of an ODF acceptability attribute was affected by the study population. 
 
6.1.10 Identification of ODF formulation variables influencing the key 
acceptability attributes 
 
The formulation variables with potential to influence patient acceptability were identified 
based on the key acceptability attribute identified, and the physics behind how the ODF 
interacts with the human body to trigger the corresponding sensory effect. For 
example, the disintegration time is perceived based on the time required for the ODF 
matrix to dissolve. In turn, the time to dissolution of a polymeric network is mediated by 
hydration and polymeric chain disentanglement processes in a liquid environment. 
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Shorter polymeric chains have a lower entanglement density than long polymeric 
chains. Therefore, the molecular weight of the film-forming polymer is likely to 
determine the disintegration time of the ODF product. These conclusions were drawn 
based on literature study, and some aspects related to the influence of other 
formulation variables on the studied ODF attribute might have been missed. However, 
the goal of proving the correlation between formulation variable and corresponding 
attribute acceptability was achieved, confirming the validity of the method. 
 
6.1.11 Identification and optimisation of in vitro methods for the 
assessment of ODF acceptability attributes 
 
In the simple cases, existing in vitro assessment methods for the measurement of ODF 
attributes were used or adapted for the prediction of ODF attributes acceptability. 
However, if an existing assessment method was not available, a novel one was 
developed. The assessment method was based on the principles governing the 
physical mechanisms mediating the interaction between the ODF sample and the 
human body, and triggering the corresponding sensation. For example, ODF perceived 
stickiness is elicited by the adhesive properties of the ODF sample onto the palate of 
the individual, upon hydration with saliva (tack). This process is also known as 
mucoadhesion, and six theories have been proposed to explain such phenomenon. 
Depending on the mucoadhesion theory considered, different testing methods can 
measure the related physical property potentially involved in the phenomenon. Several 
tack measurement methods are used to measure mucoadhesion in vitro. However, the 
simplest method that more closely recreates the conditions of the human oral cavity 
consisted in the adhesive force measurement of a hydrated ODF sample after 
compression. Because in vitro methods are not the exact reproduction of the human 
oral cavity physiological conditions, differences between the two systems might have 
determined the non-linear correlation between in vitro-predicted and the in vivo-
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evaluated perceived stickiness acceptability. However, the exclusion of some 
mucoadhesion theories, and the testing of others have led to a better understanding of 
the physical and chemical mechanisms governing ODF tack, and probably the oral 
stickiness perception in general. Such goal was also obtained by testing the 
appropriate set of ODF samples, as discussed in section 6.1.8. 
 
6.1.12 Perception dominance of ODF attributes 
 
The influence of the perceived ODF disintegration time on the perception of ODF 
stickiness was identified from the results of the pilot human panel. This finding guided 
the optimisation of the dynamic mechanical analysis (DMA) method for the prediction 
of the in vivo acceptability by including ODF disintegration time in the calculation of the 
area under the curve (AUC). This passage was important as it led to obtain a more 
accurate acceptability prediction. It also pointed to the possibility that several ODF 
acceptability attributes may influence the perception of other ODF acceptability 
attributes, which further complicated the optimisation of in vitro acceptability predictive 
methods. Literature works proved that the temporal dominance of a sensory attribute in 
foods can change over time [230]. There is the possibility that a similar phenomenon 
occurs in the perception of ODFs attributes, where further studies need to be 
conducted. The overall acceptability of ODF is therefore the result of an interplay 
between a limited set of sensory attributes that can represent the main acceptability 
predictors. In addition to ODF perceived stickiness and disintegration time, taste is very 
likely to be one of them. Therefore, the development and optimisation of in vitro 
methods predicting the acceptability of all the identified key ODF acceptability 
attributes should provide a sufficiently accurate prediction of the overall end-user 
acceptability with regards to formulation-related aspects.  
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6.1.13 Appropriateness of the DMA method for the prediction of ODF 
stickiness acceptability 
 
The in vivo/in vitro correlation between the AUC calculated by DMA, and the perceived 
stickiness participant-reported outcomes (PROs) resulted monotonic but non-linear. 
Non-linearity could be due to the used data collection methods, to the influence of 
other ODF attributes on the panel participants’ stickiness perception, or to the material 
properties of the DMA equipment. Although further optimisation of the in vitro method is 
required, an indication of the acceptability of an ODF formulation could already be 
obtained. 
 
6.1.14 Appropriateness of the oral cavity model for the prediction of ODF 
disintegration time acceptability 
 
The oral cavity model proved to be a promising experimental method for the in vitro 
prediction of the acceptability of the perceived disintegration time. However, the 
compression stress applied to the ODF samples did not seem to be sufficient to 
accurately measure the disintegration time. With the purpose of predicting the 
acceptability of ODF disintegration time, the oral cavity model allowed the identification 
of the ODF samples that were considered comfortable from those that were considered 
uncomfortable by the human panel participants. The difference was consistent with the 
shape of the ODF volume reduction vs. time curves obtained from the oral cavity model 
analysis. An extended set of purposely-designed ODF samples could confirm the 
relationship between ODF disintegration time acceptability PROs, and sample 
disintegration curve. The integration of both compression and shear stresses in the 
same equipment might lead to a more accurate measurement of the in vitro 
disintegration time. 
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6.2 Future work 
 
The present work provided data of the initial experimental steps taken towards the 
development and optimisation of a new strategy for the assessment of the patient 
acceptability of the ODF formulation platform. When successfully optimised, such 
strategy might lead to the provision of in vitro decision-supporting tools for the 
prediction of the end-user acceptability that can be implemented in the early drug 
development process. In order to achieve such goal more research work and 
optimisation are required.  
 
• The new terminology adopted for the description of ODF acceptability attributes 
should be further refined, or a method for the training of panel participants should 
be designed. Such method could involve a short briefing before the assessment 
session in which the definition of the sensory attribute is given and examples are 
made. A Q&A session could also be useful to ensure panel participants have 
understood the description and are able to evaluate the attribute. 
• Provided that panel participants could be effectively trained to use the 
appropriate terminology for the assessment of ODF acceptability attributes, an 
extended range of attributes with the potential to affect patient acceptability 
should be tested, in order to obtain a comprehensive overview of the ODF 
platform acceptability, and to identify more key formulation variables. 
• Human panel testing of ODFs should also be carried out in different populations, 
particularly in those potentially benefitting from the use of such dosage form 
platform. In this respect, children, elderly, and patients affected by dry mouth 
syndrome should be prioritised. 
• Particular attention should be given to the scaling system used to assess ODF 
attribute acceptability. The selection of the appropriate scales was carried out 
based on the target patient population assessing ODF acceptability. However, 
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the expression of comfort/discomfort by five-point scales/score systems might be 
one of the factors causing the non-linearity of the correlation between AUC values 
and PROs on the perceived stickiness acceptability. Therefore, a revision of the 
selection of the scaling system in ODF attribute acceptability assessment should 
depend on the confirmation that in vivo/in vitro correlation linearity in ODF 
perceived stickiness is the correct description of the relationship between the two 
variables, and the hypothesis that scaling systems with more than five points can 
improve correlation linearity, and still be comfortably used by the population 
assessed. 
• More formulation variables, and a wider set of samples should be tested with the 
currently developed method to further drive the optimisation of the DMA method, 
and the development of new in vitro acceptability-predicting methods. In this 
respect, more polymer types with different molecular weight and grades could be 
tested. Formulation variables other than film-forming polymer type and molecular 
weight could be influencing ODF attributes. The adoption of a factorial design 
approach might be beneficial in this sense. 
• The developed DMA method for the in vitro prediction of ODF perceived 
stickiness acceptability should be further optimised, particularly with regards to 
the integration of the influence of other attributes in the calculation of the AUC. 
This implies that the predictive system should move from a two-dimensional 
(integration of ODF tack and disintegration time), to a multi-dimensional one, and 
be able to work with limited datasets. 
• The developed in vitro oral cavity model for the acceptability assessment of the 
perceived ODF disintegration time should be further tested with additional ODF 
samples in order to confirm the relationship between ODF volume reduction vs. 
time curve and perceived disintegration time PROs. Moreover, the method could 
be implemented with the ability to apply shear stresses to the sample, thus 
potentially improving the accuracy of the sample disintegration time 
measurement.  
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• Finally, when the whole strategy will be optimised and validated, it could be 
assessed for suitability for the acceptability prediction of other dosage forms. 
 
6.3 Conclusions 
 
The increasing need to gather information on patient acceptability has prompted the 
scientific community to propose a range of assessment methods. A harmonised 
approach has, however, not yet been achieved. The acceptability assessment of oral 
dosage form acceptability attributes was proposed in this work as a novel strategy to 
help the manufacturers to optimise the drug product at an early development stage. The 
strategy has been designed and optimised around ODFs, example of a “challenging” 
dosage form known for its patient-centric design. The study led to the identification of 
key ODF acceptability attributes influencing patient acceptability, and guided the 
development of in vitro methods for the prediction of ODF attribute acceptability. 
Although both the developed in vivo and in vitro methods will require further optimisation, 
the concept of an acceptability assessment of oral dosage form individual attributes has 
been proven feasible. When appropriately optimised, and adapted for other 
pharmaceutical dosage forms, such a strategy can provide a set of in vitro methods for 
the prediction of individual dosage form attribute acceptability. Such a set of in vitro 
methods represents a decision-supporting toolkit that can be implemented in the pre-
clinical formulation development phase, potentially facilitating the development of highly-
acceptable medicinal products, and minimising post-marketing risks. Translated into 
benefits for the patient, the present work is expected to promote the engagement of the 
patients in the design of highly-acceptable medicinal products, thus providing 
manufacturers with a real-world feedback, and consequently bringing about significant 
improvements in the patients’ quality of life. 
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